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reality of all created beings. Make them to hear the hidden truths that are
written and embedded in the heart of all that is.” - Bahá’i Writings
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Abstract
Objectives:
1. To explore visual performance status through a range of psychophysical
methods beyond corrected distance visual acuity (CDVA), in subjects with agerelated macular degeneration (AMD).
2. To investigate the effects on these visual performance parameters in subjects
with neovascular age-related macular degeneration (nv-AMD) and in subjects
with early AMD undergoing anti-VEGF (vascular endothelial growth factor)
therapy and macular carotenoid supplementation, respectively.
3. To understand the role of a supplement containing meso-zeaxanthin (MZ; the
third, and currently least explored, macular carotenoid) on the augmentation of
macular pigment (MP), on visual performance and on disease progression
(graded according to the AREDS [Age-Related Eye Disease Study] criteria), in
subjects with early AMD.
4. To explore the impact of macular carotenoid supplementation on vision in
subjects presenting with atypical macular pigment optical density (MPOD)
spatial profiles at baseline.
Outcomes: This study has shown that CDVA is not the most appropriate measure of
visual function and does not reflect retinal morphology in cases of early AMD or in
cases of nv-AMD. Retinotopic ocular sensitivity (ROS), however, appears to be a more
reflective measure of disease severity, where it correlates well with AMD-severity
grade (in cases of early AMD) and also with mean foveal thickness (MFT; in cases of
nv-AMD).
In eyes with nv-AMD undergoing monthly intravitreal ranibizumab injections,
there have been demonstrable improvements in a range of parameters of visual function,
namely, contrast sensitivity (CS), glare disability (GD), and ROS but no significant
change in CDVA, despite a reduction in MFT.
MP can be augmented, and CS enhanced, in subjects with early AMD who
receive supplemental macular carotenoids. Subjects with low baseline central MPOD
had the greatest increases in MPOD and the greatest improvements in CS, when
compared with subjects with medium or high baseline MPOD, suggesting that the
3

optimisation of CS (and putatively visual performance in general) is somewhat
dependent on central MP levels.
The literature review has concluded that supplementation with the macular
carotenoids offers the best means of fortifying the antioxidant defenses of the macula,
thus putatively reducing the risk of AMD and/or its progression, and of optimising
visual performance.

Conclusions: The findings of this work suggest the incorporation of tests,
complimentary to CDVA, such as CS, GD, and particularly ROS, when attempting to
understand disease severity in cases of AMD. In terms of monitoring change over time,
the results of this study do seem to indicate that measures of ROS may be particularly
useful in monitoring subjects with nv-AMD, while measures of CS and GD may be
more apt in monitoring change in subjects with early AMD. Macular carotenoid
supplementation can enhance visual performance in subjects with early AMD.
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Key findings
1. CDVA poorly reflects retinal morphology in cases of early AMD and in cases of
nv-AMD. ROS, however, appears to be a measure which is more reflective of
disease severity in these conditions, where it correlates well with AMD-severity
grade (in cases of early AMD) and also with MFT (in cases of nv-AMD).
2. In eyes with nv-AMD undergoing monthly intravitreal ranibizumab injections,
there have been demonstrable improvements in a range of parameters of visual
function, including CS, GD and ROS, but no significant change in CDVA, despite
a reduction in mean MFT.
3. Early AMD is visually consequential: while CDVA may not be greatly affected by
early stages of the condition, it is clear that measures such as CS and GD are
depressed compared to normal subjects and, therefore, should be considered in the
diagnosis and monitoring of patients with AMD.
4. MP can be augmented, and CS enhanced, in subjects with early AMD who receive
supplemental macular carotenoids. A formulation containing MZ appears to offer
advantages over a formulation that does not contain MZ, in terms of improvements
in psychophysical function and in terms of MP augmentation.
5. Optimisation of CS (and putatively visual performance in general) is influenced by
central MP levels. Subjects with low baseline central MPOD had the greatest
increases in MPOD and the greatest improvements in CS, when compared with
subjects with medium or high baseline MPOD.
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Chapter 1. Introduction

Age-related macular degeneration (AMD), a degenerative condition of the macula
typically encountered amongst individuals fifty years or older, is the leading cause of
blind registration in the developed world1 (Figure 1.1). AMD affects an individual’s
central vision, whilst peripheral vision is preserved. The advanced stages of the
condition, however, can have a considerable impact on an individual’s quality of life
and independence, as daily tasks, such as reading, driving, and recognising faces, are
hampered.
The measurement of visual performance is a long established practice in the
assessment and monitoring of ocular disease. It assists clinicians to understand disease
severity and its corresponding impact on quality of life. It has also been used, in certain
cases, to determine when to commence, continue or cease treatment, as well as to judge
the efficacy of intervention, for clinical and research purposes, particularly following
the introduction of new treatments or new treatment strategies.
Historically, the quantification of visual performance (in subjects with and
without AMD) has been, and remains dominated by measures of corrected distance
visual acuity (CDVA), a measure of the angular resolution limits of the eye at high
contrast.2 However, there is a general consensus that CDVA is not a true reflection of
daily visual experience, and research studies have, in more recent times, started to
incorporate alternative methods of assessing visual performance in clinical trials. Such
trials have demonstrated the capacity of these additional measures to provide a more
comprehensive overall assessment of visual performance compared to CDVA alone.3-13
The universality of the measure of CDVA, however, along with other factors such as
the cost and inconvenience associated with introducing additional methods of visual
21

assessment, has hindered the translation of these important research findings into
clinical practice which, for the most part, has not materialised.14 This has influenced a
clinician’s appreciation of disease severity and/or of the efficacy of intervention and
also potentially influences decisions clinicians make with respect to commencing,
continuing, or ceasing a given intervention.
AMD is generally classified as either ‘early’ or ‘late’. The early form involves
both hypotrophic and hypertrophic changes of the retinal pigment epithelium (RPE)
underlying the central macula, accompanied by drusen formation beneath the RPE, and
such changes are, typically at least, of little or moderate visual importance. Late AMD
is sub-divided into atrophic and neovascular AMD (nv-AMD). The atrophic form
causes degeneration and thinning of the RPE and choriocapillaris, weakening the RPE’s
capacity to nourish, and remove waste products from, the retina. Nv-AMD is
characterised by the growth of abnormal blood vessels from the choroid, which
penetrate Bruch’s membrane and sometimes the RPE.15 If left untreated, the leakage
results in subretinal and/or retinal scarring, and associated photoreceptor damage with
consequential and irreversible loss of central vision.16 Nv- AMD can develop very
rapidly relative to the atrophic form, which typically develops over months or years.
Approximately 7% of people 75 years and older have progressed to the late stage of this
disease.17
A global estimate has reported that 8.7% (approximately 14 million cases) of
visual impairment is attributable to AMD.18 It is estimated that the late form of the
condition affects approximately 1.4 million individuals in the United States, 417,000
people in the United Kingdom and 70,000 people in the Republic of Ireland,19 numbers
which are likely to increase due to increasing longevity (Figure 1.2). Further, and as a
result of a continued demographic shift towards an elderly population, the socioeconomic implications of visually consequential AMD is becoming more important.20
22

Figure 1.1 Distribution of the causes of blindness in the developed world. (Data from
the World Health Organisation: Magnitude and causes of visual impairment. Factsheet
282. November 2004; image courtesy of the Macular Pigment Research Group
[MPRG], Waterford).

Figure 1.2 European life expectancy (1950 – 2050). (Data from the United Nations,
World Population prospects [2006]
http://www.un.org/esa/population/publications/wpp2006/WPP2006_Highlights_rev.pdf
; figure adapted by the MPRG, Waterford)
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Intravitreal anti-VEGF therapy is now the most commonly used treatment for
nv-AMD. Studies have conclusively demonstrated the morphological and visual
benefits of treatment, yet anti-VEGF therapy has cost and logistical implications for the
healthcare system and for the patient. In addition, there is, as yet, no effective treatment
for atrophic AMD, which has similarly detrimental effects on a patient’s quality of
life.21 One of the well-established risk factors for developing the late, more debilitating,
forms of the condition is having early AMD.22, 23 There is a clear and urgent need,
therefore, to understand how the onset of this condition can be prevented, delayed or, at
least, its progression retarded.
Macular pigment (MP), a yellow-coloured pigment located in the inner retinal
layers of the macula, has generated interest in recent years because of its possible
protective role for AMD, putatively (assumably) attributable to its antioxidant
properties and/or its pre-receptoral filtration of damaging (short-wavelength) blue light,
given that (photo)-oxidative retinal injury is known to be important in the pathogenesis
of this condition.24, 25 MP is composed of the two dietary carotenoids, lutein (L) and
zeaxanthin (Z), and a third carotenoid, meso-zeaxanthin (MZ), which is not found in a
typical diet.26, 27 The anatomical (central retinal), biochemical (anti-oxidant) and optical
(short-wavelength filtering) properties of MP have generated interest in the biologically
plausible rationale that MP may confer protection against AMD.
A study design to conclusively prove MP’s role in disease prevention would
need to be at least fifteen years in duration, and would involve recruiting subjects who
are not afflicted with the condition, and evaluating the incidence of AMD with respect
to dietary intake of the carotenoids and with respect to MP optical density (MPOD).
Such a study has yet to be undertaken, most likely due to the prohibitive cost and
methodological difficulties inherent to the required study design. In the interim, the role
of MP in reducing the risk of progression of the disease can be more readily
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investigated. Evidence from a large scale clinical trial has shown that supplementation
with dietary antioxidants can reduce the risk of progression from intermediate to late
AMD by 25%.28 Furthermore, there is now sufficient evidence to suggest that
supplementation with the macular carotenoids can reduce the risk of disease
progression, although conclusive evidence from a large scale randomised and placebocontrolled trial (RCT) is not yet available.
The influence of MP (and its augmentation) on visual performance has also been
the focus of scientific investigation. The bulk of the experimental evidence supports the
concept that MP has a functional influence on visual performance.29-33 Supplementation
with the macular carotenoids has been shown to be related to improvements in visual
performance amongst subjects with and without AMD,34-36 putatively through its
ability to filter short-wavelength blue light, reducing the effects of chromatic aberration
(CA) and light scatter, thereby enhancing contrast and reducing glare. A measure as
crude as CDVA is unlikely to detect the changes in vision that might be attributable to
MP carotenoid supplementation. Any improvement (or even stabilisation) in vision,
however, has important implications for patients with or without macular disease.
Considering the degenerative nature of AMD, it is important to assess visual
performance as accurately and as comprehensively as possible, for the benefit of the
patient, clinician and for the betterment of research.
In addition, the nature of the macular carotenoid formulation that maximises the
visual benefit, if any, of MP at the macula has yet to be determined, i.e. the constituent
carotenoids, individual carotenoid dosage.
This study was designed to look beyond CDVA in the assessment of visual
performance, through a range of psychophysical methods, in subjects with AMD, in
general. Also, this study investigates the effects on these visual performance parameters
in subjects with nv-AMD and in subjects with early AMD undergoing anti-VEGF
25

therapy and macular carotenoid supplementation, respectively. This study has also
sought to investigate the role of a supplement containing MZ (the third, and currently
least explored, macular carotenoid) on the augmentation of MP, on visual performance
and on disease progression, in subjects with early AMD.
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Chapter 2. Age-related macular degeneration

Age-related macular degeneration (AMD) is a degenerative condition of the macula, a
specialised area of the retina, responsible for central and colour vision.37 Whilst
peripheral (navigational) vision is maintained in cases of AMD (regardless of stage), it
is central vision that is needed for seeing fine detail and for common daily tasks such as
reading, driving and face recognition.38-40 Therefore, the loss of central vision has a
significant impact on an individual’s independence and his/her quality of life.
The retina is a light-sensitive tissue at the back of the eye, which converts light
images into electrical impulses, which are sent to the brain. The macula, the centre of
which is the foveola, has a diameter of approximately 5mm at the posterior retina and,
unlike the rest of the retina, has a particularly high density of cones. Typically, the
macula has a characteristic yellow colour, which is usually detectable on fundoscopy.
Its yellow colour attracted the attention of anatomists in the late 18th century, who later
coined the term “macula lutea” or “yellow spot”. It is now known that the yellow
colouration is a characteristic of the highly concentrated presence of the macular
carotenoids, collectively referred to as MP.

2.1 Classification of AMD
The International age-related maculopathy Epidemiological Study Group delineated the
parameters of a core grading system to create a universal method with which to classify
and define AMD for future clinical and epidemiological purposes.41 “Age-related
maculopathy” was the term used to define early stages of the condition and “AMD” was
used to describe late, more advanced, stages of the disease, namely choroidal
neovascularisation (CNV; a manifestation of nv-AMD), and geographic atrophy (GA).
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For the purposes of this thesis, AMD will be used to define the condition in general,
“early AMD” will be used to describe early manifestations of the disease and “late
AMD” will be used to denote CNV and/or GA.

2.1.1 Early AMD

Early AMD is defined as a disorder of the macular area and is apparent clinically in
subjects typically after the age of fifty. It is characterised by any of the following
findings, when not associated with another disorder:
1. Soft drusen ≥ 63µm in diameter. Drusen are focal collections of extracellular
material that lie external to the neurosensory retina and the RPE and appear as
whitish-yellow spots on fundoscopy (Figure 2.1). Drusen may be soft and
confluent, soft distinct, or soft indistinct. Hard drusen appear as small, round,
discrete, yellow-white spots, while soft drusen are larger and have indistinct
edges. Soft drusen may enlarge and coalesce (confluent drusen).42 Hard drusen,
alone, does not characterise AMD.
2. Hyperpigmentation (increased pigment) in the outer retina or choroid, associated
with drusen (hard or soft).
3. Hypopigmentation (depigmentation) of the RPE, typically more sharply
demarcated than drusen, without any visible choroidal vessels, associated with
drusen (hard or soft). (See Figure 2.2 for hypo- and hyperpigmentation, in
association with drusen).
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Figure 2.1 Macular drusen (hard and soft present). (Image obtained from the Institute of
Eye Surgery, Waterford).

Figure 2.2 Macular drusen and pigmentary (hypo and hyper) changes (Image obtained
from the Institute of Eye Surgery, Waterford).

2.1.2 Late AMD

The presence of early AMD predisposes the individual to late AMD, which is
subdivided and defined as follows:
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1. GA is described as any sharply delineated area of hypopigmentation or apparent
absence of the RPE, in which the choroidal vasculature is more visible that the
surrounding area. The area of atrophy must be ≥ 175µm in diameter (see
example Figure 2.3).

Figure 2.3 Geographic atrophy. (Image obtained from the Institute of Eye Surgery,
Waterford).

2. Nv-AMD, also commonly referred to as “wet AMD” or “exudative AMD”, is
characterised by any of the following:
a. RPE detachment(s), which may/may not be associated with neurosensory
retinal detachment, associated with other signs of early AMD.
b. Sub-retinal or sub-RPE neovascularisation.
c. Epiretinal, intraretinal, subretinal, or sub-RPE glial tissue of fibrin-like
deposits.
d. Subretinal haemorrhage, unrelated to other retinal vascular disease (Figure
2.4).
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e. Hard exudates (lipids) within the macular area, related to any of the above,
in the absence of other retinal vascular disease.

Figure 2.4 Neovascular AMD, showing subretinal haemorrhage. (Image obtained from
the Institute of Eye Surgery, Waterford).

2.2 Aetiopathogenesis of AMD
2.2.1 Oxidative stress

As AMD is an age-related condition, the free radical theory of ageing is believed to be
relevant to its aetiopathogenesis. This theory proposes that age-related disorders are the
result of cumulative tissue damage following interaction with reactive oxygen
intermediates (ROIs).43, 44 ROIs, which include free radicals, hydrogen peroxide and
singlet oxygen, are unstable by-products of oxygen metabolism. Free radicals, for
example, lack an electron in their outer orbit (see Figure 2.5), and are therefore
inherently unstable, causing them to scavenge an electron from another readily available
source. The membranes of the photoreceptor outer segments have the highest
concentration of polyunsaturated fatty acids (PUFAs) in the mammalian world.45 These
PUFAs are one such available source of electrons and are readily oxidised by ROIs,
thus generating a cytotoxic chain reaction of events, thereby producing yet more ROIs
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and further and consequential oxidative injury46, 47 (in this case, impaired photoreceptor
function and cell death).48 The body’s natural defence against ROIs includes their
neutralisation by enzymes and/or antioxidants.49 However, generation of ROIs
increases in response to environmental stresses, such as atmospheric pollution, asbestos
exposure, tobacco use, irradiation and alcohol consumption.47, 50 Oxidative injury
occurs, therefore, when the level of oxidants (ROIs) in a system exceeds the detoxifying
capacity of its antioxidant defence system.51

Figure 2.5 Schematic representation of the generation of a reactive oxygen intermediate
(ROI). ‘A’ represents an atom in stable state (full array of electrons in its outer orbit); B
shows the loss of an electron from the atom’s outer orbit, thus generating a ROI (C),
which is, as a result, unstable. (Image obtained from
http://www.health2know.com/2007-03/)
The retina is made up of ten definable layers, nine of which are collectively
termed the neurosensory retina (containing the photoreceptors and neuron axons), the
remaining outermost layer being the dark, melanin-rich, RPE. The RPE plays an
important role in facilitating visual function; not only does it nurture, and remove waste
products from, the neurosensory retina,52, 53 it also protects against photic injury through
the absorbance of light-induced heat. The melanin pigment of the RPE also allows for
the absorbance of scattered and excess light, thus providing optical benefits.54
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AMD is characterised by loss of photoreceptors and by RPE cell dysfunction,55
the latter being largely attributable to an age-related accumulation of lipofuscin (yellowbrown pigment granules representing lipid-containing residues of lysosomal
digestion).56 Of note, the accumulation of lipofuscin within the RPE cells increases as a
result of incomplete digestion of oxidatively damaged photoreceptor outer segment
membranes.57 In turn, this yellow age pigment then acts as a chromophore (a
compound which, when irradiated with light of an appropriate wavelength, emits an
electron, thereby generating an ROI),46, 58 thus provoking further oxidative injury.57, 59
The retina is an ideal tissue for the production of ROIs, because of its high
oxygen demand and consumption, exposure to visible light, metabolic activities (such
as RPE phagocytosis) and the presence of photosensitisers (chromophores).60 In
addition, the photoreceptor outer segments contain a high concentration of PUFAs,
which are readily oxidised by ROIs, thus generating a cytotoxic chain reaction of
events, thereby producing yet more ROIs and further and consequential oxidative
injury.46, 47
Light of shorter wavelengths (blue, ultraviolet [UV]) has greater energy than
that of longer wavelengths (e.g. red, yellow) and is, therefore, more injurious to retinal
tissue.61 In the human eye, the cornea and crystalline lens efficiently filter most of the
UV light.62 However, substantial amounts of damaging, high energy, short-wavelength
(visible) light is incident upon the retina, even in an ambient setting.63
Damage to the RPE and to the photoreceptors by visible light was first
demonstrated in 1966.64 Later, it was shown that the short-wavelength component of
the visible spectrum is most injurious.65 Of note, it has also been demonstrated that
such short-wavelength light induced photo-oxidative retinal damage is greater in the
presence of high oxygen tension.66 Lipofuscin also appears to play a decisive role in
photo-oxidative stress in the retina, inducing the production of ROIs when irradiated
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with short-wavelength light, as this pigment acts as a chromophore.67 Indeed, and
consistent with this, it has been shown that lipofuscin in RPE cells stimulates cell
apoptosis when exposed to short wavelength visible light.68, 69
There is a growing consensus that cumulative lifetime exposure to visible light
increases the risk of AMD,70, 71 consistent with the aforementioned findings. AMD-like
lesions have been demonstrated in laboratory rats reared in ambient levels of light,
when compared with rats reared in the dark.72 Subsequent investigators have
demonstrated that the generation of AMD-like lesions in monkey retinas, following
exposure to light of varying wavelengths, requires 70-1000 times less power when
using short-wavelength light compared to infrared wavelengths.73 Furthermore the
administration of antioxidants to laboratory rats exposed to continuous illumination has
been shown to confer protection against photoreceptor loss.74 A recent analysis by the
European Eye Study (n=4753) found a significant correlation between cumulative
exposure to visible light and nv-AMD in those patients with low intake of dietary
antioxidants, including L and Z.75 There is, therefore, a compelling body of evidence to
suggest that cumulative exposure to visible (short-wavelength) light is an important
contributor to the development of AMD and that the mechanism of its contribution rests
on the (photo)-oxidative injury that such short wavelengths of visible light inflict upon
the retina.
Of interest, ROI production (and, therefore, oxidative injury) peaks at the
macula,76, 77 where, coincidently, MP peaks, and which is also the site where AMD
manifests.

2.2.2 Inflammation

There is a consensus that inflammation also plays a role in the pathogenesis of AMD.78,
79

Inflammation is part of the complex, biological, non-specific, immune response
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of vascular tissue to harmful stimuli, such as pathogens, damaged cells, or irritants.80 It
is believed that inflammation within the retina is a precursor to the formation of drusen
and the alteration of the extracellular matrix.81, 82 These changes alter the RPEchoriocapillaris relationship, ultimately causing CNV and other manifestations of
advanced AMD.79, 83 Of note, drusen have been shown to contain proteins associated
with immune-mediated response and inflammation.83, 84 Indeed, histological studies
have consistently demonstrated the presence of chronic inflammatory cells in retinas
afflicted with AMD.85, 86 It is believed that these inflammatory cells damage tissue by
releasing proteolytic enzymes and oxidants, thus compounding the effects of oxidative
stress.
The inflammatory hypothesis of AMD has generated a lot of interest, especially
given the discovery that subjects with a certain gene variant, one which is closely
connected to the mediation of inflammatory processes, are significantly more at risk of
developing AMD.87, 88
It has been shown that oxidative damage-induced inflammation is the initiator of
AMD.89 The investigators demonstrated AMD-like lesions in mice immunized with
carboxyethylpyrrole, a unique oxidation product of docosahexaenoic acid found in
drusen from AMD donor eyes. As a result, immunized mice develop antibodies to this
hapten, fix complement component-3, in Bruch’s membrane (the site of drusen
formation), accumulate drusen below the RPE during ageing, and develop atrophic
changes within the RPE. It appears, therefore, that oxidative damage represents the
trigger for the development of AMD, the pathogenesis of which is mediated by the
inflammatory response to that insult, which in turn is determined by genetic
background. It follows, therefore, that prevention or attenuation of the initial oxidative
injury will reduce the risk of developing AMD, regardless of genetic background.90
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2.3 AMD Risk Factors
The three undisputed risk factors for AMD are: ageing, genetic pre-disposition (positive
family history of AMD) and tobacco use.
The free radical theory of ageing (discussed above) suggests that the observation
that advancing age is a strong risk factor in the development of AMD, is attributable
primarily to increasing levels of oxidative stress. Population-based studies have
consistently shown that the prevalence, incidence and progression of AMD increase
exponentially with advancing age.91-93
The prevalence of AMD among first-degree relatives of subjects with AMD,
particularly those with nv-AMD, is greater than that of first-degree relatives of subjects
without disease, suggesting a genetic component may contribute to the development of
AMD.94 A study compared patients with AMD (n = 457) with age- and sex-matched
controls (n = 1071). Patients who carried the susceptibility alleles for either CFH
(complement factor H) or LOC387715 were found to have a 3- to 8-fold increased risk
for developing AMD.95 A 50-fold increase in risk was reported in patients who had two
copies of the susceptibility alleles in both genes. Tobacco use and obesity multiplied the
risks associated with these variants.96 This study (amongst others97-99 ) suggests that
genetic predisposition to AMD is subject to environmental provocation.
Tobacco use is the third, and the only environmental (modifiable), established
risk factor for AMD. Almost all epidemiological studies have shown that tobacco use is
associated with increased incidence and prevalence of the condition, 100, 101 and has been
confirmed by a number of meta-analyses.102, 103
Other possible risk factors, for which findings have been inconclusive thus far,
include: obesity, female gender, previous cataract surgery, cardiovascular disease,
Caucasian race, and lack of physical activity. There is a growing body of evidence that
cumulative exposure to visible light, in association with a lack of dietary intake of key
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antioxidants,104 also represents an increased risk of AMD.105 Of note, an inverse
association has been shown between risk of AMD and the amounts of L and Z in the
retina.106
Interestingly, the three established risk factors for AMD (age, genetic
background and tobacco use) are associated with a relative lack of MP prior to disease
onset.107 Furthermore, obesity (a putative risk factor for AMD), which is known to be
related to poor diet (and, therefore, consequential low serum and retinal carotenoid
levels), is associated with increased oxidative stress and inflammation, and has also
been shown to be inversely and significantly related to MP levels. Moreover, a recent
study has identified that age and tobacco use are also associated with an atypical, and
most likely undesirable, central dip in the spatial profile of MP,108 which may be
attributable to a relative lack of the macular carotenoid, MZ (this will be further
discussed later).

2.4 AMD Treatment
2.4.1 Previous interventions for nv-AMD

Nv-AMD is the only form of AMD for which a proven treatment is available. Until
recently, the available therapeutic interventions for nv-AMD were largely aimed at the
preservation of the presenting visual acuity (VA). These included: laser
photocoagulation, photodynamic therapy and submacular surgery, and are summarised
below.

Laser photocoagulation: Laser was the first treatment introduced to retard the
progression of nv-AMD and is still used in some cases of well-defined extrafoveal
CNV. With the advent of newer therapies, however, and the concern for the impact of
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iatrogenic scotoma in subfoveal CNV, laser photocoagulation of peri- and subfoveal
CNV is no longer recommended.109

Photodynamic therapy (PDT): Choroidal neovascular tissue contains a high
concentration of low-density lipo-protein (LDL) receptors. Verteporfin, (Visudyne®,
Novartis, Basel, Switzerland) when infused intravenously complexes with LDLs and
accumulates in CNV membranes. Non-thermal laser activation (689nm) of verteporfin
induces endothelial damage with thrombus formation via ROI formation, without
damage to the overlying retina.110, 111 PDT has been effective in reducing the rate of
vision loss in patients with subfoveal predominantly classic CNV due to AMD.112
However, the VIO (Visudyne In Occult CNV) study failed to show any benefit in cases
of subfoveal occult CNV.113

Surgery: Subretinal removal of CNV by pars plana vitrectomy has been a proposed
treatment for nv-AMD. The Submacular Surgery Trial114 found that submacular surgery
was not a superior method to (less invasive) laser photocoagulation of subfoveal CNV
and was abandoned with the advent of PDT and, later, anti-angiogenic therapies. The
poor results of this particular study are attributed to the collateral damage to the RPE,
responsible for the nutritional supply of the overlying macula.115 Another surgical
method, macular translocation surgery, has also been used in cases of nv-AMD. The
procedure involves relocating the fovea to an area where the RPE is healthier than it is
centrally, the aim allowing for the recovery of some useful vision.116
2.4.2 Anti-VEGF therapy

Current treatment interventions, specifically anti-VEGF agents, have resulted in better
visual outcomes for patients with nv-AMD, providing, for the first time, a relatively
strong probability of visual gain amongst patients with the condition.
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VEGF, a signal protein (cytokine), is an important regulator of vascular
permeability and angiogenesis.117, 118 The functional role of VEGF is to stimulate new
blood vessel growth, for example, during embryonic development, after injury, or to bypass blocked blood vessels. The production of VEGF significantly increases in hypoxic
conditions, and VEGF also has a role in tumour-angiogenesis and in other ischaemic
and inflammatory conditions.119
VEGF encompasses a family of proteins, which include: PGF (Placenta Growth
Factor), VEGF-A, VEGF-B, VEGF-C, VEGF-D and the viral and snake venom
homologues, VEGF-E and F, respectively. VEGF-A is most relevant for angiogenesis
and vascular permeability. Nine human VEGF-A isoforms have been identified to date,
with varying numbers of amino acids: VEGF121, VEGF145, VEGF148, VEGF162,
VEGF165b5, VEGF165, VEGF183, VEGF189 and VEGF206. VEGF165 is the most abundant
isoform.120, 121
VEGF functions by binding to one of three VEGF receptors (VEGFR-1, -2 and 3) on the cell surface. VEGFR-2 appears to be the receptor that mediates the major
signalling effects of VEGF-A (angiogenesis and vascular permeability).122 The function
of VEGFR-1 is less clear, although evidence suggests that it functions as a “decoy”
receptor, thus regulating the activity of VEGF-A by making it less available for binding
on VEGFR-2. VEGFR-3, on the other hand, does not bind VEGF-A, and is instead, a
receptor for VEGF-C and -D.
The two most important forms of ocular angiogenesis are preretinal
angiogenesis (originating from the retinal vasculature), and subretinal (choroidal)
angiogenesis. Preretinal angiogensis is associated with capillary non-perfusion and
neuroretinal ischaemia, which stimulate the growth of new blood vessel along the
retina-vitreous interface, which can potentially haemorrhage, obscure vision and, in
addition, increase the risk of retinal detachment. Severe retinal ischaemia can cause new
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blood vessel formation on the iris, which can block the trabecular meshwork in the
anterior chamber angle, resulting in neovascular glaucoma. Preretinal angiogenesis is an
uncommon manifestation of diabetic retinopathy and retinal vein occlusions.123, 124
Subretinal angiogenesis (CNV) is characterised by the growth of abnormal choroidal
blood vessels, which penetrate Bruch’s membrane and sometimes the RPE,15 and is
classified according to its appearance on fluorescein angiography. Classic CNV is
located between the RPE and the neural retina, whereas occult CNV occurs between the
RPE and Bruch’s membrane. Mixed CNV also exists. If left untreated, the leakage
results in subretinal and/or retinal scarring, with consequential and irreversible loss of
central vision.16 CNV is a manifestation of nv-AMD as well as other, less common,
degenerative retinal conditions such as myopic maculopathy and angioid streaks.
It has been shown that VEGF-A is secreted basally by the RPE towards the
choriocapillaris, influencing the permeability of its fenestrated capillaries. The secretion
of VEGF-A increases 10-fold in hypoxic conditions. In addition, VEGF-2 receptors
were preferentially located at the choriocapillaris endothelium facing the RPE, which is
suggestive of a paracrine relationship between the RPE and the choriocapillaris
endothelium. An imbalance in this relationship, which potentially produces an increase
in VEGF production, or an increase in VEGF secretion simply due to hypoxic
conditions, are possible contributing factors in the pathogenesis of CNV.125
2.4.2.1 The history of anti-VEGF therapy for nv-AMD
In 1948, Michaelson suggested that the avascular foetal retina induces vascular
ingrowth by the release of a diffusible “metabolic” factor, one which also may play a
role in vascular-related retinal disease, such as diabetic retinopathy.126 In 1954, Ashton
was the first to hypothesise that this factor “X” is stimulated by hypoxia.127 It was not
until 1983 that VEGF-A was discovered as a protein,128 although its angiogenic
properties were not perceived at this time. It was given the name, Vascular Permeability
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Factor (VPF), in light of its discovered ability to influence vascular permeability.
Ferrara et al, in 1992, described VEGF’s major angiogenic role.129 Also, in 1992, and
thirty-eight years on, Ashton’s original hypothesis, that VEGF is, indeed, induced by
hypoxia, was proven.130
Further research in animal models demonstrated that the inhibition of VEGF-A
prevents the development of CNV, causes regression of existing CNV, reduces
pathological vascular permeability and prevents the development of iris
neovascularisation due to retinal ischemia.131-133 Important studies were also able to
show that VEGF-A levels are elevated in the vitreous of subjects with nv-AMD, as well
as in excised CNV membranes.134, 135
These provocative findings led to the design and the execution of clinical trials
for the purpose of investigating the effects of anti-VEGF agents in subjects with
vascular-angiogenic ocular disease.
2.4.2.2 Ocular anti-VEGF agents
Pegaptanib (Macugen®; OSI/Eyetech Pharmaceuticals, New York)
Pegaptanib is an oligonucleotide that binds and inactivates some, but not all, VEGF-A
isoforms. The VISION trial, a randomised, multicentre study, investigated the effect of
intravitreal pegaptanib (once every six weeks) in 1186 subjects with nv-AMD over a
54-week period. The study demonstrated that pegaptanib could reduce the rate of visual
loss in patients with subfoveal nv-AMD. Seventy percent of subjects receiving 0.3mg
pegaptanib lost fewer than 15 letters of VA over the study period, compared with 55%
of subjects receiving sham treatment.136 However, there was no statistically significant
improvement in vision between the treated and sham groups and 1% of patients
developed endophthalmitis. Other significant side-effects included retinal detachment
and traumatic cataract.136
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Bevacizumab (Avastin®; Genentech, South San Francisco, California)
Bevacizumab is a humanised full-size antibody that inactivates all isoforms of VEGFA, and has been approved for the treatment of metastatic colorectal cancer.137 Off-label
systemically administered bevacizumab was studied in an uncontrolled open label trial
in 18 patients with CNV attributable to AMD. VA improved in the study eyes within
the first two weeks of treatment, and by 24 weeks, mean VA increased by 14 letters
(and was accompanied by a decrease in mean central retinal thickness, determined by
optical coherence tomography [OCT]). Complications included significant elevations in
blood pressure in several patients.138 Subsequently, intravitreal bevacizumab was
administered with similar visual outcomes and a very low rate of ocular and systemic
side-effects.139-147 There is a paucity of RCTs investigating the role of intravitreal
bevacizumab for AMD. One study showed that 1.25 mg of intravitreal bevacizumab,
given as part of a six-weekly variable retreatment regimen, was superior to standard
care (intravitreal pegaptanib or verteporfin therapy, depending on lesion type), with low
rates of serious ocular adverse events.148 Mean VA increased by seven letters (from
baseline) in the bevacizumab group compared with a decrease of 9.4 letters in the
standard care group (p<0.001) over the 54 week study period.

Ranibizumab (Lucentis®; Genentech, South San Francisco, California)
Ranibizumab is a humanised antigen-binding fragment of bevacizumab that has a strong
affinity for all VEGF-A isoforms. The testing of intravitreal ranibizumab in a number of
large scale clinical trials provided an important breakthrough in the treatment of nvAMD.
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2.4.2.3 Ranibizumab trials

The MARINA study (Minimally Classic/Occult Trial of the Anti-VEGF Antibody
Ranibizumab in the Treatment of Neovascular AMD)149
The MARINA trial was a randomised, double-blind, controlled, multicentre phase III
clinical trial, which investigated the response of patients with nv-AMD (either
minimally classic or occult CNV) to ranibizumab. Seven-hundred and sixteen patients
were randomly assigned to receive either 0.3mg ranibizumab, 0.5mg ranibizumab or
sham injections every month for a period of two years. Results at 24 months were as
follows:
-

90% of the 0.5mg ranibizumab-treated patients lost fewer than 15 letters
compared with 53% in control-group (p<0.001).

-

33.3% and 26.1% of patients being treated with 0.5mg and 0.3mg ranibizumab,
respectively, gained at least 15 letters of VA, whereas 3.8% had such gains in
the control-group (p<0.001).

-

Mean VA at 24 months increased by 6.6 lines amongst those receiving 0.5mg
ranibizumab, compared to a decrease of 14.9 lines in the sham-injection group
(p<0.001) (Figure 2.6).

-

With similar baseline measurements, approximately 40% of patients treated with
ranibizumab achieved VA of 20/40 (6/12), compared to 11% in the sham group
(p<0.001).

-

Approximately 12% of patients in the ranibizumab groups had vision of 20/200
(6/60; equivalent to legal blindness) or less at 24 months, compared to 43% in
the control group (p<0.001); both groups were comparable in this respect at
baseline.
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-

The area of the CNV lesion in the sham group increased by an average of 2.5
disc diameters in the control group and showed no change in the ranibizumab
groups, over the course of 24 months (p<0.001).

-

1% of subjects (n=5) being treated with ranibizumab developed presumed
endopthalmitis over the course of the study and 1.3% developed uveitis. The
overall incidence of any serious or non-serious systemic adverse event was
similar among the groups.

Figure 2.6 MARINA: mean change in visual acuity from baseline over time; from
Rosenfeld et al.149

The ANCHOR Study (Anti-VEGF antibody for the treatment of predominantly classic
choroidal neovascularisation in AMD)150
The ANCHOR trial, another randomised, double-blind, controlled, multicentre phase III
clincial trial, assessed the effect of ranibizumab in patients with predominantly classic
CNV. Four-hundred and thirty-two patients were randomly selected to receive PDT
with verteporfin every three months plus a monthly sham injection, or sham PDT
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combined with either 0.3 mg or 0.5 mg ranibizumab. The results after 24 months were
as follows:
-

90% of both ranibizumab groups lost less than 15 letters compared with 65% in
PDT group (p<0.001).

-

41% of those treated with 0.5 mg ranibizumab and 34% treated with 0.3 mg
ranibizumab gained at least 15 letters, compared with 6% in PDT group
(p<0.001) (Figure 2.7)

-

Mean VA increased by 11.3 letters in the 0.5 mg ranibizumab-treated/sham PDT
group whereas it decreased by 10.4 letters in the PDT/sham injection group
(p<0.001).

-

Changes in lesion anatomic characteristics on fundus fluorescein angiography
(FFA) favoured ranibizumab (all comparisons p<0.0001 vs. PDT).

-

Similar to the MARINA trial, the risk of presumed endopthalmitis was 1%
amongst the ranibizumab-treated subjects and there was no imbalance among
the groups in terms of rates of serious ocular and non-ocular adverse events.

Figure 2.7 ANCHOR: Gain ≥15 letters after 1 and 2 years; from Brown et al.150
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There was no significant evidence of toxicity with either dose of ranibizumab in
either of the trials. It was suggested that the 0.5 mg dose was superior and has now been
approved for intravitreal use in patients with nv-AMD.

The PIER study151
The PIER study was designed to evaluate the efficacy and safety of ranibizumab using a
less frequent injection schedule than that used in MARINA and ANCHOR. One
hundred and eighty-four patients were randomised to receive 0.3 mg ranibizumab, 0.5
ranibizumab or a sham injection every month for three months, followed by injections
every three months. After one year, there was an observed difference, in terms of VA,
between the ranibizumab-treated patients and those in the sham group:
-

Mean change in VA between baseline and 12 months were -16.3, -1.6, and -0.2
letters for the sham, 0.3 mg, and 0.5 mg groups, respectively (p≤0.0001,
each ranibizumab dose vs. sham) (Figure 2.8).

-

Ranibizumab arrested CNV growth and reduced leakage from CNV compared to
sham treatement (p<0.001)
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Figure 2.8 PIER: Mean change from baseline visual acuity at monthly intervals; from
Regillo et al.152
However, in the ranibizumab groups, the treatment effect declined during
quarterly dosing and the results 12 months showed poorer outcomes compared to those
observed in the MARINA and ANCHOR trials for the same time period, which used
monthly dosing. Between month 12 and month 24, changes in protocol meant that
sham-injection patients crossed over to receive 0.5 mg ranibizumab quarterly after
completing the month-12 visit. Subsequently, and in light of the 12-month PIER data,
the protocol was further amended and all patients remaining in the study rolled over to
receive 0.5 mg ranibizumab monthly for the remainder of the 2-year study. At month
24:
-

VA decreased an average of 21.4, 2.2, and 2.3 letters from baseline in the sham,
0.3mg, and 0.5mg groups (p<0.0001 for each ranibizumab group vs. sham).

-

VA of sham patients, who crossed over (and subsequently rolled over)
to ranibizumab, decreased over time, with an average loss of 3.5 letters 10
months after crossover. This reduction in VA, in spite of the initiation of
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treatment, suggests that ranibizumab has limited benefit following 12 months
without treatment, further emphasising the importance of timely intervention.
-

VA of 0.3 mg and 0.5 mg group patients who rolled over to
monthly ranibizumab increased for an average gain of 2.2 and 4.1 letters,
respectively, 4 months after rollover.

-

The ocular safety profile of ranibizumab was favorable and consistent with
previous reports, with no events of endophthalmitis or serious intraocular
inflammation.

After 12 months, subjects in the treatment groups who rolled over to receive monthly
ranibizumab, had further increases in VA, suggesting that more effective outcomes are
obtained with a more frequent treatment regimen.

The PrONTO study (Prospective Optical Coherence Tomography Imaging of Patients
with Neovascular Age-Related Macular Degeneration (AMD) Treated with
intraOcular Ranibizumab)153
PrONTO investigated the effect of a variable-dosing regimen based on OCT findings
and other clinical outcomes. Forty patients received three monthly injections of 0.5 mg
ranibizumab and further injections thereafter, depending on the presence of defined
criteria, as follows. During the first year, retreatment with ranibizumab was performed
at each monthly visit if any of the following criteria were met: an increase central retinal
thickness, as observed by OCT, of at least 100µm, or a loss of five letters or more on
the acuity chart. The retreatment criteria were amended in the second year of the study
to include any qualitative increase in the fluid detected using OCT.
-

At month 24, mean VA improved from baseline by 11.1 letters (p<0.001).

-

Central retinal thickness decreased by 212µ (p<0.001).

-

VA improved by 15 letters or more in 43% of patients.
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In brief, visual outcomes were similar to those acheived in MARINA and ANCHOR
and were achieved with an average of 9.9 injections over 24 months. In other words,
fewer intravitreal injections were required.

Other ranibizumab studies

The HORIZON trial was an open-label extension trial (of MARINA and ANCHOR) in
which re-injections of ranibizumab were given at the clinician’s discretion.154 Half of
the patients required re-injections within the first six months and the authors report that
multiple ranibizumab injections were well tolerated for ≥ 4 years.

The EXCITE trial (Efficacy and safety of monthly versus
quarterly ranibizumab treatment in neovascular age-related macular degeneration)
compared 0.3mg quarterly, 0.5mg quarterly, and 0.3mg monthly ranibizumab.155
Treatment consisted of a 3-month loading phase, followed by a 9-month maintenence
phase (injection frequency depending on group). VA increased from baseline to month
12 by 4.9, 3.8, and 8.3 letters in the 0.3 mg quarterly (n=104), 0.5 mg quarterly (n=88),
and 0.3 mg monthly (n=101) dosing groups, respectively, confirming the superiority of
a monthly dosing regimen. The safety profile was similar to that reported in prior
ranibizumab studies.

The SUSTAIN trial (Safety and efficacy of a flexible dosing regimen of ranibizumab in
neovascular age-related macular degeneration), undertaken on 513 ranibizumab-naive
subjects, investigated the efficacy of three initial monthly injections of ranibizumab (0.3
mg) followed by pro re nata (PRN) retreatment for the remaining nine months of the
study.156 Retreatment was based on the following pre-specified criteria: a) more than
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five-letter loss in VA from the previous highest VA score during the first three months;
or b) 100µm increase in central retinal thickness from the previous lowest measurement
during the first three months. The average number of re-treatments from months three to
11 was 2.7. Mean VA increased steadily from baseline to month three (reaching +5.8
letters), decreased slightly from month three to six, and remained stable from month six
to 12, reaching +3.6 at month 12. Central retinal thickness showed a rapid and
significant decline in the first three months, which was maintained over the 12-month
study period. The safety results were comparable to those observed in the previous
clinical studies.

2.4.2.4 Bevacizumab versus Ranibizumab
The recently published 24-month results from CATT (Comparisons of Age-Related
Macular Degeneration Treatments Trial) compared the effiacy and safety of
bevacizumab and ranibizumab for nv-AMD.157 Subjects were randomised to one of
four groups: ranibizumab or bevacizumab, given either every month or as needed (pro
re nata; PRN), with monthly review. In brief, the study showed that ranibizumab and
bevacizumab had similar effects on VA over a 2-year period (p=0.21). Mean gain in
VA was greater for monthly rather than for as-needed treatment (difference, -2.4 letters;
p=0.046). There were no differences between drugs in terms of rates of death or
arteriothrombotic events (p>0.6). However, the proportion of patients with one or more
systemic serious adverse events was higher with bevacizumab than ranibizumab (39.9%
vs. 31.7%; p=0.009).
The IVAN trial (A randomised controlled trial of alternative treatments
to Inhibit VEGF in Age-related choroidal Neovascularisation) also compared the
efficacy and safety of ranibizumab and bevacizumab in cases of nv-AMD, with the
same randomisation protocol as CATT (above). Differences in VA at 12 months
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between bevacizumab and ranibizumab were found to be inconclusive. In contrast to
CATT, VA outcomes did not differ between monthly and as-needed treatment
protocols. Drugs and treatment regimens were deemed to have similar efficacy and
safety (p=0.25). Bevacizumab was less costly for both treatment regimens (p<0.0001).
A recent safety review and meta-analyses of bevacizumab and ranibizumab has raised
concern regarding the potentially increased risk of ocular and multiple systemic adverse
effects with bevacizumab.158 The authors also emphasised the need for studies that are
sufficiently powered for safety outcomes, not just for efficacy.

2.5 Conclusion
Anti-VEGF therapy may even be termed “revolutionary” in terms of its capability to
preserve and, indeed, improve vision for subjects with nv-AMD, who, if left untreated,
would ultimately develop a disciform scar, leading to the irreversible loss of central
vision. Yet, the current licensed form of anti-VEGF therapy is costly and cumbersome
to the healthcare provider and to the patient. For example, in Ireland, the cost to the
healthcare system of a year’s treatment for one eye with (monthly) intravitreal
injections of Lucentis® (ranibizumab) is in the range of €24,000. In addition, patients
and their carers have to travel at least once a month (for injections and post-operative
assessments), which is taxing on their time and finances e.g. travel costs, time off work.
There is also no effective treatment for atrophic AMD, which has a similarly
detrimental effect on a patient’s quality of life. The increasing prevalence of AMD, and
its associated consequences for the patient and the healthcare system, highlight the clear
need for attention to be directed towards the prevention of AMD and its progression.
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Chapter 3. Psychophysical assessment of visual performance in
subjects with AMD

3.1 Introduction
Psychophysics quantitatively investigates the relationship between physical stimuli and
the sensations and perceptions they affect in the observer. Psychophysics, described by
Gescheider as "the scientific study of the relation between stimulus and sensation",159
provides valuable information about the functional status of the visual system, which
includes the status of the retina, the visual pathways and the visual cortex.
Psychophysical assessment can, therefore, reflect, compliment, and even inform
physiological assessment.
AMD is the advanced stage of a degenerative process that occurs in all eyes. The
presence of excessive lipofuscin in RPE cells (typically increases with age) is associated
with RPE dysfunction and also with drusen formation (between Bruch’s membrane and
the RPE), causing further RPE damage. Loss of vision occurs due to the degeneration of
RPE cells, which no longer facilitate the absorbance of excess light necessary for
optimal visual function, nor provide nourishment to the overlying photoreceptors,
leading to photoreceptor cell death. Visual loss can also be caused by leakage from
neovascular membranes that invade the retina, disrupting its normal architecture, and
which, if left untreated, results in scar formation and irreversible visual loss.
Considering the delicate and precise nature of visual perception (in particular, that of
central vision), and the fact that the optimum perception of an image relies on the
intactness and health of a complete array of photoreceptors at the macula, a reduction in
psychophysical function would, therefore, be expected in the presence of AMD.
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An excellent review summarises psychophysical function in AMD;160 (a)
Spatial vision refers to our ability to resolve or discriminate spatially defined features
and includes: (high contrast) VA, hyperacuity, reading speed and CS. (b) Visual field
testing (perimetry): the systematic measurement of differential light sensitivity at
topographically defined loci in the visual field. (c) Temporal vision represents how we
perceive changes in luminance over time, e.g. the response of an eye to a flickering
stimulus. (d) Visual adaptation describes the processes by which the visual system alters
its functioning in response to changes in the environment. The human eye can function
over a remarkably wide range of luminances (a range of greater than eight log units).
The integrity of these visual processes can be assessed using tests, such as dark
adaptation of both rods and cones and, also, the photostress recovery test. (e) Chromatic
function (colour vision) represents the ability to discriminate between stimuli that differ
with respect to their spectral composition, regardless of other parameters, such as
intensity.
The assessment of psychophysical function is largely based on the concept of
threshold testing, the threshold being defined as the point of intensity at which the
presence of a stimulus, or the difference between two stimuli, is either just detectable or
just undetectable. There are two types of thresholds, absolute thresholds and difference
thresholds. An absolute threshold is the level of intensity of a stimulus at which it can
be detected. A difference threshold is the magnitude of the smallest detectable
difference between two stimuli of differing intensities. Humans, however, are not
perfect observers, rendering the acquisition of precise thresholds challenging. The most
common means of assessing thresholds are: the method of adjustment, the method of
limits, the modified (staircase) methods of limits, and the method of constant stimuli.
For the purpose of this publication, I will review those measures of
psychophysical function relevant to studies carried out as part of this PhD, and
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comment on some of the studies germane to the impact of AMD on these particular
measures of visual performance, where available.

3.2 Corrected distance visual acuity
Currently, CDVA a measure of the angular resolution limits of the eye at high contrast
i.e. the smallest discernible black letter on a white chart,2 represents the standard
vision-related outcome measure for the management of AMD (and for vision in general,
in subjects with and without ocular disease).14 The inherent weaknesses of the 150
year-old, and still widely used, Snellen chart have been largely overcome with the
introduction of the Bailey-Lovie and ETDRS (Early Treatment Diabetic Retinopathy
Study) logMAR charts, which allows for a more standardised measure of high contrast
acuity. These alterations, which are the novel features of the logMAR chart, include:
equal numbers of letters per line, equal (logarithmic) graduations from line to line, the
use of letters of equal legibility and the uniformity between-letter and between-row
spacing.161 However, and in spite of these important advances, there is a general
consensus that CDVA is not a true reflection of daily visual experience in a world with
few visual stimuli at such high levels of contrast, suggesting that perhaps other
measures of visual function may be more appropriate in assessing visual performance
and experience in patients with AMD.162

CDVA and AMD: Lesions associated with early AMD are associated with a decrease
in CDVA of up to two letters or fewer when compared with eyes without such
lesions,163 which is neither clinically meaningful nor reliably detectable, considering
that the test-retest variability can be up to two lines of letters on a logMAR chart.164
Also, a report has shown no statistical difference in acuity between subjects with nvAMD and subjects with GA.163 CDVA is, therefore, unlikely to be a sensitive
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psychophysical measure with the capacity to (a) detect the presence of early AMD, (b)
detect change in visual function e.g. following intervention, or (c) provide a useful
prognostic indicator of disease progression. Late AMD is associated with a more
significant decrease in CDVA (approximately seven lines of letters), but only when
signs of advanced AMD involved the central subfields of the macula.163 CDVA is a
poor indicator of disease severity. Acuity levels can vary dramatically despite similar
areas of atrophy, although foveal involvement is a key predictor of VA.165 Similarly,
lesion size in subfoveal nv-AMD cannot explain the wide variations in VA.166 Another
study has shown that for the same level of VA, eyes with GA have worse function,
particularly for dark-adapted vision tests and reading speed, than eyes with drusen (≥
6/15).167

CDVA in response to anti-VEGF therapy: The large scale clinical trials (discussed in
section 2.4.2.3) have demonstrated that CDVA improved significantly following
ranibizumab therapy. Optimum visual outcomes are observed with monthly or criteriabased dosing regimens, compared to less-frequent dosing schedules.

CDVA in response to macular carotenoid supplementation: Various studies have
also reported improvements in CDVA following macular carotenoid supplementation,
in both normal and AMD-afflicted subjects.168-171 However, there have been studies
that have not reported such changes35, 172 whilst reporting improvements in other
parameters of visual function. It is generally accepted that CDVA is not a sensitive
enough measure to detect subtle (but yet important) changes in visual performance. In
this respect, other measures of psychophysical visual function, that might better reflect
the functional status of the macula, should be considered in assessment and
management of subjects with AMD.
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3.3 Contrast sensitivity
Contrast threshold is the least amount of contrast required for an observer to discern a
target, and is typically expressed as CS, its reciprocal. A graph, plotting CS as a
function of spatial frequency, is known as the CS function (CSF) curve, which
represents the minimum contrast required to detect a grating at varying spatial
frequencies. In fact, losses in CS are associated with much smaller losses of VA (spatial
resolution).173 In normal subjects, under normal (photopic) viewing conditions, CS
function peaks at 3-6 cycles per degree (cpd), with a steep reduction in CS approaching
higher spatial frequencies and a more gradual decline in CS towards lower spatial
frequencies.174 A review has concluded that CS is an important measure of visual
function in patients with AMD,175 based on studies that have shown that, when
compared with VA, CS better relates to the ability to perform tasks accurately and
efficiently (including computer task accuracy),176 to discriminate between objects177
and to judge distances.178

CS and AMD: The aforementioned review (on psychophysical function), concluded
that the available data indicates an observed loss in CS across all spatial frequencies in
subjects with AMD. In normal subjects, reduction in CS is typically related to a
reduction in CDVA. Importantly, however, patients with AMD may present with good
CS (at low spatial frequencies) and poor CDVA (or vice versa),179 suggesting that
CDVA alone cannot account for the visual experience in subjects with AMD. In fact, a
significant association has been observed between the loss of CS at high spatial
frequencies and a number of AMD lesions including drusen confluence, focal
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hyperpigmentation of the RPE, and RPE atrophy, whereas lesion size/type (in cases of
late AMD) was not associated with CDVA (previously discussed).180

CS in response to anti-VEGF therapy: In light of the usefulness of CS as a measure
of visual function in AMD, it is interesting to note that there is a paucity of studies that
have investigated the impact of anti-VEGF therapy on CS, in cases of nv-AMD. An
unpublished report reviewing the three large scale, Phase III clinical trials, namely,
MARINA, ANCHOR and PIER, showed that, from the total of 1,323 enrolled
participants in these studies, there was a significant improvement in CS at 12 months
for all CNV lesion types, following intravitreal ranibizumab (0.3mg or 0.5mg).181
Another much smaller-scaled study of three subjects with AMD, reported improvement
in CS in one and stabilisation in two (subjects), following three consecutive
ranibizumab injections.182 The IVAN trial reported improvements in CS in subjects
being treated with either intravitreal ranibizumab or intravitreal bevacizumab (with no
significant difference reported between the two drugs).183 Another study, investigating
the impact of one injection of intravitreal ranibizumab, in combination with one PDT
treatment, observed an improvement in CS in approximately 82% of subjects (n =17).184
Also, improvements in CS scores were observed following one year of either
intravitreal ranibizumab or intravitreal bevacizumab in eyes with CNV due to myopic
maculopathy.185

CS in response to macular carotenoid supplementation: A statistically significant
improvement in contrast acuity thresholds (the contrast threshold needed to detect and
correctly identify the orientation of the gap in a Landolt ring) has been reported in
normal subjects supplemented with L under mesopic conditions.186 The MOST Vision
trial (normal subjects; discussed in detail in section 4.4.3.2) also reported improvements
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in CS following supplementation with a formulation containing all three macular
carotenoids, an improvement which was not observed either amongst subjects taking
placebo, or amongst subjects taking a supplement containing L primarily.170 In 2004,
the LAST study (Lutein Antioxidant Supplementation Trial) was carried out in an
attempt to evaluate the effect of L, either alone or in combination with co-antioxidants,
vitamins and minerals, on the progression of atrophic AMD.187 In brief, results showed
that the subjects taking MP carotenoid supplements (whether alone or in combination)
demonstrated an improvement in VA, CS, glare recovery and visual distortion.

3.4 Glare disability
Glare can be categorized as (a) discomfort glare: the discomfort caused when the overall
illumination is greater than the luminance to which the eyes are adapted, and can be
caused by both direct and indirect light sources e.g. car headlights at night, reflections
from water surfaces, snow, and (b) glare disability (GD): causes a reduction in target
visibility against its background. Discomfort glare typically produces visual fatigue or
annoyance, without necessarily reducing visual performance or visibility. It is thought
to be related to neuronal interactions similar to that of the pupillary response to light.188
GD, on the other hand, is caused by straylight (forward light scatter) either exterior to
and/or within the eye, impairing visual performance and visibility. GD typically
increases with age and/or ocular disease and can be used synonymously with straylight
according to the definition by the CIE (Commission International d’Eclairage, or the
International Committee on Illumination).189
Light travels in straight lines unless it is either absorbed, reflected or scattered
by obstructing particles. The physics of light scatter has been eloquently described as
follows: “Scattering is the process by which a particle – any bit of matter – in the path
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of an electromagnetic wave continuously 1) abstracts energy from the incident wave,
and 2) reradiates that energy into the total solid angle centered at the particle.
Scattering only occurs when the particle’s refractive index differs from the surrounding
medium.”190
The impact of light scatter on CS and visibility has been eloquently described in
a review33 where the effects of scatter by air particles are explored, in particular scatter
caused by haze aerosols (a dispersed system of small particles suspended in a gas,190 the
most common component of the atmosphere), on visibility i.e. “how far one can see and
how well details can be resolved.” Light scatter is wavelength-dependent for small
particles (e.g. 0.2µm), such as those found in haze aerosols. As light passes through the
atmosphere, shorter wavelengths are more prone to scatter than longer wavelengths. The
scattering of short-wavelength light creates a bluish veiling luminance, often termed
“blue haze”, which, when superimposed on the retinal image, reduces the contrast of
targets being observed.

GD and AMD: The effect of straylight is exacerbated in the presence of retinal disease,
such as AMD. AMD is associated with RPE dysfunction (discussed above), which in
turn increases the effects of straylight. In addition, the orientation of photoreceptors is
an important anatomical consideration with respect to glare. In a normal, healthy eye,
photoreceptors are orientated in such a way that light entering the eye (though the pupil
centre) is incident on the “top” of the photoreceptors. This limits the response to light
scatter in the healthy eye (the Stiles-Crawford effect), particularly in the case of
cones.191 Photoreceptors that are irregularly oriented are less likely to respond to light
than normally oriented receptors. In AMD, for example, the presence of drusen, retinal
cysts, fluid, pigment epithelial detachments, alter the normal architecture (orientation)

59

of the photoreceptors, causing them to be less responsive to incoming light and more
responsive to scattered light within the eye, exacerbated by an ageing RPE.

GD in response to anti-VEGF therapy: To my knowledge, no study has investigated
the impact of anti-VEGF therapy in cases of nv-AMD on a subject’s vision measured in
the presence of glare.

GD in response to macular carotenoid supplementation: MP’s short-wavelength
filtering properties render it capable, in theory at least, of attenuating straylight incident
upon the retina, reducing GD. Wooten and Hammond have proposed that having
MPOD of e.g. 0.5 OD units (compared with having little or no MPOD) can attenuate
the veiling luminance of a short-wavelength dominant background by 17%, thereby
increasing the visibility and discriminability of objects in natural viewing conditions.33
Studies have shown the inverse relationship between levels of MP and GD.32 A study
has shown that supplementation with 10mg of L and 2mg of Z for a period of 4-6
months significantly increases MPOD and improves visual performance in the presence
of glare in normal healthy subjects.36 Similarly, demonstrable improvements in mesopic
and photopic GD for a range of spatial frequencies amongst normal healthy subjects
supplementing with 10mg MZ, 10mg L and 2mg Z over a six-month period, have been
observed. Of note, there were no statistically significant improvements in these
parameters of visual performance amongst subjects supplementing with either placebo
or L and Z alone.170
Improvements in GD have been reported in AMD subjects following
supplementation with 15mg dietary L, improvements which were not observed amongst
those supplementing with placebo, albeit in a small sample (n=5). To the best of my
knowledge, no other study has looked at the impact of macular carotenoid
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supplementation on GD in subjects with AMD. Of note, GD has also been shown to
improve amongst subjects with cataract taking dietary supplementation of 15mg L three
times a week, compared with subjects on placebo.192 However, the presence of AMD
was not an exclusion criterion in this study. Therefore, ascertaining whether or not the
observed visual benefits of supplementation were related to regression in macular
disease is not possible.

3.5 Reading speed
Word reading is a complex task comprising of a combination of visual, neural, motor
and cognitive processes, and is influenced by stimulus conditions such as size of print,
contrast, colour, and optical defocus.193 Reading speed is also strongly associated with
vision-related quality of life.194 Reading speed is measured in words per minute (wpm)
and is reported to have a mean (range) of 215 (169-273) wpm in subjects with normal
vision.38

Reading speed and AMD: The intactness of the central field is one of the most
important factors for accurate reading,195 and is likely, therefore, to be of primary
concern to subjects with late stages of AMD. Differences in maximum reading speed
have been observed between subjects with nv-AMD and subjects with GA, with
significantly higher reading speeds achieved by subjects with macular scotomas due to
nv-AMD compared to those due to GA.196 The authors postulate that this difference
might be as a result of the different time-courses of the two conditions, which involve
different types of visuo-motor and adaptation processes. The loss of central field elicits
the use of eccentric viewing, thus impacting the size of the visual span (the number of
letters recognised with each glance, which shrinks in peripheral compared to central
61

vision197 ) and, consequently, reading speed. Central field loss also impacts fixation
ability, which is an important contributing factor to comfortable reading.198 Bullimore
et al reported that subjects with AMD (not defined by the authors as early or late) show
similar fixation rates to normals, but they average fewer letters per forward saccade and
make more frequent regressions.199

Reading speed and anti-VEGF therapy: There are very few studies that have
investigated the impact of anti-VEGF therapy on reading speed. Two are of particular
interest. A statistically significant improvement was reported in mean[±sd] reading
speed (59[±40] to 85[±50] wpm; p < 0.0001) over a three month period in a group of
thirty subjects being treated with ranibizumab for nv-AMD.200 This study also showed
that there was no significant relationship between change in CDVA and change in
reading speed following intervention, indicating that change in CDVA alone cannot
predict a change in reading speed, which was shown to relate more strongly to patient
quality of life than CDVA. Another study has shown a shift in the critical print size
towards smaller print sizes after three intravitreal injections of ranibizumab, i.e. subjects
reached their maximum reading speed for smaller print sizes than those achieved at
baseline, requiring less magnification for effortless reading following treatment.201

Reading speed and macular carotenoid supplementation: There is little information
known about the relationship between MP and reading speed, or on the influence of
macular carotenoid supplementation on this measure of visual function over time.
Further research in this area is required. It has been reported, however, that the use of
yellow filters (similar to MP) improve magnocellular function, which has been shown
to enhance reading performance in children with reading difficulties.202
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Another study investigated the effects of four different light filters (the yellow
Corning Photochromic Filter [CPF] 450 [absorbing wavelengths below 450 nm], a grey
neural density filter, an individualised filter obtained using the Intuitive Colorimeter®,
and a clear filter) on reading speed in normal subjects and in subjects with (nonneovascular) AMD associated with central field loss. There was no statistically
significant light filter effect on reading speed for normal subjects. However, the AMD
group demonstrated a statistically significant (mean = 5%) improvement
in reading speed with the CPF450 compared with the other filters, and some subjects
had improvements of 10-15%. This suggests that the filtration of short-wavelength light
may be of greater visual benefit for subjects with AMD than for normal subjects.203

3.6 Retinotopic ocular sensitivity
Retinotopic ocular sensitivity (ROS), as determined using Microperimetry (devices such
as the Microperimeter (MP 1)®, Nidek Technologies, Padova, Italy), provides
information regarding ocular functional performance by examining the differential light
threshold at specific points on the retina, under direct visualisation of the fundus. It
allows a point-to-point correlation between fundus lesions and functional defects and
simultaneously corrects for eye movements. Other important features of the technique
include real-time automated fundus tracking, the automatic, accurate mapping of the
location and quality of fixation, and the facility to analyse eyes over time, using point to
point comparisons from visit to visit. ROS uses a more sophisticated method of
psychophysical assessment (compared to CDVA) and is, therefore, inherently more
sensitive to subtle changes in retinal physiology.
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ROS and AMD: ROS overlying areas of drusen and pigment abnormalities, using the
MP 1, was examined in 13 patients with early AMD and good VA (6/6).204 The results
showed that, in subjects with early AMD, ROS diminishes in areas overlying drusen
and/or pigment abnormalities, despite good VA. The reduction in sensitivity was greater
when both types of lesion were present. These findings suggest that microperimetry
provides additional and possibly more useful information than CDVA with respect to
visual function in cases of AMD.

ROS and anti-VEGF therapy: Microperimetry has been shown to provide additional
and valuable information in cases of nv-AMD undergoing anti-VEGF therapy. A study
has demonstrated a progressive improvement of ROS, in response to ranibizumab
therapy, as far as 24 months following the initiation of treatment, despite stabilisation of
VA after six months.7 Changes in macular morphology following anti-VEGF therapy
have been shown to correlate with changes in central ROS, as measured by
microperimetry.205 Changes in microperimetry have also been shown to reflect changes
in macular thickness for other eye conditions, such as diabetic macular oedema.206, 207
A study has shown that, compared with microperimetry, CDVA seems to significantly
underestimate the change in visual function experienced by patients following treatment
(three consecutive monthly intravitreal ranibizumab injections) for nv-AMD. In that
particular study, one patient exhibited a significant improvement in CDVA compared
with eight patients who exhibited a significant improvement in mean ROS (but not
CDVA).208 This difference in the proportion of patients who had improved visual
function as assessed by microperimetry compared with CDVA was statistically
signiﬁcant.
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ROS and macular carotenoid supplementation: The first study that investigated the
impact of macular carotenoid supplementation on macular function as examined by
microperimetry in subjects with early AMD reported a tendency towards improvement
following supplementation with L for six months (20mg for first three months and
10mg for the remaining three months), although the observed improvement did not
reach statistical significance.35 However, the authors report a significant correlation
between the increase in MPOD and the increase in ROS over the study period. No other
studies to date have investigated the impact of macular carotenoid supplementation on
ROS.

3.7. Preferential Hyperacuity Perimetry
Preferential Hyperacuity Perimetry (PHP) is based on the phenomenon of vernier
acuity, which reflects the ability to discern a subtle misalignment of an object. Vernier
acuity, a form of hyperacuity, has a resolution threshold of three to six seconds of arc at
the fovea, which is approximately 10-fold lower than that required for optimal
resolution of an object on, for example, a letter chart (30 to 60 seconds of arc).209 It is
unaffected by patient age or physical condition,210 as well as being quite resistant to
image degradation e.g. as a result of lens opacities, when compared to resolution
acuity.211

PHP and AMD: It has been suggested that measures of hyperacuity (such as vernier
acuity) may better detect early loss of visual function in patients with age-related retinal
disease, such as AMD.212 The Foresee PHP® has demonstrated high sensitivity and
specificity in differentiating between patients with intermediate AMD and recent-onset
CNV,213 and also greater sensitivity in detecting macular changes and AMD when
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compared to the Amsler grid.214 The PHP has, however, demonstrated a higher number
of false-positive results amongst healthy individuals, compared with the Amsler grid.215

PHP and anti-VEGF therapy: A study has shown that improvements in the PHP
metamorphopsia test score correlated closely with improvements in several OCT
parameters, following a single intravitreal ranibizumab injection, amongst 14 subjects
with nv-AMD.216 A longer prospective study (by the same authors) in a similar group
of subjects, over a period of six months has shown that improvements in OCT
parameters correlated with functional improvements as evaluated by PHP (r = 0.9; p <
0.05), following intravitreal ranibizumab therapy. In addition, the PHP could predict the
need for further injections with an accuracy of 75% (sensitivity, 83±12%; speciﬁcity,
67±15%), whereas a combination of all the measurements (PHP, CDVA, and OCT)
yielded a higher accuracy of 87% (sensitivity, 83±12%; speciﬁcity, 90±10%),217
rendering it a potentially useful tool for monitoring patients undergoing treatment for
nv-AMD.

PHP and macular carotenoid supplementation: To date, PHP has not been assessed
in conjunction with macular carotenoid supplementation.

3.8 Subjective Experience and Quality of Life.
Quantification of disease severity or any observed improvement or deterioration in a
given patient’s condition, judged by a clinician according to defined morphological or
even psychophysical criteria, in many ways falls below the importance of subjective
experience i.e. how the patient experiences the world as a result of the condition and/or
its treatment. Whether or not the patient notices appreciable change in vision or in their
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quality of life (QoL) is central to understanding the impact of any disease or resulting
treatment strategy. This is interesting considering that ophthalmologists often
underestimate the impact of AMD on a patient’s QoL.218 In addition, patient-reported
outcomes are now part of US FDA guidelines for the design of clinical trials.219
There is considerable evidence to highlight the significantly negative impact of
AMD on QoL.220-223 Compared to age-matched normals, subjects with AMD are eight
times more likely to report difficulty shopping, 13 times more likely to have difficulty
managing finances, four times more likely to experience difficulty with meal
preparation, 12 times more likely to have problems using a telephone, and nine times
more likely to have difficulty carrying out housework.223
A number of studies have looked at the impact of AMD on psychological wellbeing. Patients with AMD and VA of 6/60 or worse in at least one eye are more likely
to experience emotional distress than age-matched normals (from the Profile of Mood
States).224 However, QoL scores are dependent on stage, where late stages of the
condition have a more profound impact.39 Longer duration of the condition was
associated with reduced levels of distress, most probably due to adaptation. However,
poor adaptation was shown to be associated with depression.225 A US-based crosssectional study found that rates of depression amongst patients with advanced visual
loss attributable to AMD were twice those found among a general sample of
community-dwelling elderly subjects.226
There are obvious limitations to measuring QoL using standard questionnaires.
As is implied, QoL is a subjective perception and will have a different meaning to
different people. Many QoL measures, although obtaining a score or quantifying the
degree of difficulty with respect to a given task, do not necessarily take into
consideration the relevance of that particular task or aspect of daily life for the patient in
question. For example, two patients with similar deterioration in reading speed may
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exhibit vastly different QoL scores, depending on whether or not reading is an
important part of their daily lives. The availability of support and rehabilitation may
also contribute to variations in QoL scores. Patient to patient variability in QoL scores
are further confounded when one considers the influence of the presence or absence of
disease in the fellow eye.
Vision-related QoL questionnaires that have been validated for use amongst
subjects with AMD include: the National Eye Institute Visual-Function Questionnaire
(NEI-VFQ), the Visual Function-14 (VF-14) questionnaire, Daily Living Tasks
dependent on Vision (DLTV) questionnaire and the Activities of Daily Vision (ADV)
scale. Of these, NEI-VFQ227 is the only questionnaire that investigates psychological
aspects of visual impairment (social functioning, mental health, dependency), in
addition to items specifically related to vision-related tasks.
A study investigating the responsiveness of the NEI-VFQ to changes in VA,
using data from the MARINA and ANCHOR trials, has shown that the NEI-VFQ was a
responsive and sensitive measure of vision-related function amongst patients with nvAMD receiving anti-VEGF therapy.228 However, it must be borne in mind that the
criterion for change in VA in these studies was defined as >15 letters (three lines of a
logMAR chart), which is a change of relatively large magnitude. The sensitivity of the
NEI-VFQ to smaller changes, e.g. one or two lines, has yet to be ascertained.
NEI-VFQ has been critiqued with respect to its unidimensionality, a
characteristic essential for a valid questionnaire. The overall composite score (a score
between 0 and 100), which combines the scores of 11 subscales encompassing items
related to socio-emotional state, and items related to visual functioning, should be
interpreted with caution, considering the differing nature of these two concepts.
Although there is overlap between the two, simply combining them in one common
score will not accurately reflect the contribution of each to the overall output measure.
68

This has largely been remedied through recently derived scales (socioemotional and
visual functioning scales) in combination with Rasch analysis.229 Rasch analysis
transforms raw nominal numeric questionnaire values into a continuous scale, reducing
noise and allowing for parametric statistical analyses of the data.230 Rasch analysis is
now widely recognised as a valuable measure in the revalidation of questionnaires,
including within the area of ophthalmology.231-233
All things considered, and in spite of limitations, a measurement designed to
quantify a patient’s QoL, either as a result of a condition such as AMD or following
therapeutic intervention for the condition, should be given due consideration in studies
investigating visual performance.

3.9 Conclusion
Considering the wide range and scope of psychophysical visual function and the
importance of the information yielded with respect to assessment of subjective visual
function, it would seem unwise to rely solely on one measure of visual performance
when attempting to quantify disease severity, or when assessing the need for
intervention, or when evaluating functional outcomes of intervention, both clinically
and in research studies.
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Chapter 4. The evidence germane to the role of macular pigment for
the enhancement of vision, and its putative protective function against
age-related macular degeneration

4.1 Study rationale, aims and objectives
There is a consensus that AMD is the result of (photo)-oxidative-induced retinal injury
and its inflammatory sequelae, the latter being influenced by genetic background.
MP is a yellow-coloured pigment which accumulates primarily within the inner
retinal layers at the macula,234 and is optically undetectable beyond 7° eccentricity.235
MP is composed of two dietary carotenoids, L and Z, and a third carotenoid, MZ, which
is not found in a typical diet26, 27 (chemical structure given in Figure 4.1) MP has
generated interest in recent years because of its (now generally accepted) role in the
enhancement of visual performance and its possible protective role for AMD, putatively
attributable to its antioxidant properties and/or its pre-receptoral filtration of damaging
short-wavelength visible light, given that photo-oxidative retinal injury is known to be
important in the pathogenesis of this condition.24, 25
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Figure 4.1 Chemical strutures of zeaxanthin ([3R,3’R]-β,β-Carotene-3,3’-diol), mesozeaxanthin ([3R,3’S]-β,β-Carotene-3,3’-diol), and lutein ([3R,3’R,6R]-β,ε-Carotene3,3’-diol). Image obtained from the MPRG, Waterford.
Evidence quality is typically graded on the basis of study design, where
systematic reviews or meta-analyses of RCTs are widely accepted as providing the best
evidence (Level 1) on the effects of preventative, as well as other, interventions in
medicine.236 (see Table 4.1)
RCTs are regarded as the “gold standard” in clinical research, yet they have
certain limitations237 such as inappropriate outcome measures and/or biased sample
recruitment. Given that studies involving humans are laden with ethical issues and, in
many cases, may not be feasible, practical or indeed appropriate,237, 238 many important
epidemiologic findings have been the result of observational studies. The weight
accorded to RCTs can, in some instances, result in the exclusion of evidence arising
from other valid study designs. In other words, studies with alternative designs should
be seen as complementary, rather than an alternative, to RCTs.
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Table 4.1 Levels of evidence for therapy or prevention
Level
1a
1b
2a
2b
3a
3b
4
5

Type of study
Systematic review (homogeneous) of RCTs
Individual RCT (with narrow confidence interval)
Systematic review of (homogeneous) cohort studies
Individual cohort study / Low quality RCT
Systematic review of (homogeneous) case-control studies
Individual case-control studies
Case series, low-quality cohort or case-control studies
Expert opinions without explicit critical appraisal, or based
on physiology, bench research or “first principles”

Abbreviations: RCT=randomised control trial
Material adapted from the recommendations for evidence-based medicine in Oxford.239

Level 1 evidence has shown that dietary supplementation with broad-spectrum
antioxidants results in risk reduction for AMD progression. Studies have demonstrated
that MP rises in response to supplementation with the macular carotenoids, although
Level 1 evidence that such supplementation results in risk reduction of AMD and/or its
progression is still lacking. Although appropriately weighted attention should be
accorded to higher levels of evidence, the totality of available data should be appraised
in an attempt to inform clinical practice. In this context, I have reviewed the literature
with respect to macular carotenoid supplementation and its putative protective role in
the onset/progression of AMD and also its impact on visual performance, in subjects
with and without the condition.

4.2 The Origins of Macular Pigment
The macula lutea (“yellow spot”) was first identified more than two centuries ago
(1792) by a Milanese ophthalmologist, Francesco Buzzi (1751-1805). Whilst dissecting
and analysing eyes, he noticed a constant finding in the retina: the existence of a small
area of yellowish colour lateral to the optic disc. He reported this finding in his famous
work “Nuovo sperienze fatte sull' occhio umano” – new experiments on the human
eye.240
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Buzzi’s finding was independently confirmed in 1795 by the German physician,
Samuel Thomas von Soemmering (1775-1830), who observed yellow pigment at the
macula during dissection of the eyes of a young man who had drowned. He described it
as a “yellow round spot, and a small hole in the middle.” Soemmering did, in fact,
believe it to be a hole at the centre of the retina and named it (in Italian),
foramine centrali limbo luteo - the central yellow-edged hole. He published his finding
in a communication in 1799.241
Sir Everard Home, a British physician, took great interest in the discovery and
carried out further research to investigate the presence of the pigment in human eyes, as
well as those of other species, such as monkeys, cows and sheep. He concluded that
only human and monkey eyes had the pigment. In 1798, he published the first review on
the “macular yellow”,242 beginning an era of investigation into the composition, and
function, of what has become known as macular pigment,243 a term first coined in 1933
by Walls et al.244
The visual performance and protective hypotheses of MP was first discussed by
Schultze in 1866 where, in his paper, “The retina’s yellow spot – it’s influence on vision
and on colour-blindness”, he concluded, “Therefore, under an otherwise equal
organisation, a retina without a yellow spot would see more blue light than one with
such a spot.” He believed that absorption of the “most refractable violet” reduced CA,
but also hypothesised that macular yellow might provide some protection against the
hazards of short-wavelength visible light.245 MP’s function was further discussed in a
series of studies in the early 20th century.246-249
In 1945, Wald demonstrated the spectral sensitivity of MP (using a spectral
adaptometer), indicating that it had a characteristic carotenoid absorption spectrum and
belonged to a family of xanthophylls found in green leaves. Extraction of pigment
yielded a hydroxy-carotenoid that Wald believed to be L.250
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However, it was not until 1985 that Bone and Landrum first reported that the
pigment was composed of the carotenoids L and Z,251 and this was later confirmed in
1993, at which point the authors also identified MZ as being the third carotenoid present
in the central retina, where it is the dominant carotenoid at the epicentre of the
macula.252 Bone et al proposed that MZ was primarily formed at the macula following
conversion from retinal L,253 and this has subsequently been confirmed.254-256

4.3 The Functions of Macular Pigment
The putative protective role of MP for AMD derives from its anatomical position in the
retina (central and pre-receptoral), and from two functional properties of this pigment:
its absorbance spectrum (peak absorption of this pigment is 460nm), and its ability to
quench ROIs, referred to as antioxidant capacity (see Figure 4.2).

Figure 4.2 The antioxidant and blue-light filtering properties of macular pigment.
Image obtained from the Macular Pigment Research Group, Waterford, Ireland.

74

4.3.1 Short wavelength light filtration

Although almost all UV-B (320-290nm) and UV-A (320-400nm) light is absorbed by
the cornea and lens, light of slightly longer wavelength (400-520nm) passes through the
anterior media, and irradiates the retina.257 Given that the peak absorption of MP is at
460nm,250 it has the ideal light filtration properties to screen short-wavelength light prereceptorally. This allows MP to attenuate the amount of short-wavelength light incident
upon the central retina.
L is reported to be a superior filter of short-wavelength light when compared to
Z, due to its orientation with respect to the plane of the phospholipid bilayer of the cell
membrane (see Figure 4.3),258 which is both parallel and perpendicular. In contrast, Z
and MZ only exhibit perpendicular orientation to this layer. However, it is important to
note that the different absorption spectra of these pigments (L, Z and MZ) result in a
collective optimal filtration of short-wave light at the macula, which would not be
achieved by any of these carotenoids in isolation.258-260

Figure 4.3 Lutein and zeaxanthin within the cell membrane. Image obtained from
Krinsky et al.261
A recent analysis by the European Eye Study (n=4753) found a significant
correlation between cumulative exposure to visible light and nv-AMD in those patients
with low intake of dietary antioxidants, including L and Z.75 A further study has
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recently reported the effect of low-power laser light (476nm [blue]) on the retinae of
eight rhesus monkeys who had lifelong deprivation of the dietary xanthophylls, and
therefore no detectable MP. A further four monkeys (controls) had a typical dietary
intake of L and Z from birth. The retinae of primates deprived of dietary xanthophylls
until exposed to the low-power laser light, but then supplemented with either L or Z,
were then exposed once again to the same laser light six months later. The relationship
between lesion size and exposure energy was then analysed. The controls (primates with
typical dietary intake of L and Z from birth) exhibited less severe short-wavelength light
induced lesions in the foveal region of the retina when compared to the parafoveal
region (where there is no MP), whereas those with lifetime deprivation of xanthophylls,
and no measurable MP, exhibited no difference between the fovea and parafovea in
terms of blue light induced retinal damage prior to supplementation, thus supporting the
hypothesis that foveal photo-protection is indeed attributable to MP. This was further
confirmed by the observation that, following either L or Z supplementation, relative
foveal protection was restored, and those animals with prior lifelong deprivation of
dietary xanthophylls no longer exhibited greater relative vulnerability of the fovea when
compared with the parafovea, and were, therefore, similar to the control group in this
respect following supplementation.262

4.3.2 Antioxidant Properties

L, Z and MZ are structural isomers of one another and are characterised, biochemically,
by their high number of double-bonds.253 Their supply of readily available electrons
enables these carotenoids to quench ROIs, thus limiting membrane phospholipid
peroxidation and attenuating oxidative injury.258, 263, 264 Kirschfeld was the first to
propose the idea that carotenoids protect the macula against oxidative stress.265
However, it was not until 1997 that the presence of direct oxidation products of L and
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Z in human retinal tissue was confirmed, supporting the hypothesis that MP does indeed
protect against oxidative damage in this tissue.266
The antioxidant capacity of Z (and other carotenoids), however, has been shown
to decrease with increasing oxygen tensions in tissue.267 Of note, MP is at its highest
concentration in the receptor axon layer of the foveola and in the inner plexiform
layer.268, 269 Also, the concentration of the carotenoids within each retinal layer peaks
at the foveola. Importantly, it is at this central retinal location where ROI production is
greatest.270
In vitro studies of human RPE cells, subjected to oxidative stress, have shown
enhanced survival of these cells in the presence of Z and other antioxidants, when
compared with controls.271 Furthermore, L and Z are also more resistant to degradation
than other carotenoids when subjected to oxidative stress.272 Z appears to be a more
potent antioxidant than L273 and MZ is yet more efficacious, but only in conjunction
with its binding protein274 (binding proteins are likely to mediate the uptake of the
carotenoids at the macula275 ). Another study has demonstrated that light-induced
photoreceptor apoptosis is limited in response to supplemental Z in quail (the retinae of
which, like those of primates, selectively accumulate L and Z).276 Chucair et al
provided the first evidence of direct neuroprotection of photoreceptors by the macular
carotenoids,277 by demonstrating that the retinal neurons of rats in culture were
protected from oxidative stress when pre-treated with L and Z, compared to those not
pre-treated with these carotenoids. Recently, it has been demonstrated that a mixture of
L, Z and MZ (in a ratio of 1:1:1) quenches more singlet oxygen than any of these
carotenoids individually at the same total concentration.278
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4.3.3 MP for vision

The optical properties of MP, and its selective accumulation at the macula, prompted
the original hypothesis that MP is important for visual performance and comfort.
Indeed, the evidence-based consensus is that the principal function of MP at the central
retina relates to its contribution to visual performance and experience. MP contributes in
this respect through its short-wavelength light-filtering properties at a pre-receptoral
level, thereby attenuating CA and light scatter (which are the result of defocus and
scatter, primarily of short-wavelength visible light), with consequentially enhanced CS
and reduced GD, respectively. The dichroic properties of MP may further contribute to
glare reduction due to the preferential absorption of plane-polarised light.279
Furthermore, MP’s antioxidant properties may also contribute to the enhancement of
visual function by neutralising damaging ROIs, which would otherwise, over time,
impair the physiological functionality of the photoreceptors, and this putative
contribution of MP to visual performance has been termed “neural efficiency”.170
Many cross-sectional studies have shown a positive association between MP and
measures of visual performance, including VA, CS, photostress recovery and GD
(amongst others).29-33 Early AMD is associated with the loss of psychophysical
function,160 and it has been shown that supplementation with the macular carotenoids
improves parameters of visual function in patients afflicted with the early form of this
condition.34, 169, 171, 280 However, no study has yet investigated the impact of a
formulation containing MZ on visual function in subjects with early AMD, or on the
natural course of this condition.
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4.4 The Source of the Macular Carotenoids
An average western diet contains 1.3-3 mg/day of L and Z combined, with significantly
more L than Z (represented by an estimated ratio of circa 7:1).281 It has been reported
that approximately 78% of dietary L and Z is sourced from vegetables, with L found in
highest concentrations in dark green leafy vegetables (including spinach, broccoli, kale,
and collard greens).282 However, as most current dietary databases report intakes of L
and Z combined, it has been difficult to assess the respective and relative intakes of the
individual macular carotenoids. However, a recent study reported concentrations of L
and Z separately within the major food sources, as determined by the National Health
and Nutrition Examination Survey (NHANES).283 The authors confirmed that green
leafy vegetables were the richest source of L (e.g. cooked spinach and kale), whereas
corn and corn products were confirmed as being a major source of Z. Eggs are also a
good source of L and Z, especially given the enhanced bioavailability of these
carotenoids in this form because of co-ingestion of fat.284
It appears that humans ingest relatively low concentrations of MZ (if any). Eggs
from hens fed MZ are known to be a rich human dietary source of this carotenoid.285
Also, in 1986 a study reported that MZ and Z are present in twenty-one species of
edible fish, shrimp, and sea turtles.286 However, it should be noted that there is a paucity
of studies conducted to test foods for the presence of MZ, and further study is this area
is needed. The presence of MZ in the serum of unsupplemented individuals has never
been unambiguously demonstrated, although efforts to extract and quantify MZ in
human blood have demonstrated that, if it is present, the concentrations of this
carotenoid are low.287 Interestingly, and in spite of its absence or low concentration in a
normal diet, MZ accounts for about one third of total MP at the macula, consistent with
the finding that retinal MZ is produced primarily by isomerisation of retinal L at the
macula.253, 256 L differs from MZ (structurally) with respect to the location of the
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double bond in one of the end rings (see Figure 4.1). The conversion of L into MZ
requires a shift in this carbon-carbon double bond. The exact mechanism of the
conversion, however, remains unknown.
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4.5 The Evidence
4.5.1 Types of Evidence

There is the notable challenge of fitting carotenoid research into the, sometimes rigid,
paradigm of evidence-based medicine.
A systematic review is a thorough, comprehensive, and explicit means by which
to identify, critically appraise and evaluate medical literature related to a specific
research question. A meta-analysis is a statistical approach to combine and analyse the
data derived from a systematic-review. RCTs are studies in which participants are
allocated at random, rather than by conscious decision of clinician or patient (which is
the case in non-randomised trials), to receive one of several clinical interventions, one
of which typically acts as a control (placebo). The greater the sample size, the reduced
likelihood of bias. In contrast, an observational study is one in which conclusions are
drawn by observation alone, examples of which may include case-control and cohort
studies.
AMD is a slow, complex disorder, and the carotenoids under review,
particularly L and Z, are already commonly found in the daily diet and are easily
available in supplement form on the open market. This makes the conduct of gold
standard RCTs particularly difficult. What is important to acknowledge is that all study
designs contribute to an ever-growing body of knowledge in a given area. This point has
been eloquently made by Hennekens:“Every research strategy within a discipline,
contributes importantly relevant and complimentary information to a totality of
evidence upon which rational clinical decision making and public policy can be reliably
based. In this context, observational evidence has provided and will continue to make
unique and important contributions to this totality of evidence upon which to support a
judgment of proof beyond a reasonable doubt in the evaluation of interventions.”288
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While recognising the importance of study design in public health research, we
are encouraged to give adequate attention to the completeness and transferability of
evidence when interpreting the results of such studies. This has been eloquently
articulated, as follows: “Care is needed that the use of evidence hierarchies to compare
the potential for bias between study designs does not translate into unrealistic or overly
expensive demands for level 1 or 2 evidence, particularly if there is a good or adequate
level 3 evidence to inform a decision.”289
The reader should also be aware that the capacity and resources of competing
stakeholders (e.g. pharmaceutical companies, academic institutions) to generate and
disseminate evidence has a profound influence on the prestige and volume of available
and published literature on a given subject.289

4.5.2 Clinical trials investigating the macular carotenoids in subjects with AMD

4.5.2.1 Proof of Principle
In 2001, the Age-Related Eye Disease Study (AREDS) was published, having been
conducted by the National Eye Institute (NEI). This was a double-masked, randomised,
placebo-controlled trial of 4757 subjects over a period of 5 years. In brief, it was shown
that supplementation with vitamins C and E, beta carotene, and zinc, in combination,
resulted in a 25% risk reduction of progression from intermediate to advanced AMD.28
Of note, the AREDS formulation did not contain any of the macular carotenoids,
primarily because these compounds were not available in supplement form at the
inception of that study. This landmark work did, however, provide Level 1 evidence
that supplemental dietary antioxidants were of benefit to patients with AMD.
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4.5.2.2 Interventional studies
Following AREDS, and in consideration of the possible protective role that MP plays in
AMD, given its anatomical, antioxidant and optical properties, investigators began to
direct their attention towards studies designed to explore the possible benefits of
supplementation with MP’s constiuent carotenoids. There now exists a plethora of
published interventional studies reporting on supplementation with macular carotenoids
and its impact on AMD (Table 4.2), ranging from case series to RCTs.35, 168, 169, 171, 187,
280, 290-293

In 2004, the LAST study was carried out in an attempt to evaluate the effect of
L, either alone or in combination with co-antioxidants, vitamins and minerals, on the
progression of atrophic AMD.187 This study was a prospective, 12-month, randomised,
double-masked, placebo-controlled trial, involving 90 subjects with atrophic (dry)
AMD. The subjects were assigned to one of three groups: group 1 received L (10mg)
only; group 2 received a broad-spectrum supplementation formula containing L (10mg)
as well as co-antioxidants, vitamins and minerals; group 3 received a placebo. Results
showed that the subjects in groups 1 and 2 demonstrated an increase in mean MP optical
density as well as an improvement in VA, CS, glare recovery and visual distortion. This
study, therefore, demonstrated that visual function is improved in patients with atrophic
AMD following supplementation with either L alone or L in combination with coantioxidants, vitamins and minerals. However, the LAST study is open to legitimate
criticism on the basis of the small number of patients recruited into each arm of the
investigation, and the short follow-up i.e. only 12 months (compared to e.g. AREDS).
The Carotenoids in Age-Related Maculopathy (CARMA) study was a
randomised, double blind, placebo controlled clinical trial of L (12mg) and Z (0.6mg)
supplementation with co-antioxidants versus placebo in patients with AMD.294 This
study included 433 subjects, who were recruited and randomly assigned to the treatment
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or the placebo arms of the study. Although the primary outcome measure (CDVA at one
year) did not differ between the placebo and the intervention arms of the study, it was
noted that CDVA was significantly better in the intervention arm of the study at 36
months follow-up. In addition, an increase in serum L was associated with significantly
improved CDVA and slowing of progression along the AMD severity scale.171 It is
important, however, to note there are several limitations in the CARMA study design,
despite it being an RCT. These limitations include a relatively small sample size,
particularly at 36 months (n = 41, 20 in the intervention group and 21 in the placebo
group), and the questionable appropriateness of its primary outcome measure (CDVA at
12 months), given the chronic nature of AMD.

Table 4.2 Interventional studies investigating the effect of supplementation with the macular
carortenoids in subjects with AMD
Principal Author
Richer et al
Olmedilla et al
Richer et al
Bartlett et al
Beatty et al
Weigart et al
Richer et al
Sasamoto et al
Piermarocchi et al
Jentsch et al

Study
LAST
CARMA
LISA
ZVF
CARMIS
Lutega

Year
1999
2001
2004
2007
2007
2011
2011
2011
2011
2011

n
14
5
90
25
433
126
60
33
145
172

Study Design
Case Series
Case Series
RCT
RCT
RCT
RCT
RCT
Case Series
PRS
RCT

Age
61-79
69-75
68-82
55-82
50+
50-90
75(±10)†
65(±9)†
50+

Carotenoids
L (14mg)
L (15mg)
L (10mg)
L (6mg)
L (12mg) & Z (0.6mg)
L (20mg/10mg)*
Z (8mg) & L (9mg)
L (6mg)
L (10mg) & Z (1mg)
L (10mg/20mg) & Z (1mg/2mg)

Finding
Improved VP
Improved VP
Improved VP¹
No benefit
Improved VP¹
Improved VP¹
Improved VP¹
Improved VP¹
Improved VP
Improved VP¹

Carotenoids = Macular carotenoids assessed in the study; L = Lutein; Z = Zeaxanthin; VP = Visual Performance; n =
number of subjects participating in study; Age = Age range (years) of subjects in study; RCT = Randomised control
trial; LAST = Lutein Antioxidant Supplementation Trial; CARMA = Carotenoids in Age-Related Maculopathy; LISA
= Lutein Intervention Study Austria; ZVF = Zeaxanthin Visual Function; CARMIS = Carotenoids in Age-related
Maculopathy Italian Study; PRS = prospective randomised study; - = data unavailable.
*20mg taken for first 3 months and 10mg taken for remaining 3 months
†mean(±sd)
¹macular pigment measurements were obtained in the study

The optical, anatomical and antioxidant properties of MP have generated a
consensus that MP plays an important role in vision. Many studies have already
demonstrated the positive cross-sectional association between measures of MPOD and
measures of visual performance, including: CDVA, CS, GD, photostress recovery,
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critical flicker fusion frequency, colour vision (amongst others).29-33, 295, 296 One might
hypothesise, therefore, that an increase in MPOD will be paralleled by an improvement
in vision. Indeed, increases in MPOD correlated significantly with decreases in mean
differential light threshold (assessed by microperimetry), suggesting that augmentation
of MPOD enhances ROS.35 It is important to note that psychophysical function is
adversely affected in AMD,160 and this is confounded by age-related decline in many
aspects of visual function in the absence of macular pathology.297-299 Therefore, a
demonstrable improvement (or even stabilisation) in visual function in response to
supplemental macular carotenoids in an older population with a known degenerative
disease should be deemed beneficial. In this context, it is interesting to note that nine of
the ten studies investigating changes in visual performance following supplementation
with macular carotenoids in AMD subjects have demonstrated an improvement in visual
function, and the remaining study consisted of only 25 subjects supplemented with only
6mg L (alone), and even here vision did not deteriorate.

Trials awaiting completion
There are a number of trials underway investigating the putative protective role of L and
Z in individuals with AMD. The AREDS 2 is an on-going multi-centre RCT (n=circa.
4000) evaluating the impact of supplemental L and Z (and/or omega-3) on the
progression of intermediate to advanced AMD and the influence of these supplements
on VA. Additionally, it seeks to assess whether modified forms of the original AREDS
supplement, with reduced zinc and no beta-carotene, work as effectively as the original
supplement in reducing the risk of progression to advanced AMD.
AREDS 2 is expected to be completed in December 2012
(http://clinicaltrials.gov/ct2/show/NCT00345176?term=AREDS2&rank=1). The results
of AREDS 2 will provide valuable and timely data on the potential role of antioxidants,
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including L and Z, in delaying AMD progression, and will inform current professional
practice with respect to the role of dietary modification and/or supplementation in
patients with AMD. A limitation of the trial, however, rests on the fact that MP is not
being measured. Therefore, a finding that supplemental L and Z in AREDS 2 are not
beneficial cannot be interpreted to mean that MP augmentation is not beneficial, as the
latter will not have been demonstrated. Further, it is likely that a very high proportion of
participants in the US-based AREDS 2 will have been supplementing with dietary
antioxidants for many years, thereby contaminating the baseline findings for all study
groups (further hindered by a short wash-out period of only thirty days in subjects who
may have been supplementing for many years), and, therefore, compromising the trial’s
capacity to demonstrate a beneficial effect of supplementation. In fact, a recent baseline
analysis on AREDS 2 subjects from one AREDS 2 centre that is assessing MP levels
has reported unusually high baseline MPOD levels relative to an age-matched control
group which did not regularly consume carotenoid supplements.300 Also, since AREDS
2 is only investigating rates of progression among high risk patients (for advanced
AMD), it therefore, cannot answer one of the most crucial questions with respect to
carotenoid supplementation – does it prevent/delay AMD onset, or does it reduce
progression in earlier stages of the condition?
4.5.2.3 Observational studies
A large number of studies have investigated the relationship between dietary intake of
the macular carotenoids and AMD.104, 301-307 Of these ten published observational
studies, six reported that a high dietary intake of the carotenoids was associated with a
reduced risk of AMD. The relationship between AMD and serum concentration of the
macular carotenoids has also been investigated,75, 303, 308-315 and of the ten published
studies in this respect, seven have shown that low serum concentrations of the macular
carotenoids are associated with increased risk of this condition. (Table 4.3)
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Table 4.3. Observational studies investigating the relationship between the macular carotenoids and age-related macular degeneration.
Observational Dietary Studies

Principal Author
Seddon et al
VandenLangenberg et al
Mares-Perlman et al
Flood et al
Snellen et al
Moeller et al
San Giovanni et al
Tan et al
Cho et al
Olea et al

Study

Year

n

Study Design

Age

Carotenoids

EDCCS
BDES
NHANES III
BMES
CAREDS
AREDS
BMES
-

1994
1996
2001
2002
2002
2006
2007
2008
2008
2012

356/520*
1968
8222
2335
72/66*
1787
4519
2454
66,993
52

Case Control
Cohort
Cross-sectional
Cohort
Case Control
Cross-sectional
Case Control
Cohort
Cohort
Cross-sectional

55-80
45-86
40+
49+
60+
50-79
60-80
49+
50+
mean=79

L&Z
L&Z
L&Z
L&Z
L
L&Z
L&Z
L&Z
L&Z
L&Z

Nutrient/AMD
relationship
Inverse
None
Inverse
None
Inverse
None
Inverse
Inverse
None
Inverse‡

EDCCS
BDES
NHANES III
POLA
EES
-

1993
1995
2001
2002
2003
2005
2006
2008
2009
2011

421/615*
167/167*
8222
48/46*
380
34/21*
899
2283/2117*
722
263

Case Control
Case Control
Cross-sectional
Case Control
Cross-sectional
Case Control
Cohort
Cross-sectional
Cross-sectional
Cross-sectional

43-86
40+
mean=67
66-75
72-74
60+
65+
65+
50-88

L&Z
L&Z
L&Z
L&Z
L&Z; L; Z
L; Z
L&Z
L; Z
L&Z
L&Z

Inverse
None
Inverse
None
Inverse (Z only)
None
Inverse (esp. Z)
Inverse (esp. Z)
Inverse‡
Inverse‡

Observational Serum Studies
Mares-Perlman et al
Mares-Perlman et al
Simonelli et al
Gale et al
Cardinault et al
Delcourt et al
Fletcher et al
Michikawa et al
Zhao et al

Abbreviations: carotenoids = macular carotenoids assessed in the study; L = lutein; Z = zeaxanthin; n = number of subjects; Age = age range (years) of subjects in
study; EDCCS = Eye Disease Case Control Study; BDES = Beaver Dam Eye Study; NHANES = National Health and Nutrition Examination Survey; BMES = Blue
Mountains Eye Study; CAREDS = Carotenoids in Age-Related Eye Disease Study; AREDS = Age-Related Eye Disease Study; POLA = Pathologies Oculaires Liées à
l'Age; EES = European Eye Study; - = data unavailable.
*cases/controls
‡for late stages of AMD
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4.5.3 Clinical trials investigating the macular carotenoids in normal subjects

Many studies have reported on the cross-sectional relationship between MP and a
plethora of visual performance parameters, and a number of trials have investigated the
impact of supplementation with the macular carotenoids on visual performance in
subjects without disease (see Table 4.4)
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Table 4.4 Interventional studies investigating the impact of the macular carotenoids on visual performance in normal subjects.
Principal author(s)

Year

n

Placebocontrol

Carotenoids

Monjea

1948

14

No

L dipalmitate

1951

7

No

L dipalmitate

Dark adaptation &
scotopic VA
Dark adaptation

1951

-

No

L dipalmitate

1956

10

No

Wustenberg

a

Klaes & Riegel
Andreani & Volpia
Mosci

a

Study duration
(months)

Observed visual benefit
following supplementation

2-6

Yes‡

-

No

Dark adaptation

-

Yes

L dipalmitate

Dark adaptation

-

Yes

Visual performance tests

1956

-

No

L dipalmitate

Light sensitivity

-

Yes

Hayanoa

1959

-

No

L dipalmitate

Dark adaptation

-

Yes†

Wenzel

2006

10

Yes

Photophobia

3

Yes

Rodriguez-Carmona

2006

24

Yes*

B/Y colour discrimination

12

No

Kvansakul

2006

34

Yes

30mg L + 2.7mg Z
10mg/20mg of
L/Z/L+Z
10mg L/10mg
Z/combination

Mesopic CS

6

Yes

VA (dist.&near), CS,
18
No
photostress recovery
Photostress recovery &
Stringham &
2008 40
No
10mg L + 2mg Z
6
Yes; both
grating visibility
Hammond
VA, CS, GD, photostress
2010 121 Yes
12mg L + 1mg Z
12
Yes; CS, GD
Nolan
recovery
10mg L+2mg Z+10mg VA, CS, GD, photostress
2012 36
Yes
6
Yes; VA, CS, GD
Loughman
MZ/20mg L+2mg Z
recovery
Abbreviations: carotenoids=macular carotenoids investigated; L=lutein; VA=visual acuity; Z=zeaxanthin; B/Y=blue/yellow; CS=contrast sensitivity; GD=glare
disability; MZ=meso-zeaxanthin; - =data not available.
a
data obtained from Nussbaum316
*for second 6 months of the study
†proportional to serum L
‡described as having a “transient” benefit
Barlett & Eperjesi

2008

29

Yes

6mg L
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4.5.3.1 COMPASS
The Collaborative Optical Macular Pigment ASsessment Study (COMPASS) was a
RCT designed to investigate the impact of supplementation with macular carotenoids
versus placebo, on MPOD and visual performance. One hundred and twenty-one normal
subjects were recruited (age range: 18 - 41 years) to COMPASS. The active group
consumed 12mg of L and 1mg of Z (but no MZ) every day for 12 months (n=61), while
the remaining subjects were assigned to placebo. A range of psychophysical tests were
used to assess visual performance, including: CDVA, CS, GD and photostress recovery.
Subjective visual function was determined by questionnaire and MPOD was measured
using customized heterochromatic flicker photometry (cHFP). The results of this study
showed that central MPOD increased significantly in the active group (but only at the
12 month time point), whereas no such augmentation was demonstrable in the placebo
group. Although this observed increase in MPOD did not result, generally, in a
demonstrable improvement in visual performance, statistically significant differences in
mesopic CS (with and without glare) were observed between those who had high
MPOD and those who had low MPOD at 12 months, whereas this was not the case at
baseline.172

4.5.3.2 MOST Vision
The widest range of short-wavelength light filtration is achieved in the presence of all
three macular carotenoids (L, Z and MZ).317, 318 Emerging data further indicates that
supplementation with all three macular carotenoids increases MPOD faster and to a
greater extent when compared to a formulation that does not contain MZ. In vitro
studies have also shown that maximum anti-oxidant capacity of the pigment is
dependent upon the presence of all three macular carotenoids.319 Investigators,
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therefore, have begun to study the impact of supplementation with a formulation
containing L, Z and MZ on MPOD and on visual performance.
The Meso-zeaxanthin Ocular Supplementation Vision Trial (MOST Vision)
investigated the effect of supplementation of different carotenoid dose combinations, on
visual performance in normal subjects.170 The 36 recruited subjects were assigned to
one of three groups, as follows: the first was given a high dose (20mg) of L and 2mg Z
(Group 1); the second group was given 10mg L, 10mg MZ and 2mg Z (Group 2); and
the third group was given placebo (Group 3), every day for six months. A statistically
significant rise in MP was observed (notably, three months following commencement of
supplementation) only among subjects supplemented with a formulation containing all
three macular carotenoids, including MZ (Group 2). Statistically significant
improvements in CDVA were observed at six months, but only for subjects in Group 2.
Statistically significant improvements in CS were noted across a range of spatial
frequencies, under photopic (3, 12 and 18cpd) and mesopic conditions (1.5, 3, 12 and
18cpd), again only among subjects in Group 2 (with a single exception of improved CS
at a single spatial frequency [6cpd] in the high L group [Group 1]). There were no
statistically significant improvements in mesopic or photopic GD between baseline and
six months in Groups 1 and 3. However, there was a demonstrable improvement in
mesopic and photopic GD for subjects in Group 2 for all spatial frequencies tested (with
the exception of 18cpd).

4.5.3.3 Supplementation with the macular carotenoids in subjects with an atypical
MPOD spatial profile
A study investigated the relationship between MP and known risk factors for
developing AMD amongst 828 normal subjects between the ages of 18 and 55. The
study demonstrated a relative lack of MP in association with tobacco use and with a
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family history of AMD. Also, the authors report an age-related decline in MP,
suggesting that the risk that such variables represent for AMD may be attributable, at
least in part, to a parallel lack of MP. It appears, therefore, that, prior to disease onset,
known risk factors for AMD are independently associated with a relative lack of MP.320
Of the 828 subjects, a proportion (12%) exhibited a “central dip” (i.e. they did
not exhibit the typical central peak that declines in from the foveal centre) in their
MPOD spatial profile. Interestingly, this central dip was associated with tobacco use
and increasing age,321 suggesting that such atypical spatial profiles of MP may
(independently) represent risk for AMD. Given that MZ is the dominant carotenoid in
the foveal centre, it has been hypothesised that the observed central dip in the MP
spatial profile (found in 12% of the study population) is attributable to a relative lack of
this carotenoid. Further, and since retinal MZ is formed from retinal L (but not retinal
Z), the observed central dip in the MP spatial profile may be the result of an inability
among these subjects to convert retinal L to MZ, and therefore such subjects may
require this carotenoid in supplement form if they are to achieve a typical and desirable
spatial profile characterised by a central peak and an associated decline from the foveal
centre.
The effect of supplementation on a group of subjects that exhibited a central dip
in their MP spatial profile has also been investigated.322 Thirty-one subjects were
assigned to one of three intervention groups, as follows: one given a 20mg of L and
2mg of Z (Group 1); the second group was given 10mg L, 10mg MZ and 2mg Z (Group
2); and the third group was supplemented 17mg MZ and 3mg L (Group 3). Subjects
took one capsule a day for eight weeks. A significant increase in MPOD was not
demonstrable among subjects supplemented with high doses of L (Group 1), at any
eccentricity. Subjects supplemented with high doses of MZ (Group 3) exhibited
significant increases in MPOD at the centre of the MP spatial profile, but at no other
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eccentricity. Subjects in the combined carotenoid group (Group 2, containing L, Z and
MZ) exhibited a significant augmentation of MPOD at 0.25° and at 0.5° eccentricity,
and a trend towards a rise in MP approaching statistical significance at all other
eccentricities. The authors concluded that these atypical spatial profiles of MP,
characterised by central dips, which have been shown to be associated with risk for
AMD,321 can be normalised following supplementation with a formulation containing
MZ, but not with a formulation that is lacking this carotenoid, at least not over an eightweek study period. Augmentation of MPOD across its spatial profile was best achieved
with a formulation containing all three macular carotenoids during the study period.
Further trials, of longer duration and that explore different supplement
doses/combinations, are required to support this finding.

4.5.4 Serum and retinal response to supplementation with the macular carotenoids

There have been many published studies on serum (Table 4.5) and retinal response (i.e.
MPOD; Table 4.6) to supplementation with the macular carotenoids, in normal and in
AMD subjects, and it is clear that serum carotenoid levels and MPOD rise in response
to supplementation with MP’s constituent carotenoids. However, it is important to point
out that the magnitude of response is influenced by many factors, including the type of
carotenoid used (i.e. L, Z, MZ, independently or in combination), the concentration of
carotenoid present in the supplement (dose), the duration of supplementation (time),
individual characteristics (e.g. adiposity), and baseline MP levels.323
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Table 4.5 Serum carotenoid response per milligram of supplemental carotenoid, following supplementation with the macular carotenoids.
Principal Author

Journal

Year

n

Age

L(mg)

Z(mg)

MZ(mg)

Normal Subjects
Bone et al.
Bone et al.

JN
ABB

2003
2010

Koh et al.
Berendschot et al.
Zhao et al.
Hughes et al.
Hartmann et al.

EER
IOVS
AJCN
JID
AJCN

2004
2000
2006
2000
2004

Schalch et al.
Bone et al.
Thürmann et al.

ABB
JN
AJCN
AJCN
ABB

2007*
2003
2005
2005
2007*
2008
2008
2011
2000
2003
2010
2008
2007*
2012

19-59
18-30
18-30
18-30
51-64
58-72
18-50
50-70
26–56
28-38
28-43
18-45
21-53
21-37
24-34
18-45
18-45
64-86
60-80
18-41
33–54
42-53
18-60
21-46
21-58
56±8
51±13

2.4
5
10
20
20
10
10
12
15
4.1
20.5
10.7
10.2
10
12
12
19.7
30
3.7
10.8
5.5
20
10

1
10
12.6
30
0.58
2.9
0.8
11.9
2
0.5
1
1
1.5
0.8
1.2
1.4
1
2

-

IOVS
AJCN
VR
AJCN
JN
CER
BJN
NM

21
17
22
24
14
6
8
8
21
10
10
16
2
8
8
18
19
40
11
61
7
2
5
19
10
12
12

Schalch et al.
Huang et al.
Johnson et al.
Nolan et al.
Johnson et al.
Bone et al.
Connolly et al.
Thurnham et al.
Bone et al.
Loughman et al.‡

7.3
8
14.9
10
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L Response
(µmol/L/mg)

Z Response
(µmol/L/mg)

MZ Response
(µmol/L/mg)

Duration

0.100 (p <0.05)
0.035 (p<0.0001)
0.071 (p<0.0001)
0.053 (p<0.0001)
0.071 (p<0.0001)
0.168 (p n/a)
0.072 (p<0.001)
0.116 (p<0.01)
0.092 (p<0.01)
0.093 (p n/a)
0.064 (p n/a)
0.078 (p n/a)
0.037 (p n/a)
0.041 (p n/a)
0.022 (p<0.001)
0.053 (p<0.001)
0.018 (p<0.05)
0.063 (p n/a)
0.019 (p<0.05)
0.056 (p<0.01)
0.014 (p n/a)
0.014 (p=0.139)
0.066 (p=0.001)

0.152 (p n/a)
0.087 (p n/a)
0.064 (p n/a)
0.014 (p n/a)
0.063 (p n/a)
0.046 (p n/a)
0.046 (p n/a)
0.030 (p n/a)
-0.003 (p>0.05)
0.016 (p<0.003)
0 (p n/a)
-0.028 (p>0.05)
0.088 (p<0.001)
0.121^ (p n/a)
0.010 (p=0.045)
0.015 (p=0.023)

0.006 (p<0.05)
0.026 (p=0.004)
0.009 (p=0.001)

24
20
20
20
20
19
12
8
4
42
42
24
12
42
42
24
24
24
16
48
15
20
8
3
17
24
24

AMD Subjects
CER
2010
5
18-60
3.7
0.8
7.3
0.012 (p<0.05)
0.035 (p>0.05)
0.004 (p<0.05)
8
Connolly et al.
EER
2004
7
60-81
10
0.157 (p n/a)
19
Koh et al.
IOVS
2006
15
60+
10
0.5
0.079 (p<0.0001)
0.076 (p<0.0001)
24
Khachik et al.
EER
2007
97
51-87
12
1
0.036 (p<0.001)
0.004 (p=0.007)
36
Trieschmann et al.
Abbreviations: L=lutein; Z=zeaxanthin; MZ=meso-zeaxanthin; n=number of subjects participating in study; Age=age range (years) of subjects in study; duration=duration of
supplementation (weeks); ABB=Archives of Biochemistry and Biophysics; BJN=British Journal of Nutrition; IOVS=Investigative Ophthalmology and Visual Science;
AJCN=American Journal of Clinical Nutrition; JN=Journal of Nutrition; JID=Journal of Infectious Diseases; VR=Vision Research; EER=Experimental Eye Research;
CER=Current Eye Research; NM=Nutrition and Metabolism; OPO=Ophthalmic and Physiological Optics; (-)=data unavailable; n/a=not available.
*free (un-esterified) carotenoid supplement
†includes MZ supplementation
^refers to total Z+MZ
‡ARVO abstract
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Table 4.6 Studies reporting on macular pigment optical density response to supplementation with the macular carotenoids.
Principal Author

Year

n

Age

L
mg/d

Z
mg/d

MZ
mg/d

Duration
(weeks)

Tec

Retinal
ecc

PF

MP
rise

Sig.

30-65
30-65
30-65
33-54

11.2
0.4
10.8
11.2

0.6
0.3
0.3
0.57

0
0
0
0

15
15
15
15

HFP
HFP
HFP
HFP

0.5°
0.5°
0.5°
0.5°

5.5°
5.5°
5.5°
5.5°

~ 0.05
~ 0.05
~ 0.05
~ 0.07

p < 0.05
p < 0.05
p < 0.05

NORMAL subjects - supplement modification
Landrum et al.326
1997
2
42-51
327
Berendschot et al.
2000
8
18-50
8
18-50
Aleman et al.328
2001
8
11-59
8
11-59
8
11-59
8
11-59
Bone et al.329
2003
2
19-59
1
53
21
19-59
12
19-60
2
26-27
Koh et al.330
2004
6
64-81
Bernstein et al.331
2004
8
<61
8
<61
Bone et al.332
2007
10
21-58
Wenzel et al.333
2007
3
24-52
3
24-52
3
24-52
3
24-52
Schalch et al.334
2007
23
18-45
23
18-45
23
18-45
Johnson et al.335
2008
11
60-80
11
60-80
Stringham et al.336
2008
40
17-41

30
10
10
20
20
20
20
30
0
2.4
20
5
20
20
20
5.5
30
30
30
30
10.7
0
10.2
12
12
10

0
0
0
0
0
0
0
1.5
30
0
0
0
0
0
0
1.4
2.7
2.7
2.7
2.7
0.8
12.6
11.9
0.5
0.5
2

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
15
0
0
0
0
0
0
0
0
0
0

20
12
12
24
24
24
24
20
17
17
17
17
20
16
16
17
17
17
17
17
17
17
17
16
16
24

HFP
SLO
SA
HFP
HFP
HFP
HFP
HFP
HFP
HFP
HFP
HFP
HFP
HFP
RRS
HFP
HFP
HFP
HFP
HFP
HFP
HFP
HFP
HFP
HFP
HFP

0.75°
0.75°
0.75°
0.17°
0.5°
1°
2°
0.75°
0.75°
0.75°
0.75°
0.75°
0.5°
0.75°
0.75°
0.33°
0.5°
1°
2°
0.5°
0.5°
0.5°
1.5°
3°
0.25°

8°
14°
5-7°
5-7°
5-7°
5-7°
8°
8°
8°
8°
8°
6°
8°
8°
7°
7°
7°
7°
5.5°
5.5°
5.5°
7°
7°
10°

~ 0.20
~ 0.05
~ 0.04
0.07
0.07
0.08
0.04
~ 0.20
~ 0.07
~ 0.04
~ 0.06
~ 0.03
0.07
0.04
76RC
~ 0.07
0.07
0.07
0.046
0
0.06
0.01
0.06
0.19

p = 0.022
p < 0.001
p = 0.04
p < 0.05
p > 0.05
p < 0.05
p < 0.001
p < 0.002
p< 0.002
p = 0.04
p > 0.1
p = 0.04
p < 0.05
p < 0.01
-

NORMAL subjects - dietary modification
Hammond et al.324
1997
10
2
1
Johnson et al.325
2000
7

96

Connolly et al.287

2010

Nolan et al.337

2011

Loughman et al.170

2012
2012

40
40
40
40
5
5
61
62
12
12

AMD subjects
Principal Author

Year

n

Koh et al.330
Trieschmann et al.338
Richer et al.339
Connolly et al.287

2004
2007
2007
2010

Weigert35
Richer280

2011
2011

Beatty et al.

2012

7
108
76
5
5
84
25
25
10
246/63‡

17-41
17-41
17-41
17-41
30-85
30-85
18-41
18-42
56±8
51±13

10
10
10
10
3.7
3.7
12
12
20
10

2
2
2
2
0.8
0.8
1
1
2
2

0
0
0
0
7.3
7.3
0
0
0
10

24
24
24
24
8
8
52
52
24
24

HFP
HFP
HFP
HFP
HFP
HFP
HFP
HFP
HFP
HFP

0.5°
1°
3°
7°
0.25°
0.5°
0.25°
0.5°
0.25°
0.25°

10°
10°
10°
10°
7°
7°
7°
7°
7°
7°

0.16
0.1
0.07
0.03
0.16
0.16
0.12
0.11
0.09
0.13

p < 0.05
p < 0.05
p = 0.001
p = 0.001
p = 0.092
p = 0.002

Age

L
mg/d
20
12
10
3.7
3.7
15
0
9
9
12

Z
mg/d
0
1
0
0.8
0.8
0
8
8
0
0.6

MZ
mg/d
0
0
0
7.3
7.3
0
0
0
0
0

Duration
(weeks)
20
24
52
8
8
24
52
52
52
104

Tech

Retinal
ecc.
1°
1°
1°
0.25°
0.5°
0.25°
1°
1°
1°
central 3°

PF

MP
rise
0.07
0.1
0.25
1.6
1.6
0.08
0.13†
0.20†
0.18†
61 (RC)

Sig.

64-81
51-87
30-85
30-85
72±9
76±9
74±11
74±9
55+

HFP
AF
HFP
HFP
HFP
HFP
HFP*
HFP
HFP
RRS

6°
6°
7°
7°
7°
7°
7°
7°
7°
-

p > 0.05
p < 0.001
p < 0.05
p < 0.05
p < 0.05
p <0.001
p = 0.03
p = 0.06
p = 0.03
p < 0.001

Abbreviations: L = Lutein (mg/day); Z = Zeaxanthin (mg/day); MZ = Meso-zeaxanthin (mg/day); Tec = technique used to measure MPOD (macular pigment optical density);
n = Number of subjects participating in study; Age = Age range (years) of subjects in study; Retinal ecc.= retinal eccentricity; PF = Parafovea stimulus; AJCN = American
Journal of Clinical Nutrition; IOVS = Investigative Ophthalmology and Visual Science; ABB = Archives of Biochemistry and Biophysics; OPO = Ophthalmic and
Physiological Optics; EER = Experimental Eye Research; NM = Nutrition and Metabolism; OPT = Optometry; JN = Journal of Nutrition; OVS = Optometry and Vision
Science; RC = Raman counts; ODU = Optical density units; HFP = Heterochromatic flicker photometry; AF = Autofluorescence; SLO = Scanning Laser ophthalmoscope; SA
= Spectral Analysis; AMD = Age related Macular Degeneration; RRS = Resonance Raman Spectroscopy; RC = raman count- = data unavailable.
*modified HFP technique (QuantifEYE®)
†measurements from right eyes in the study
‡246 at baseline, 63 at year 2
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The data suggest that supplementation with all three macular carotenoids results
in the greatest and broadest response in terms of MP augmentation and changes in its
spatial profile. Therefore, and given that the antioxidant capacity of MP is maximised in
the presence of all three macular carotenoids,319 and where the objective is to augment
MP and to thereby putatively confer protection against AMD, current evidence suggests
that supplementation with all three macular carotenoids is most likely to (1) limit
(photo)-oxidative retinal injury with a consequential reduction in risk of AMD
development or progression and (2) maximally enhance visual performance and
ameliorate GD.
Interestingly, a study by Bone and Landrum has shown that serum levels of L
and Z rise and fall rapidly following commencement and discontinuation of
supplementation with the macular carotenoids, respectively. In contrast, MP optical
density increases more slowly from baseline following commencement of
supplementation with the macular carotenoids, and returns to baseline levels more
slowly following discontinuation of supplementation, reflecting a slow biological
turnover or these carotenoids at the macula.326 A recent study investigated the impact of
dietary deprivation of all L- and Z-containing foodstuffs on serum carotenoid levels and
on MPOD, over a period of six weeks. In brief, a rapid decline in serum levels of L and
Z, and also in MPOD, was observed in response to this dramatic dietary change by
week three. The resumption of a normal diet resulted in a 40% recovery in MPOD
levels within two weeks.340

4.5.5 Conclusion
In summary, the properties of MP, namely its central retinal location, its pre-receptoral
filtration of damaging short-wavelength light and its ability to quench free radicals,
suggest that it plays a key role in the aetiopathogenesis of AMD and its progression, in
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addition to contributing to the optimisation of visual performance (in subjects with and
without disease). Level 1 evidence has demonstrated that supplemental dietary
antioxidants reduce the risk of vision loss in AMD, although evidence of this quality for
supplementation with the macular carotenoids is still lacking. The visual performance
hypothesis of MP, on the other hand, is now accepted, with many clinical trials
reporting that macular carotenoid supplementation demonstrably enhances visual
performance in subjects with and without disease. Clinical trials have repeatedly shown
that dietary supplementation with the macular carotenoids (L, Z and/or MZ) results in
augmentation of MP, and the best response in terms of augmentation, changes in spatial
profile of the pigment, global fortification of the antioxidant defenses of the tissue to be
protected and in terms of visual performance, appears to be a supplement containing all
three macular carotenoids. These trials (involving all three macular carotenoids),
however, have been limited by several factors, including small numbers of subjects and
inadequate masking, such that definitive conclusions cannot yet be drawn.
To effectively investigate the putative protective role of carotenoid supplements
in AMD, including a possible role in prevention of this condition, an RCT of
considerable length (at least a decade) would be required. As a consequence, it is
important that we appraise the totality of currently available evidence in order to assist
eyecare professionals to make well-informed decisions with respect to the prevention
and/or delay of AMD onset and/or its progression. In this context, it would appear that
supplementation with the macular carotenoids offers the best means of fortifying the
antioxidant defenses of the macula, thus putatively reducing the risk of AMD and/or its
progression, and of optimising visual performance.

This work is divided into four principal areas; the rationale, methods, results and
discussion of each is contained within its own chapter (Chapters 5-8).
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Chapter 5. Visual performance in patients undergoing intravitreal
ranibizumab for neovascular AMD.
5.1 Study rationale, aims and objectives.
Considering the emergence of new therapies and treatment regimens for subjects with
nv-AMD, and considering the complex nature of the visual experience, it is essential
that visual performance is not judged solely on the outcomes of one visual task (most
often, CDVA), either in clinical or research settings. This study was designed to assess
the effect of anti-VEGF therapy in cases of nv-AMD on a subject’s visual performance
and experience, through a range of psychophysical tests, which take into greater
consideration the complexity of the visual environment.
There is a strong rationale to support the administration of anti-VEGF therapy in
spite of good presenting CDVA,341 as early treatment is essential in terms of preventing
visual loss. However, it is well documented that the extent of visual improvement
following anti-VEGF therapy is inversely dependent upon presenting CDVA, i.e.
presenting CDVA is a prognostic indicator for improvement in CDVA following
treatment, with greater acuity benefits accruing in those with poorest baseline
CDVA.342, 343 Therefore, a patient who presents for anti-VEGF therapy with relatively
good CDVA e.g. 6/7.5, will not exhibit the same level of improvement as a patient who
presents with CDVA of 6/30, for example, purely due to ceiling effects. This finding
may lead one to believe that the treatment is not having a functional benefit in the case
of the high acuity patient, whereas there may be important parameters of visual function
that are improving/changing but that are not being detected by a measure as crude as
CDVA. In addition, if other measures of vision are depleted (and CDVA preserved),
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then CDVA is also not detecting a certain amount of functional loss, which is important
with respect to (re)treatment strategies.
The vast majority of studies investigating visual function in subjects with nvAMD (i.e. assessing disease severity, determining when to commence, cease or
recommence treatment), have depended, for the most part, on the measurement of
CDVA. Considering the complexity of visual experience, and the known range of
methods available to ascertain a more realistic and thorough appreciation of visual
function, it would seem reasonable to conclude that the full extent of the effect of antiVEGF therapy on visual function has yet to be elucidated. The current study has sought
to more deeply probe and investigate visual performance beyond CDVA, both in terms
of understanding how to evaluate disease severity, and also in terms of assessing
functional outcomes of visual performance following intravitreal anti-VEGF therapy in
subjects with nv-AMD.

5.2 Methods
5.2.1 Study design

Suitability for inclusion in this prospective study was confirmed by an ophthalmologist,
in compliance with the following inclusion criteria: the study eye must be suffering
from active nv-AMD, and be scheduled to commence, recommence or continue a
course of intravitreal ranibizumab and have a baseline CDVA of logMAR 0.7 or better.
Exclusion criteria included a history of diabetes mellitus, the presence of physical or
mental impairment, or any visually important ocular comorbidity. All patients were
recruited from the Institute of Eye Surgery, Whitfield Clinic, Waterford. In cases where
both eyes were being treated, the eye with the better CDVA was selected for the study.
Ethics approval was granted by the Dublin Institute of Techonology Ethics Committee
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(Appendix 1), and informed consent was secured from each subject (Appendix 2). The
research was conducted in accordance with the principles of the Declaration of Helsinki.
A diagnosis of nv-AMD was made by a retinal specialist on the basis of clinical
examination, OCT and FFA. The standard regime of treatment (following initial
diagnosis) included three consecutive monthly injections, followed by monthly
evaluation for further treatment. Subsequent injections were administered based on
signs of lesion activity on OCT and FFA, as per previously described protocol,344 and
typically upon resolution of fluid and/or cysts (determined by OCT), one more
intravitreal injection of ranibizumab was administered. Two weeks following that
intraocular injection, FFA was repeated. Where lesion inactivity was angiographically
confirmed, treatment was discontinued.
Data were collected at baseline, and at monthly intervals (midway between
monthly ranibizumab injections) within the 11 month study period. An exit visit was
defined as the patient’s final study visit (two weeks after the preceding and final
intravitreal injection in the study). Subjects exited the study either when the study
period came to an end (n=20; after a maximum follow-up of 11 months; some of these
patients may have continued with further intravitreal injections of ranibizumab
following closure of the study), when treatment was discontinued on clinical grounds
(n=23; in these cases it was deemed, clinically, that maximum realisable benefits of
treatment had been achieved i.e. fluid/cysts resolution and absence of leakage on FFA),
when the patient was unable to continue in the study for unrelated health reasons (n=2)
or when the patient elected to discontinue his/her participation in the study (n=2).
Patients were naïve to all the tests involved, with the exception of CDVA.
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5.2.2 The technique for the administration of an intravitreal injection of a
pharmacological agent (ranibizumab 0.5mg)

Valid and informed consent was obtained prior to the procedure, which included
informing the patient of all risks inherent in the procedure. Patients were instructed to
instill prophylactic antibiotics drops (chloramphenicol or exocin [ofloxacin]) into the
conjunctival sac four times daily for three days prior to the date of each injection.
On the day of injection, the following steps were taken: the pupil was
pharmacologically dilated (tropicamide); povodine iodine was instilled into the
conjunctival sac ten minutes prior to the injection; anesthetic (proxymethacaine) was
instilled into the conjunctival sac five minutes prior to the injection; povodine iodine
was once again instilled into the conjunctival sac approximately two minutes prior to
the injection.
The technique of intravitreal injection. Patient was supine. A sterile drape was
used to cover the eye, and a speculum was used keep the eye open during the procedure.
The intravitreal pharmocological agent (ranibizumab 0.5mg) was drawn up in a sterile
syringe. Using a callipers, the intravitreal pharmocological agent was then injected (at
90 degrees to the sclera), through the pars plana into the vitreous cavity (3.5mm and
4mm from the limbus in pseudophakic and phakic eyes, respectively; Figure 5.1). Using
the indirect ophthalmoscope, the central retinal artery was examined (the central retinal
artery should be either pulsatile and/or pink in colour, and if pale in colour and nonpulsatile, paracentesis should be considered). A topical antibiotic was then instilled, the
lid speculum removed, and the eye and lid margins rinsed with sterile saline. Following
the procedure, the patient was told to continue the antibiotic drops for five or six days,
and to contact the eye clinic should any problems arise (a detailed information leaflet
with contact numbers, was furnished to the patient with respect to such a need).
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Figure 5.1 Left: The administration of intravitreal ranibizumab. Image courtesy of the
Institute of Eye Surgery, Waterford, Ireland. Right: Schematic representation of an
intravitreal injection through the pars plana. Image obtained from My Vision Test www.myvisiontest.com/newsarchive.php?id=1321

5.2.3 Visual acuity

CDVA was measured for the study eye monocularly using the logMAR chart provided
by Test Chart 2000 PRO® (Thomson Software Solutions, Herts, UK) at a test distance
of 4m. The logMAR form of the ETDRS letterset were selected due to the benefits of
regular logarithmic progression and equal legibility of letters.345, 346 CDVA was
determined with the patient’s best subjective (distance) refraction. All tests were
performed at a constant room illuminance of 870 lux. The patients were told that the
charts have letters only, that they are allowed to guess, and that they should read slowly
to achieve the best identification of each letter. The letters were presented in one
isolated row at a time. The testing did not proceed until the patient had given a definite
response. A visual acuity rating (VAR) was calculated for each patient (see below).29
Points were awarded for all fully read lines. At the first incompletely read line, the
letters of the line were changed using the software’s randomisation function and the
patient was encouraged to attempt to read the new line. This process was repeated
resulting in the patient being shown three different lines of letters of equal size. Each
time, the score was recorded (each correctly identified letter was awarded one point, and
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a full line of five correctly identified letters was awarded five points) and an average of
the three scores was taken as the score of the line with the smallest legible letters read.
After that, the next (smaller) line was presented and the patient was encouraged to read
it. If any of the letters were identified correctly, one point per letter was added to the
previous score and that was the VAR for the eye of that patient. For example, a patient
achieving CDVA of logMAR 0.0 would receive a VAR of 100, and all additional letters
identified would be added, so that logMAR -0.1, for example, would be recorded as
105, while logMAR 0.1 would be recorded as 95.

5.2.4 Contrast sensitivity and glare disability (Functional Vision Analyzer™)

CS was measured using the Functional Vision Analyser™ (FVA; Stereo Optical Co.,
Inc – Chicago, USA), a sine wave grating contrast test system. CS was measured for the
study eye, monocularly, at a constant room illuminance of 1.5 lux, with distance
correction. Each patient was asked to look at five linear sine-wave grating charts of 1.5,
3, 6, 12 and 18 cpd, respectively. Each chart consisted of nine circular patches
containing gratings of decreasing contrast. The background of each patch tapered into a
grey field (i.e. Gabor patch) to maintain the retinal illumination and avoid ghost images.
The nine patches were arranged in two rows (five patches above, four patches below).
The contrast step between each patch was 0.15 log units i.e. there was a 50% loss of
contrast between consecutive patches. The patch subtended an angle of approximately
1.7 degrees. Patients were instructed to identify the orientation of the gratings by
choosing one of three options: gratings tilted left (+15°), gratings upright (0°) or
gratings tilted right (-15°). Patients were instructed not to guess the orientation of the
gratings (in order to optimize the accuracy of the measurement, as guessing would yield
a 33% chance of a correct response). In cases of uncertainty, patients were advised to
report that they were unable to determine the orientation of the gratings. The three105

alternative forced-choice method was stopped after the first incorrect or “don’t know”
response, and the last correct answer was recorded. The CS corresponding to that
grating was taken as the CS score for that spatial frequency. The test was then repeated
for the other spatial frequencies (increasing while testing), with the grating charts
mounted as slides on a rotatable drum.
Testing was performed under: mesopic (3 cd/m2) and photopic (85 cd/m2)
background illumination conditions, in that order. Each patient was tested at a
maximum of nine contrast levels at five spatial frequencies. If a subject could not
determine the orientation of the highest contrast stimulus at any particular spatial
frequency, they were given a nominal baseline value, which was chosen as half of the
lowest CS value achievable for the particular spatial frequency.
The procedure was repeated in a similar manner for GD, but with an additional
glare light; 1 Lux for mesopic conditions, and 10 Lux for photopic conditions, inducing
an estimated luminance increase of 30% and 12%, respectively. Glare light was
achieved by 12 inbuilt white light emitting diodes (LEDs) arranged circumferentially in
an oval pattern surrounding the gratings (ranging from 4.5° to 6° from central
fixation).347 The LED glare source rendered a daylight simulating colour temperature of
6500°K, and a spectral emission profile with a single large peak at 453 nm (close to
peak MP spectral absorbance).

5.2.5 Retinotopic ocular sensitivity

ROS was measured by performing microperimetry, using the Microperimeter MP 1®
(Nidek Technologies Srl, 6/A - 35020 Albignasego, Padova, Italy). ROS performs a
similar function to visual field analysis, but has the added advantage of being able to
test at the site of a lesion.
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ROS was measured monocularly and without correction, at a constant room
illuminance of 1.5 lux. The study eye was pharmacologically dilated with one drop of
guttae Tropicamide BP 1% w/v minims® (Chauvin Pharmaceuticals Ltd, Ashton Road,
Harold Hill, Routond, Essex, RM3 8SL, UK) fifteen minutes prior to the test. The other
eye was covered for the duration of the test. The patient was given a hand-button, and
was instructed to fixate at the presented fixation target, a red cross spanning three
degrees from fixation. They were informed that they will see small lights appear, either
on the fixation target or close to it, and were instructed to press the hand-button every
time they see such a light, no matter how dim or bright it may appear.
The central 16 degrees of fixation were examined. The examination pattern
comprised 21 stimuli, presented under mesopic background illumination of 1.27 cd/m2
(4 asb). The stimulus size was Goldmann III (26 minutes of arc), of white colour and of
200 msec presentation duration. Stimulus intensity ranged from 20 dB (dimmest [4
asb]) to 0 dB (brightest [400 asb]); an increase of 1 dB equates to 0.1 log reduction in
stimulus intensity (asb). In order to reduce testing time, the threshold values were
determined for four paracentral loci (one in each quadrant of the visual field being
examined); the initial attenuation of the stimulus was set at 10 dB, in this case. The
thresholds for these four test loci were then used as the starting intensities for testing
sensitivities of the remaining loci in each of the corresponding quadrants. This protocol
has been previously utilised.348 Thresholds were determined using a 4-2 linear staircase
strategy (which uses one reversal to determine threshold). At any given locus, the initial
(pre-test) intensity value was presented, and depending on whether this stimulus was
seen or not seen, the intensity of the stimulus was then either decreased or increased by
4 dB, respectively. At reversal, the intensity of the stimulus then increased/decreased in
increments corresponding to 2dB, until such a point as the stimulus was no longer
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detectable. The eye tracking function was used for the duration of the test. Once all 21
stimuli had been presented, a fundus colour photograph of 45 degrees of the field of
view was taken using the built-in colour camera (resolution 1392x1038) using a flash
intensity of 10 W/second. ROS was calculated for three areas: fixation (one stimulus);
within central 5 degrees (including fixation) using an average of nine stimuli; and
within 16 degrees of fixation (average of 21 stimuli).

5.2.6 Reading performance

Reading speed and near VA were measured with an English version of the standardised
Radner Reading Chart (can assess both reading acuity and reading speed), the reliability
and reproducibility of which have been established, both for subjects with normal
vision, and for those with visual impairment.349 The reading chart consists of "sentence
optotypes” that are highly comparable in terms of number of words (14 words), word
length, position of words, lexical difficulty and syntactical complexity. Language
specific characteristics were taken into account as were the number of letters and
syllables per word, line, and sentence. Reading ability was tested monocularly with the
patient’s reading correction on. The patient was instructed to hold the chart at a distance
of 40cm, which was measured by the examiner, advised not to alter it during the
examination, and was monitored for compliance by the examiner throughout the
procedure. The sentences were covered with a piece of paper, and the patient was asked
to uncover sentence after sentence, reading each one aloud as quickly and as accurately
as possible. Reading acuity (the sentence of smallest print that was read with a fluency
i.e. in less than 20 seconds) was expressed in logRAD (logarithm of the reading acuity;
the angular subtense of these letters at the fixation distance used; the reading equivalent
of logMAR). Reading errors were calculated by noting the number of missed or
misspoken word(s) in the sentence. Errors were counted, even when immediately
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corrected, and those of the last sentence were then included in the calculation of the
reading acuity score (logRAD score = logRAD + 0.005, for each incorrectly read word
of a subject’s last sentence). For example, a subject reads the 0.3 logRAD line and
incorrectly reads two words, his/her score is 0.3 + (2 x 0.005) = 0.310.
Reading speed was measured in seconds using a stopwatch (www.onlinestopwatch.com). Reading speed (wpm) was calculated for each sentence (acuity level)
based on the number of words in a sentence and the time required to read the sentence
(14 words x 60 seconds divided by the reading time in seconds). Reading speed was
calculated at each visit based on the highest level of logRAD acuity achieved at baseline
i.e. even if the logRAD value improved at the following visit, the best baseline logRAD
value was used to calculate the reading speed to maintain continuity. Mean reading
speed was calculated using the reading speed of each of the sentences read (across the
range of print sizes) at any given study visit.

5.2.7 Preferential hyperacuity

Preferential Hyperacuity was measured using the Reichert Foresee PHP® Preferential
Hyperacuity Perimeter (Figure 5.2). The PHP exploits the principle of visual attention
being attracted to a more prominent stimulus350 and uses this to determine the size of
any pathological distortion (PD) that may be present. The stimulus generated is a linear
series of horizontal or vertical white dots (on a black background), and utilises the
technique of dot misalignment to create a discontinuity, or artificial distortion (AD), in
the line contour (see example on monitor in Figure 5.2). Depending on the size of the
AD the patient may see one of four things: only the AD (if there is no PD or the PD is
small), only the PD (if the AD is small), both the AD and the PD (if the two are of
similar size), or neither (if the AD falls on a region of scotoma).351
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Figure 5.2 The Reichert Foresee Preferential Hyperacuity Perimeter®. Image obtained
from Grafton Optical.
An explanatory tutorial and trial run were performed before each test (according
to the standardized protocol) and the patients were supervised for the duration of the
test. The patient’s chin was placed on an adjustable rest at a fixed distance from the
screen (50cm), so that the patient’s line of sight was perpendicular to the centre of the
screen. The normal reading correction was worn and the fellow eye was occluded. A
trial frame was also available to provide the appropriate refractive correction, if required
i.e. in cases where the subject presented with bifocals or multifocals, or without his/her
reading spectacles.
The device assesses approximately a total of 500 data points within the central
14° of the subject’s visual field, each data point at a spatial resolution of 0.75°. Each
stimulus was ﬂashed (for 160ms) and the patient was asked to identify the location of
perceived misalignments at each stimulus presentation, using a pen, on the touchsensitive screen. The technique relies on the presumption that when photoreceptors are
anatomically undisturbed, no extra misalignment is perceived, other than the AD
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presented. However, if the subject’s photoreceptors are slightly misaligned due to, for
example, the presence of fluid as a result of CNV, or due to the elevation of the RPE as
a result of drusen, additional pathological misalignments can be perceived by the patient
and recorded by the PHP.

The PHP output is presented in Figure 5.3 and its features are described, as follows:
-

Within/Outside normal limits: Within normal limits means that similar visual
field findings are found in the normal population of intermediate AMD patients
(dry AMD) in the normative database. Outside normal limits means that similar
visual field findings are found in the population of CNV patients in the
normative database. If the deviation is outside normal limits, a “p” value is
given. For example, p < 1% means that the visual field defect in this test is
found among 1% of the intermediate AMD population. Categories for p values
are: p < 10%, p < 5%, p < 1%.

-

Reliability is determined by two indices, 1) False negative errors: the frequency
with which the patient failed to respond to stimuli expected to be visible and 2)
False positive errors: the frequency with which the patient responded to stimuli
that could not have been seen. The test is reliable only if both reliability indices
are reliable, which is reflected in an overall reliability result (“Yes” or “No”).

-

Hyperacuity deviation map: displays a spatial representation of the patient’s
metamorphopsia (compiled using all the test parameters). The cross in the centre
represents fixation. Each point in the map has a colour corresponding to the
level of disturbance at this point. A metamorphopsia scale legend is provided,
where darker colours correspond to larger disturbances.

-

A test score: an arbitrary score generated by the algorithm used to compare the
presenting results to the normative database of intermediate and CNV patients.
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The score is interpreted by looking at the p-value, which gives an indication of
the chance of a test with this score of being an intermediate AMD (non-CNV)
patient. In the example below (Figure 5.3), there is a 0.93% chance that this
subject does not have intermediate AMD and is, therefore, very (99.07%) likely
to have CNV. Of note, more recent versions of the PHP have removed the test
score, which was deemed to be causing confusion.
-

Numbers of clusters: the number of detected metamorphopsia clusters in the
data.

-

Total Integrated Intensity: Displays the progression in time of the integrated
intensity of the distortion detected over all clusters in the test.

-

Total Area: Displays the progression in time of the total areas of distortion (area
of all clusters in the test) in square degrees.
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Figure 5.3 The Reichert Foresee Preferential Hyperacuity Perimeter® output.

5.2.8 Assessment of retinal thickness

Optical Coherence Topography (OCT) was performed using a Topcon 3D OCT-1000®
(version 3.01, Mark I; Topcon Corporation, Tokyo, Japan) on each patient at each visit,
as part of their normal pre- and post-injection assessment.
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OCT is a non-invasive, cross sectional imaging technique, which uses lowcoherence interferometry to produce a high resolution, two-dimensional image of
optical scattering from the internal microstructure of the eye.352 Image resolutions of 1–
15 µm (twice the magnitude of conventional ultrasound) can be achieved.
Approximately twenty minutes following pupil dilation with Tropicamide (as
described in ROS section, above), OCT was performed on each eye, separately. The
patient placed his/her chin on a chinrest, was asked to look ahead at the centre of a large
cross and keep their eyes open for five seconds.
The central 1 mm mean foveal thickness (MFT), which has also been described
as central subfield thickness in previous studies, was obtained from typical ETDRS
macular thickness maps.353-356 Foveal thickness was defined as the distance between the
inner and outer boundaries of the scanned image, identified using a validated internal
algorithm, and did not include any fluid under the RPE.

5.2.9 Subjective Visual Function (NEI VFQ)

Subjectively perceived visual impairment in everyday life was evaluated using the NEI
VFQ-25, Version 2000 (Appendix 3). The NEI VFQ-25 was developed to measure
patients’ perception of vision-related function357-359 and is a reliable and valid visionspecific quality-of-life instrument.358, 360 It is also the most frequently used measure of
patient-reported, vision-related function in studies of nv-AMD.359, 361, 362 It has been
validated by a study which confirms the responsiveness of the NEI VFQ-25 to changes
in VA over time and the benefit of using it for a nv-AMD population receiving
pharmacologic therapy.363 Further studies have shown its effectiveness in detecting
differences in patients’ reading speed and CS.364, 365
The NEI VFQ-25 contains 25 questions that measure different components of
visual function, with thirteen additional optional items that enhance the reliability of
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certain activities, all grouped within subscales. The 38-question version was used in this
study. Scores range from 0 (worst) to 100 (best, perfect vision-related function). The 38
questions fall within 12 subscales: one general health subscale and eleven related to
vision including: general vision, near- and distance-vision activities, driving, visionspecific dependency, social functioning, role difficulties, peripheral and colour vision,
ocular pain, and mental health issues related to vision. The overall composite score (a
number between 0 and 100) is calculated by taking the mean of all the subscales,
excluding the general health subscale (see
www.nei.nih.gov/resources/visionfunction/manual_cm2000.pdf).
Two versions of the questionnaire are available; one, a self-administered
version, the other, examiner administered (used in this study). The questions, and the
possible answers, were read aloud by the examiner, and the patient was required to
verbally indicate their choice. The questionnaire was administered at baseline, six
months, and at the final study visit (either when their treatment concluded or the study
period ended). In cases where a patient had less than six study visits, the questionnaire
was administered at baseline and when the treatment concluded. Rasch analysis was
applied to the questionnaire data, according to a recently developed protocol,366 using
commercial software (WINSTEPS Rasch measurement computer program, version
3.70.0.2; Beaverton, Oregon [http://www.Winsteps.com]), thus calibrating item
difficulty and patient ability on the same scale. Values for the long-form visual function
score (LFVFS), near vision score (NVS) and overall composite score are reported in
this study. The overall composite score (a score between 0 and 100) combines the
scores of 11 subscales encompassing items related to socio-emotional state, and items
related to visual functioning. However, simply combining them in one common score
will not accurately reflect the contribution of each to this overall score. This has largely
been remedied through recently derived scales (socioemotional and visual functioning
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scales) in combination with Rasch analysis.229 Rasch analysis transforms raw nominal
numeric questionnaire values into a continuous scale, reducing noise and allowing for
parametric statistical analyses of the data.230
Since a clinically meaningful change in NEI VFQ is difficult to quantify, a
additional supplementary question was asked at every visit (excluding baseline), where
the patients were simply asked if their vision had “improved”, “deteriorated” or
exhibited “no change” since their most recent injection (supplementary questionnaire;
see Appendix 4). These results were used to generate an individual’s overall description
of his/her experience over the course of the study period. Eligibility for inclusion in this
aspect of the analysis required that an individual did not report both improvement and
deterioration over the course of the study.

5.2.10 Statistical Analysis

Descriptive statistics were calculated for all measured variables, including demographic,
ocular, psychophysical and morphological data, as well as data on subjective visual
functioning (the questionnaire). VAR scores were used for the statistical analysis of
CDVA data. Statistical analysis was performed using the software package PASW
Statistics 18.0 (IBM Corp., Somers, NY, USA).
Baseline and exit visit measures were compared using the paired-samples t test.
Correlations between observed changes in MFT (and MFV) and observed changes in
psychophysical measures following serial anti-VEGF therapy were investigated using
Pearson correlations. Power analysis, for the sample size of 43 subjects (following
dropouts), yielded the following results: for detecting a correlation of 0.5, the power of
a sample of this size is 0.94; for detecting a change of half a standard deviation on a
paired t test, the power is 0.89. Tests were 2-sided in all analyses and the 5% level of
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significance was used throughout. Bonferroni adjustment was incorporated when
multiple tests were performed.

5.3 Results
5.3.1 Baseline data

Forty-seven patients (47 study eyes) met the inclusion criteria and were recruited into
this study. Of the study eyes, 26 (55%) where pseudophakic and 21 (45%) were phakic,
with no eyes with visually important lens opacities included. Baseline data were
typically collected one or two days prior to intravitreal injection of ranibizumab in those
cases where a course of anti-VEGF therapy was commencing or recommencing. The
demographic, ocular, psychophysical and morphological data, as well as data on
subjective visual difficulty, are given in Table 5.1. Of the 47 eyes, it was possible to
obtain baseline measurements prior to the first injection (of that course of injections) in
16 participants who were commencing or recommencing treatment, one of whom did
not continue beyond baseline. It was hypothesised that data from the subgroup might
differ from study eyes where serial intravitreal treatment was already underway,
because of the recent (re)activation of nv-AMD in this subgroup, and therefore
warranted separate analyses. The remaining 31 study eyes were already undergoing
treatment when recruited into the study (mean [±sd] and range of duration of prior
treatment: 7 [±5] and 1-20 months, respectively). Eight of the 47 study patients were
concurrently undergoing serial intravitreal ranibizumab treatment in their fellow eye, at
enrolment. A total of 248 injections of ranibizumab were administered to the study eyes
over the course of the investigation. The mean (±sd) and range number of injections per
patient was 5.4 (±2.8) and 1-10, respectively, over the course of the study period.
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Table 5.1 Baseline demographic, ocular, psychophysical, morphological and subjective
visual difficulty data, in subjects with nv-AMD.
Variable
Demographic
Age (years)

n (%)

Mean (±sd)

Range

47 (100%)

72.02 (9.61)

53 – 97

Gender
Male
Female

11 (23.4%)
36 (76.6%)

Ocular
Eye
Right
Left

24 (51.1%)
23 (48.9%)

Psychophysical
CDVA
Study eye
Fellow eye

47 (100%)
47 (100%)

87.64 (9.04)
74.57 (31.15)

64 – 104
2 – 103

Reading performance
LogRad
Reading speed (wpm)
Mean reading speed (wpm)

47 (100%)
47 (100%)
47 (100%)

0.320 (0.2)
85 (27)
136 (35)

0.005 – 0.905
31 – 142
32 – 216

PHP
Total area
Total integrated intensity

35 (74.5%)†
35 (74.5%)†

54.53 (44.60)
11.10 (14.16)

0.00 – 166.4
0.00 – 54.60

CS (mesopic conditions)
Frequency (cpd)
1.5
3
6
12
18

46 (97.9%)†
46 (97.9%)†
46 (97.9%)†
46 (97.9%)†
46 (97.9%)†

20.43 (9.68)
29.28(18.81)
11.24 (9.45)
4.15 (1.03)
2.00 (0.00)

3.50 – 36.00
5.00 – 80.00
6.00 – 45.00
4.00 – 11.00
2.00 – 2.00

CS (photopic conditions)
Frequency (cpd)
1.5
3
6
12
18

46 (97.9%)†
46 (97.9%)†
46 (97.9%)†
46 (97.9%)†
46 (97.9%)†

22.10 (13.24)
35.74 (22.35)
20.59 (18.80)
5.67 (4.22)
2.48 (2.50)

3.50 – 71.00
10.00 – 114.00
6.00 – 64.00
4.00 – 22.00
2.00 – 18.00

GD (mesopic conditions)
Frequency (cpd)
1.5
3
6
12
18

46 (97.9%)†
46 (97.9%)†
46 (97.9%)†
46 (97.9%)†
46 (97.9%)†

11.46 (7.83)
16.54 (12.32)
7.65 (5.78)
4.09 (0.59)
2.00 (0.00)

3.50 – 36.00
5.00 – 57.00
6.00 – 33.00
4.00 – 8.00
2.00 – 2.00
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GD (photopic conditions)
Frequency (cpd)
1.5
3
6
12
18

46 (97.9%)†
46 (97.9%)†
46 (97.9%)†
46 (97.9%)†
46 (97.9%)†

20.31 (12.09)
35.98 (24.67)
19.28 (19.23)
5.78 (5.73)
2.39 (1.61)

3.50 – 71.00
5.00 – 114.00
6.00 – 90.00
4.00 – 30.00
2.00 – 12.00

Mean retinotopic ocular sensitivity (dB)
Fixation
45 (95.7%)†
Central 5°
45 (95.7%)†
Central 16°
45 (95.7%)†

8.71 (5.92)
9.70 (4.85)
11.02 (4.53)

0.00 – 20
0.44 – 19.56
1.40 – 19.10

Morphological (OCT)
MFT (µm)
MFV (µm)

232 (57)
0.18 (0.05)

126 – 403
0.10 – 0.32

47 (100%)
47 (100%)

Subjective visual disability
(questionnaire)
Composite score
47 (100%)
89.92 (8.12)
65.91 – 100.00
Rasch-scaled LFVFS
47 (100%)
-1.71 (1.37)
-6.07 – -0.07
Rasch-scaled NVS
47 (100%)
-2.19 (1.29)
-4.38 – 0.10
Abbreviations: nv-AMD=neovascular age-related macular degeneration; n=number of subjects;
CDVA=corrected-distance visual acuity; LogRad=log reading acuity; Reading speed (at best baseline
LogRad value); mean reading speed (for range of LogRad values); wpm=words per minute;
PHP=preferential hyperacuity perimeter; CS=contrast sensitivity; cpd=cycles per degree; GD=glare
disability; dB=decibel; OCT=optical coherence tomography; MFT=mean foveal thickness; MFV=mean
foveal volume; LFVFS=long-form visual functioning score;
†n≠47 as certain tests/measures could not be obtained or were unreliable

5.3.2 Follow-up data

Of the 47 patients recruited at baseline, four did not participate further. Of these, two
fell ill (one patient was immobile due to a car accident, the other [aged 97] was not well
enough to attend for further injections, and clinical review deemed that these events
were unrelated to intravitreal injections of ranibizumab). A further two withdrew from
the study for personal reasons. The mean (±sd) number of visits for the remaining 43
subjects was 6 (±2.6), with a range of 2-10 study visits. Patients were assessed, and data
collected, approximately two weeks following each monthly injection of ranibizumab.
An analysis (2-tailed paired t test) was performed to investigate which, if any, of
the measured parameters exhibited significant change over the course of the study
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period (Table 5.2). The two time points chosen for this purpose were baseline and exit
visits, respectively. An exit visit was defined as the patient’s final study visit (two
weeks after the preceding and final intravitreal injection in the study period). Therefore,
in some cases, the exit visit was associated with cessation of treatment (n=23) as it was
deemed, clinically, that maximum realisable benefits of treatment had been reached i.e.
no evidence of active CNV (on FFA). The remainder (n=20) coincided with the
termination of the study period (11 months; and these patients may have, therefore,
continued with further intravitreal injections of ranibizumab following closure of the
study).

120

Table 5.2 Baseline and exit data for study eyes in the entire study group and subgroup, between baseline and exit study visits.
Entire group

Subgroup

Baseline

Exit

Baseline

Exit

Variable

Mean (±sd)

Mean (±sd)

p

Bon.?

Mean (±sd)

Mean (±sd)

p

Bon.?

CDVA study eye

87.9 (9.3)

88.7 (10.3)

0.480

N

89.1 (12.1)

91.3 (13.1)

0.387

N

CDVA non-study eye

74.7 (30.2)

75.6 (30.1)

0.419

N

80.8 (23.3)

84.3 (21.9)

0.134

N

Reading performance
logRAD

0.33 (0.20)

0.28 (0.22)

0.032†

N

0.25 (0.18)

0.19 (0.19)

0.139

N

Reading speed

85 (28)

103 (46)

0.019

N

85 (26)

118 (56)

0.037

N

Mean reading speed

136 (36)

146 (42)

0.005

N

148 (28)

166 (36)

0.005

N

60.3 (45.4)

0.165

N

45.1 (32.8)

48.7 (46.0)

0.810

N

Preferential Hyperacuity Perimetry
Ta
51.2 (41.5)
Tii
CS (mesopic)*
Frequency (cpd)
1.5

9.8 (12.4)

11.9 (14.0)

0.250†

N

6.9 (6.2)

9.6 (11.4)

0.674†

N

19.47 (10.1)

30.22 (21.00)

0.003

N

20.30 (12.15)

39.43 (26.12)

0.008

N

3

28.93 (19.72)

42.02 (34.04)

0.004†

N

32.47 (24.01)

53.13 (33.87)

N

12.80 (11.19)

26.67 (25.14)

0.036
0.070

6

11.26 (9.78)

15.91 (17.32)

0.002†

Y

12

4.09 (1.17)

4.88 (2.27)

p<0.001†

Y

3.80 (0.77)

6.27 (3.35)

0.001†

Y

18
CS (photopic)*
Frequency (cpd)
1.5

1.98 (0.15)

2.37 (1.25)

p<0.001†

Y

1.93 (0.26)

3.07 (1.98)

0.001†

Y

21.50 (14.03)

27.22 (18.69)

0.163†

N

25.20 (18.18)

34.50 (23.06)

0.347

N

3

35.05 (23.68)

47.63 (30.12)

0.005†

N

40.00 (30.72

61.07 (32.54)

N

25.93 (22.52)

47.13 (42.60)

0.020
0.221

N

6

19.56 (19.28)

28.44 (30.98)

0.001†

Y

12

5.72 (4.00)

10.16 (15.29)

p<0.001†

Y

7.40 (6.53)

19.47 (23.08)

0.025

N

18

2.49 (2.59)

3.58 (4.01)

p<0.001†

Y

2.33 (1.59)

6.53 (5.82)

0.016

N

GD (mesopic)*
Frequency (cpd)
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N

1.5

11.10 (7.88)

18.76 (15.03)

0.002†

Y

12.40 (9.79)

27.87 (17.80)

0.019†

N

3

16.47 (12.63)

29.28 (23.67)

p<0.001

Y

17.93 (14.80)

42.13 (30.51)

Y

6

7.51 (6.02)

11.49 (11.71)

p<0.001†

Y

10.33 (9.77)

19.87 (16.83)

0.001
0.134

12

4.02 (0.77)

4.70 (2.89)

p<0.001†

Y

3.80 (0.77)

6.00 (4.72)

0.001†

Y

1.98 (0.15)

2.09 (0.43)

p<0.001†

Y

1.93 (0.26)

2.27 (0.70)

p<0.001†

Y

19.50 (12.57)

24.77 (14.71)

0.081†

N

20.40 (11.44)

30.80 (15.82)

0.220†

N

43.13 (30.86)

67.67 (39.65)

N

18

N

GD (photopic)*
Frequency (cpd)
1.5
3

35.16 (25.82)

47.33 (33.20)

p<0.001†

Y

6

19.04 (19.46)

28.42 (31.20)

0.001†

Y

26.13 (25.76)

46.93 (40.53)

0.039
0.069

12

5.84 (5.96)

7.86 (9.21)

p<0.001†

Y

7.53 (9.21)

13.80 (13.66)

0.022

N

18

2.40 (1.68)

3.63 (4.05)

p<0.001†

Y

2.73 (2.63)

6.67 (5.83)

0.021†

N

Mean ROS (dB)
Fixation

8.56 (5.91)

10.20 (5.71)

0.026

N

8.36 (7.32)

11.64 (6.72)

0.056

N

Central 5°

9.63 (4.83)

11.18 (4.48)

0.003

N

9.27 (6.46)

12.34 (5.17)

0.013

N

Central 16°

11.03 (4.49)

12.11 (4.00)

0.005†

N

10.32 (5.51)

12.55 (4.42)

0.017†

N

Optical Coherence Tomography
MFT (µm)
233 (59)

205 (40)

0.001†

Y

275 (64)

208 (25)

0.002

Y

MFV (µm)

0.16 (0.03)

p<0.001†

Y

0.22 (0.05)

0.16 (0.02)

0.002†

Y

-1.86 (1.61)

0.222†

N

-2.21 (1.85)

-2.38 (1.77)

0.414

N

0.18 (0.05)

Subjective visual function
Rasch-scaled LFVFS
-1.70 (1.41)

N

N
0.041†
Abbreviations: Bon.=significant following Bonferroni correction?; Y=yes; N=no; CDVA=corrected distance visual acuity; reading speed (at best baseline LogRad
Rasch-scaled NVS

-2.21 (1.32)

-2.49 (1.48)

0.210†

N

-2.48 (1.28)

-3.10 (1.28)

value); wpm=words per minute; mean reading speed (for range of LogRad values); CS=contrast sensitivity; mesopic=under mesopic conditions; cpd=cycles per
degree; photopic=under photopic conditions; GD=glare disability; ROS=retinotopic ocular sensitivity; dB=decibel; OCT=optical coherence tomography; MFT=mean
foveal thickness; MFV=mean foveal volume; NVS=near vision score.
*all tests were performed on log-transformed data
†non-parametric tests were used as data was not normally distributed.
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For the study group (n=43), a statistically significant improvement over time
was observed for the following parameters: reading acuity (p=0.03); mean reading
speed (p<0.01); reading speed at best baseline reading acuity (p=0.019); mesopic CS, at
all spatial frequencies (p<0.01 for all values); photopic CS at 3, 6, 12 and 18 cpd
(p<0.01, for all); mesopic GD, at all spatial frequencies (p<0.01, for all); photopic GD
at 3, 6, 12 and 18 cpd (p<0.01, for all); ROS at fixation (p=0.026) and within the central
5 and central 16 degrees of fixation (p<0.01) (Figure 5.4); MFT and MFV (p<0.01, for
both). Of note, there was no significant change in CDVA in the study group (Figure 5.5)
or subgroup (p>0.05, for all).

Figure 5.4 Box plot values for measures of mean retinotopic ocular sensitivity at
baseline and exit study visits at fixation, within the central 5 degrees of fixation and
within the central 16 degrees of fixation, for the entire study group (paired t test: p=
0.026, p=0.003 and p=0.005, respectively).
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Figure 5.5 Corrected distance visual acuity (CDVA) at baseline and at exit study visits
in the study group.
Possible correlations were investigated between baseline data and observed
changes in MFT over the course of the study period for the study group and subgroup to
investigate prognostic indicators for change in MFT. Significant associations are given
in Table 5.3. All other parameters were non-significant (p>0.05, for all). Figure 5.6
graphically represents the relationship between baseline ROS (within the central 5°) and
change in MFT.
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Table 5.3 Statistically significant correlations between baseline psychophysical
measures of visual function and change in mean foveal thickness (baseline to exit) for
the study group and subgroup.
Entire study group
Variable

Sig. after
Bonferroni?

Subgroup

Sig. after
Bonferroni?

CDVA

r
0.353*

p
0.020

No

r
-

p
-

-

LogRad

-

-

-

-0.762**

0.001

Yes

LogCSmesopic_3cpd

-

-

-

0.644*

0.013

No

LogCSmesopic_6cpd

-

-

-

0.716**

0.004

No

LogGDmesopic_1.5cpd

-

-

-

0.639*

0.014

No

LogGDmesopic_3cpd

-

-

-

0.685*

0.007

No

LogGDphotopic_6cpd

-

-

-

0.735**

0.003

No

ROS fixation

0.494**

0.001

Yes

0.808**

<0.001

Yes

ROS central 5°

0.472**

0.002

Yes

0.708**

0.005

No

ROS central 16°

0.370*

0.017

No

0.623*

0.017

No

Abbreviations: CDVA=corrected-distance visual acuity; LogRad=log reading acuity; CS=contrast
sensitivity; cpd=cycles per degree; GD=glare disability; ROS=retinotopic ocular sensitivity
ROS=retinotopic ocular sensitivity; -=not significant
*correlation significant at the 0.05 level (2 tailed)
**correlation significant at the 0.01 level (2 tailed)

Figure 5.6 Relationship between change in mean foveal thickness (MFT) and baseline
measures of retinotopic ocular sensitivity (ROS) within the central 5° of fixation.
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An analysis was performed to investigate the relationship between observed
changes in MFT and observed changes in other parameters for the entire study group
and subgroup, and statistically significant findings are displayed in Table 5.4. Figure 5.7
graphically represents the relationship between change in ROS (within the central 5°)
and change in MFT, and Figure 5.8 displays the relationship between change in CDVA
and change in MFT (following the removal of three outliers).
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Table 5.4 Significant correlations between observed changes in mean foveal thickness
and observed changes in other parameters for the entire study group and subgroup.
Variable

Entire group

CDVA†

r
-0.311*

p
0.042

LogGDmesopic_1.5cpd

-0.334*

LogGDmesopic_3cpd
LogGDmesopic_18cpd

Sig. after
Bonferroni?

Subgroup

Sig. after
Bonferroni?

No

r
-0.569*

p
0.027

No

0.031

No

-

-

-

-0.344*

0.026

No

-

-

-

-0.348*

0.024

No

-

-

-

ROS fixation

-0.411**

0.008

No

-

-

-

ROS central 5°

-0.592**

<0.001

Yes

-0.611*

0.020

No

ROS central 16°

-0.536**

<0.001

Yes

-0.554*

0.040

No

Abbreviations: CDVA=corrected-distance visual acuity; CS=contrast sensitivity;
mesopic/photopic=under mesopic/photopic conditions; cpd=cycles per degree; GD=glare disability;
ROS=retinotopic ocular sensitivity; MFV=mean foveal thickness.
*correlation significant at the 0.05 level (2 tailed)
**correlation significant at the 0.01 level (2 tailed)
†becomes non-significant with the removal of 3 outliers (r=-0.271; p=0.091); an outlier was defined as
having a change in CDVA of more than 2 standard deviations from the mean.

Figure 5.7 Relationship between change in mean foveal thickness (MFT) and change in
retinotopic ocular sensitivity (ROS) within the central 5° of fixation
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Figure 5.8 Relationship between change in mean foveal thickness (MFT) and change in
corrected distance visual acuity (CDVA) (following the removal of three outliers).
Analysis was then performed to investigate the relationship between observed
changes in Rasch-scaled LFVFS and NVS over the study period, and observed changes
in other parameters (psychophysical and measures of retinal thickness), and statistically
significant correlations are given in Table 5.5. Of note, there was no significant
correlation between observed changes in LFVFS and observed changes in CDVA (r=0.278; p=0.082).

128

Table 5.5 Statistically significant correlations between observed changes in Raschscaled LFVFS and NVS, and observed changes in psychophysical measures over the
study period for the entire study group and subgroup.
Variable

Entire group

LFVFS

r

p

Reading acuity

-

-

LogCSphotopic_3cpd

-0.400*

0.012

LogCSphotopic_6cpd

-0.407*

LogGDphotopic_6cpd

Sig. after
Bonferroni?

Sig. after
Bonferroni?

Subgroup
r

p

-

0.537

0.039

No

No

-

-

-

0.010

No

-

-

-

-0.380*

0.017

No

-

-

-

ROS fixation

-0.392*

0.015

No

-

-

-

NVS

r

p

r

p

CDVA

-0.372*

0.018

No

-0.653**

0.008

No

Reading acuity

-

-

-

0.706**

0.003

No

LogCSphotopic_3cpd

-0.324*

0.044

No

-

-

-

ROS fixation

-0.464**

0.003

No

-0.754**

0.002

Yes

-0.663**
0.010
No
ROS central 5°
Abbreviations: LFVFS=long-form visual function score; reading acuity=best LogRad value; CS=contrast
sensitivity: photopic=under photopic conditions; cpd=cycles per degree; GD=glare disability;
ROS=retinotopic ocular sensitivity; CDVA=corrected distance visual acuity.
*correlation significant at the 0.05 level (2 tailed)
** correlation significant at the 0.01 level (2 tailed)

Thirty-seven patients met the criteria for the supplementary questionnaire
analysis; 24 (65%) indicated an overall improvement, 9 (24%) noted no change and 4
(11%) reported deterioration in their vision, over the course of the study. Analysis of
variance was then used to investigate the relationship between study eyes that were selfreported by participants as exhibiting an “improvement”, “no change” or “deterioration”
with respect to changes in parameters of visual function and macular thickness over the
course of the study period. Significant relationships were identified between changes in
mesopic CS (and GD) at 6 cpd and self-reported improvement in visual function in the
study eye (p=0.030 and p=0.043, respectively), but for no other parameter of visual
function (p >0.05 for all).
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5.4 Discussion
This study investigated visual function, and its response to treatment, through a range of
psychophysical tests, in patients with nv-AMD undergoing serial intravitreal injections
of ranibizumab, and explored whether alternative measures of visual function are more
appropriate than, or complimentary to, CDVA in reflecting the patient’s visual
experience. In addition, I investigated if any such alternative parameters were more
sensitive to changes in retinal thickness than CDVA and whether or not they were of
prognostic value.
Values for MFT and MFV decreased in response to treatment, between first and
final visits, consistent with previous studies (see example Figure 5.11).153, 344, 367 In this
analysis, CDVA did not change significantly for the study group or subgroup, between
baseline and exit visits. Parameters of visual function that did improve for the study
group and subgroup, however, included: reading acuity and reading speed, CS under
mesopic and photopic conditions, GD under mesopic and photopic conditions, and
ROS. The study eyes in subgroup exhibited an additional and statistically significant
improvement in the Rasch-scaled NVS. Interestingly, this observed improvement in
Rasch-scaled NVS within this subgroup was significantly associated with an observed
improvement in reading acuity (LogRAD), over the course of the study period.
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Figure 5.9 OCT macular scans at A) baseline with presence of intraretinal fluid and
intraretinal cysts and, B) at exit, representing normal macular architecture.
Mean CDVA did not improve significantly over the course of the study for the
group or subgroup. This finding may be attributable to our inclusion criteria and to the
short period of follow-up in this study. Studies have shown that poor baseline CDVA is
associated with a greater benefit of treatment in terms of this outcome measure,342, 343
and these observations are consistent with the findings of another study, which reported
no significant improvement in CDVA in patients with nv-AMD in patients where
baseline CDVA was 6/12 (logMAR 0.3) or better.368 Given that, in the current study,
all study eyes had baseline CDVA of logMAR 0.7 or better (indeed, 42 of the 43 eyes
had baseline CDVA of logMAR 0.6 or better), and given the ceiling effect previously
discussed, it is perhaps unsurprising that no statistically significant improvement in
CDVA was observed in our study, especially in light of the short period of follow-up. In
addition, improvements in CDVA may not have been observed due to the fact that a
proportion of the subjects in our study were already undergoing anti-VEGF therapy at
the study onset.
It has been shown that CS may be an important measure of visual function in
patients with subfoveal CNV due to AMD, providing additional information that cannot
be obtained from visual acuity.175 Studies have suggested that, when compared with
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visual acuity, CS better measures the ability to perform tasks accurately and efficiently,
as well as the ability to discriminate between objects177 and judge distances.178 Also,
GD is a clinically important problem in AMD, and impacts adversely on mobility
performance.369 Interestingly, Sandberg et al have proposed that a slow recovery from
glare may be an independent risk factor for the development of CNV.370 In this study,
all measures of CS and GD for all spatial frequencies improved significantly over the
course of the study period and only two of the twenty parameters measured did not
reach statistical significance (for the entire study group). It is also interesting to note,
when testing CS under photopic conditions, 81% and 96% of study eyes could not see
any target at either 12 or 18 cpd, respectively, at baseline, and these proportions
decreased by exit visit (to 75% and 84%, respectively).
A progressive improvement in ROS in response to ranibizumab therapy for nvAMD, as far as 24 months following the initiation of treatment and in spite
of stabilisation of VA after six months, has been previously demonstrated.7 In the
current study, ROS, within the central 5 degrees and within the central 16 degrees,
improved significantly for the study group and subgroup, whereas ROS at fixation
improved significantly only when the entire study group was analysed. Microperimetry
has also proved useful in monitoring response to other modes of treatment, such as
verteporfin therapy.371
For the study group and subgroup, a significant improvement in reading speed
was observed between baseline and exit visits over the course of the study, but this
observed improvement did not correlate with a change in CDVA. Such a disparity has
been previously observed by Frennesson et al, who suggested that a change in CDVA
does not necessarily relate to a change in near vision.372 However, it should be stated
that, in the current study, the repetitive nature of the test (every month), and the
consequential patient familiarity with the test texts (despite comprehensive patient
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training at baseline) may have contributed to the observed improvement in reading
speed over the course of the study period.
PHP values (TA and TII) exhibited no change over the course of the study
period, nor did observed changes in these PHP values correlate with observed changes
in MFT or LFVFS. A study by Das et al did report a significant association between TA
(of distortion recorded) and reduction in subretinal fluid following anti-VEGF
therapy.351 It has failed, however, at least according to the results of the current study,
to exhibit significant change in study eyes with nv-AMD which are undergoing
successful serial monthly intravitreal ranibizumab therapy. Indeed, self-reported
improvement in visual function over the course of the study period was not associated
with changes in PHP. These findings may be due to the fact this test was designed
specifically to detect recent-onset CNV and distinguish it from intermediate AMD,213
and only 15 (of 43) subjects in this study could be classified as having recent-onset
CNV. The PHP, then, may not have been sensitive enough to detect a change in subjects
with nv-AMD who were already undergoing serial intravitreal anti-VEGF therapy,
particularly when one considers that the greatest visual benefit (in response therapy)
occurs within the first three months of treatment.150, 343
Measurements of subjective visual difficulty did not change over time, either
when graded according to NEI guidelines, or when questionnaire scores were subjected
to Rasch analysis for the study group or subgroup (with the exception of improvement
in the NVS for study eyes in subgroup). This finding is at odds with previous reports,
where subjectively perceived visual improvement following anti-VEGF therapy has
been detected using validated questionnaires.363, 373 Possible reasons for this finding
may include the relatively short duration of the current study, given that treatment for
this condition may last for years; only subjects with relatively good CDVA were
assessed, who are likely to be less symptomatic compared to subjects with poor CDVA,
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thus reducing the scope of potential visual improvement amongst the current study’s
recruits. Also, the confounding effect of the status of the fellow eye on overall visual
experience could be influential in respect of this aspect of our investigation. Further,
and particularly at baseline, it may be difficult for a patient to have yet gauged, much
less quantified, the impact of his/her condition on aspects of their daily quality of life
(e.g. playing golf, night driving). In the current study, this latter point may be
particularly important, as an intravitreal injection of ranibizumab was administered
within one week of diagnosis for all study eyes. Also, decision-to-treat, in cases of nvAMD, and in contrast with more insidious conditions such as cataract, is not made
solely on the basis of patient symptoms, and may even be recommended when the
patient is asymptomatic, thus rendering the usefulness of a questionnaire such as the
NEI VFQ questionable for this purpose. Finally, it should be emphasised that
stabilisation of visual function can be deemed to be a successful outcome of intravitreal
anti-VEGF therapy in cases of nv-AMD. Although the NEI VFQ did not exhibit
improvement over the course of the study period for the study group or subgroup, it is
important to note that deterioration was not observed either for the study group or
subgroup, deterioration being the expected outcome of the natural history of nv-AMD.
Of note, 66% of patients reported an overall improvement in vision over the
course of the study, when using a supplementary questionnaire. Bearing in mind this
was not a validated questionnaire and had no means of quantifying the level of
improvement or deterioration experienced by the patient, it could be considered, at least
in the context of this study, and because of its within-subject and temporal comparative
nature, to represent a truer reflection of patient experience. The results of this particular
analysis suggest that subjectively perceived improvement in visual function in cases of
nv-AMD undergoing intravitreal anti-VEGF therapy has a closer association with CS
and GD at medium spatial frequencies, than with CDVA.
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Of note, and although the study group or subgroup did not exhibit significant
change in terms of CDVA or LFVFS over the course of the study, some subjects did
exhibit change in the above parameters, thus facilitating analysis of relationships
between such changes and other outcome measures. These relationships are discussed
with full appreciation of the fact that correlations, while identifying relationships
between variables, may or may not represent causal relationships.
Given the importance of OCT in the diagnosis and decision-to-treat/decision-todiscontinue treatment in cases of nv-AMD, the relationship between observed changes
in MFT and observed changes in the psychophysical parameters over the course of the
study period was analysed. Although there was a significant correlation between
observed changes in MFT and observed changes in CDVA (which, notably, became
non-significant with the removal of outliers) and also with observed changes in GD
under mesopic conditions at low and high spatial frequencies, the strongest such
association was with observed change in ROS, both at fixation, but more robustly,
within the central 5 and 16 degrees of fixation. Changes in microperimetry have also
been shown to reflect changes in macular thickness for other eye conditions, such as
diabetic macular oedema.206, 374 Microperimetry examines the light differential
threshold at the retina, and in this respect differs from VA, a measure of the angular
resolution limits of the eye at high contrast. The advantage of ROS is that it is
retinotopic, a function which allows it to probe visual function more deeply than would
CDVA. Intuitively, therefore, one would expect that measures of ROS are more
appropriate than CDVA when attempting to correlate function and morphological
changes at the macula for conditions such as AMD. On the basis of this rationale, and
on the basis of the findings of the current study, I believe that ophthalmologists should
consider incorporating measures of ROS into the routine assessment and monitoring of
patients with AMD.
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For the entire study group, significant correlations were detected between
changes in patient-reported experience for the entire study group and changes in CS
(under photopic conditions at 3 and 6 cpd), GD (under photopic conditions) at 6 cpd,
and ROS at fixation, but not with CDVA. In other words, such measures of visual
function appear to better reflect changes in subjectively perceived visual function than
does CDVA. These results should be interpreted with full appreciation of the fact that
they were not significant at the 1% level, in the absence of correction for multiple
testing. Of note, change in CDVA was associated with change in the NVS.
The psychophysical prognostic indicators for reduction in macular thickness for
the entire study group following treatment were CDVA and ROS, ROS displaying
significance at the 1% level. Analysis on study eyes in subgroup demonstrated further
parameters of potential prognostic value, including: reading acuity, CS and GD under
mesopic conditions at 3 cpd, CS and CS and GD under photopic conditions at 6 cpd. In
other words, a greater reduction in MFT over the course of the study period was
associated with worse measures of these aspects of visual function at baseline, a finding
that is unsurprising as these measures of visual function will be grossly and adversely
affected where MFT is greater, thus allowing for a more substantial reduction in MFT
(and a parallel improvement in these parameters) over time. However, it should be
noted that this finding will have been affected in the current study by confounding
attributable to the fact that CDVA of logMAR 0.7 or better was an inclusion criterion.
While CDVA does not appear to be either the most robust or most sensitive outcome
measure in patients undergoing intravitreal anti-VEGF therapy for nv-AMD, this study
has shown that it does have some prognostic value for eyes undergoing such treatment
for this condition, at least where baseline acuity is relatively good (logMAR 0.7, or
better).
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In an attempt to achieve best outcomes without overtreating patients with nvAMD, the posology for intravitreal ranibizumab for this condition has recently been
revised
(http://www.medicines.ie/medicine/11837/SPC/Lucentis+10mg+ml+Solution+for+Injec
tion/#POSOLOGY). This revision of posology was informed by the evolving body of
literature since the publication of the phase III MARINA and ANCHOR trials, where
monthly injections were given for a period of two years. In brief, it is now
recommended that monthly injections are given until best CDVA is achieved and
maintained for three consecutive injections, when interruption of treatment is
recommended with monthly monitoring. Where deterioration in CDVA, attributable to
activity of nv-AMD, is observed, recommencement of treatment is recommended under
the same regime. In light of this revised posology, however, the results of our study
strongly suggest that CS-guided or ROS-guided re-treatments are likely to be more
sensitive indicators of functional deterioration, and would, therefore, prompt
recommencement of treatment at an earlier stage than would a deterioration in CDVA,
thereby reducing the risk of irrecoverable loss of visual function prior to re-treatment.375

5.5 Conclusion
This study has demonstrated improvements in many parameters of visual function in
eyes with nv-AMD undergoing monthly intravitreal ranibizumab injections. Outcome
measures other than CDVA, such as CS, GD and ROS, should not only be considered in
the design of studies investigating nv-AMD, but also in treatment and retreatment
strategies for patients with the condition, at least in eyes where baseline CDVA is
logMAR 0.7 or better.
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Chapter 6. Supplementation with three different macular carotenoid
formulations in subjects with early age-related macular degeneration.

6.1 Study rationale, aims and objectives
Although anti-VEGF therapy has resulted in better outcomes for patients with nvAMD,376 this treatment is cumbersome to the patient and to the healthcare provider,
often requiring many months/years of monthly intravitreal injections. In addition, there
is, as yet, no effective treatment for atrophic AMD, which has similarly detrimental
effects on a patient’s quality of life.21
Investigators interested in exploring ways of preventing or delaying the onset of
AMD, or at least retarding its progression, have directed their attention towards the
possible protective role of MP, and its constituent components: L, Z and MZ. There is
also a strong rationale to suggest that MP can enhance visual performance in subjects
with the condition.
While L and Z can be obtained from many foods,377 MZ is not present in a
conventional western diet, although it has been identified in certain types of seafood.378
However, it should be noted that there is a paucity of studies conducted to test foods for
the presence of MZ, and further study in this area is needed. Interestingly, MZ has been
found, albeit in trace amounts, in serum of subjects who have not been supplemented
with this carotenoid.379 Certain properties of MZ render this carotenoid of particular
interest to those exploring ways of preventing or delaying the onset of AMD, or
ameliorating the course of the condition, or studying the contribution MP makes to
visual performance and experience (in subjects with and without ocular disease), and
these include: MZ is generated from L in the primate retina;380 it is the dominant
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carotenoid at the epicentre of the macula (Figure 6.1);381 MZ accounts for about one
third of total MP;253 it appears to be the most powerful antioxidant of the macular
carotenoids in the presence of the xanthophyll binding proteins;382 the presence of all
three macular carotenoids is required if MP is to maximally exert its antioxidant
effects;319 the presence of MZ facilitates a wider range of pre-receptoral blue light
filtration by MP.317, 318

Figure 6.1 The ratio between MZ and Z concentrations (pink line) and the ratio
between L and Z concentrations (turquoise line), at the macula (image courtesy of Prof.
Richard Bone).
Interestingly, an atypical central dip in the spatial profile of MP, characterised
by the lack of a central peak in MPOD, is associated with risk for AMD.321 It is
reasonable to hypothesise that such atypical profiles may be attributable, at least in part,
to an inability to convert retinal L to retinal MZ, and a consequential lack of MP at the
site of dominance of this carotenoid (i.e. at the foveal centre). Interestingly,
supplementation with a formulation containing MZ has the ability, to rebuild MP
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centrally and confer a typical central peak on its spatial profile.322, 379 It has also been
shown that, in normal healthy subjects, a formulation containing all three macular
carotenoids (including MZ) has the greatest impact, in terms of enhancing visual
performance, as measured by CS (both in the presence and absence of glare), when
compared to placebo or when compared to a formulation that contains only L (and
lesser amounts of Z).
While the role of MZ for visual performance in normal subjects has been
explored,170 no trial to date has yet investigated the impact of a supplement containing
MZ on visual performance (or disease progression), in subjects with early AMD. In
addition, the majority of clinical trials that have focused on visual outcomes following
macular carotenoid supplementation have focused, for the most part, on CDVA.
Evidence suggests that other psychophysical measures of visual performance should be
considered when attempting to quantify visual changes in response to supplementation.
Further, no trial has yet investigated the impact of a supplement containing MZ on the
progression of AMD.
MOST AMD (a sister trial to MOST Vision, discussed in section 4.5.3.2) was
designed to investigate the effect of three different macular carotenoid formulations
(one of which contains all three macular carotenoids [L, Z and MZ]), on MP
enhancement, on visual performance (taking into consideration a range of
psychophysical measures) and on disease progression, in subjects with early AMD
(MOST Vision assessed normal subjects).
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6.2 Methods
6.2.1 Study design

This study was conducted at the Institute of Vision Research and Institute of Eye
Surgery, Waterford, Ireland. Early AMD was defined as the presence of drusen and
pigmentary changes and the absence of any signs of late AMD (GA or nv-AMD).
Recruitment was mediated through the Institute of Eye Surgery (ophthalmology clinic)
and Institute of Vision Research, through advertisement in local media and through
leaflet, poster and flyer distribution to optometrist practices locally and nationally.
Inclusion criteria were: early AMD in at least one eye (confirmed by an ophthalmologist
at a screening clinic and subject to subsequent corroboration by an accredited reading
centre); CDVA of ≥ 6/12 (logMAR 0.3) in the study eye. Exclusion criteria were: a
recent history (within three months of baseline visit) of macular carotenoid
supplementation; diabetes mellitus; any visually consequential ocular co-morbidity.
Ethics approval was granted by the Waterford Regional Hospital Ethics Committee
(Appendix 5), and written and informed consent was secured from each subject
(Appendix 6). The research was conducted in accordance with the principles of the
Declaration of Helsinki. All subjects were naive to the tests involved (with the
exception of CDVA).
This study, titled the Meso-zeaxanthin Ocular Supplementation Trial [MOST]:
(trial registration number: ISRCTN60816411) is a randomised single-blind clinical trial
of oral supplementation with one of three different macular carotenoid formulations.
The supplements were prepared in a soft-gel capsule. Subjects were randomly assigned
to one of three supplementation groups, as follows: Group 1: 20mg of L and 2mg of Z
(Ultra Lutein™; supplied by Nature’s Plus, Europe); Group 2: 10mg of MZ, 10mg of L
and 2mg of Z (Macushield™; supplied by MacuVision, Europe); Group 3: 17 mg MZ, 3
mg of L and 2mg of Z (supplied by Industrial Organica, Mexico). Study subjects were
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required to consume one tablet per day with a meal. Compliance was monitored by
tablet counting at each study visit and encouraged by regular phone calls. Study visits
were carried out at baseline, six and 12 months.

Visual acuity, and CS and GD using the FVA™ were carried out as outlined in Chapter
6 (sections 6.1.2 and 6.1.3, respectively). Of note, the unavailability of the FVA™ at the
study outset resulted in a reduced number of complete (baseline and 12 month) datasets
for measurements using this device (n=39).

ROS was carried out as described in Chapter 6 (section 6.1.4), the exception being the
number of retinal loci tested and the extent of the visual field that was examined. This
change in method was as follows: The central 12 degrees were examined, using a total
of 29 stimuli. ROS was calculated for the following three areas: within the central 4
degrees of fixation (using an average of 13 stimuli), within the central 8 degrees of
fixation (average of 21 stimuli), and within the central 12 degrees of fixation (average
of 29 stimuli).

6.2.2 Contrast sensitivity by letter chart

CS was measured (in the study eye only) at five separate spatial frequencies (letter
sizes) using the logMAR chart provided by Test Chart 2000 PRO® at a test distance of
4m and at a constant room illuminance of 870 lux (photopic conditions), using distance
spectacle correction, if required.
Contrast of a letter is defined as follows (Weber contrast):
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where I represents the luminance of the character and Ib represents the luminance of
the background.
Each patient was asked to identify (ETDRS) letters, presented in one isolated
row (spatial frequency) at a time. For each spatial frequency tested, the contrast of the
letters was reduced systematically using the software’s contrast adjustment function
(calibrated prior to commencement of the study using a light meter) until the contrast
threshold of the patient was reached i.e. the patient could not distinguish any more
letters. The software’s letter randomisation program selected five random letters each
time a different contrast was tested. The patients were encouraged to take their time
whilst trying to identify the letters (for adaptation purposes), particularly approaching
their threshold contrast level, and to blink regularly.
The average of three different readings was taken for the lowest contrast at
which letters were legible to the patient, in a similar manner to that used in CDVA
testing. The percentage contrast level (of the target), CS, and logCS for each spatial
frequency (row of letters) were recorded. Table 6.1 shows the contrast levels tested and
their corresponding CS and logCS values. Any missed or any additional correctly
identified letters i.e. on a subsequent line, were each assigned a (logCS) value of -0.03
and +0.03, respectively, and the total was added to the final logCS score.
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Table 6.1 Contrast levels tested using letter chart, and corresponding CS and logCS
values.
% Contrast
100
71.0
50.1
35.5
25.1
17.8
12.6
8.9
6.3
4.5
3.2
2.2
1.6
1.1
0.8
0.6

CS*
1.00
1.41
2.00
2.82
3.98
5.62
7.94
11.24
15.87
22.22
31.62
44.67
62.50
89.13
125.00
178.57

logCS
0.00
0.15
0.30
0.45
0.60
0.75
0.90
1.05
1.20
1.35
1.50
1.65
1.80
1.95
2.10
2.25

Abbreviations: CS=contrast sensitivity
*CS=100 divided by % contrast

Five different letter sizes (spatial frequencies) were tested, each having the
following angular subtense in cycles per degree (cpd): 6/120 (1.2cpd), 6/60 (2.4cpd),
6/24 (6cpd), 6/15 (9.6cpd) and 6/9.5 (15.2cpd). It should be noted that letters, by nature,
can contain many different spatial frequencies, so it is not possible to assign a precise
spatial frequency to a particular letter. However, it has been suggested that the most
important frequency for letter identification is two cycles per letter width.383 Take the
letter F, for example; it contains approximately two cycles (two dark bands and two
white bands). The spatial frequencies cited above represent those calculated on this
basis (see Appendix 7).
6.2.3 Macular pigment optical density

Each subject’s MP spatial profile was obtained using the Macular Densitometer™, a
device that has been slightly modified from that developed and described by Wooten et
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al.384 The device uses heterochromatic flicker photometry (HFP) to obtain a measure of
MPOD at five retinal eccentricities.
HFP is based on the principle that MP (a yellow pigment), located anterior to the
photoreceptor layer in the retina, absorbs incident blue light before it reaches the
photoreceptors. MP’s peak absorption is at approximately 460nm. The test requires the
subject to make iso-luminance matches between two flickering lights, which alternate
between a wavelength band absorbed by MP (blue) and one that is not (green). The
radiance of the blue light (absorbed by MP) is adjusted until the subject’s perception of
flicker is minimised or eliminated. The higher the individual MP level at a particular
retinal eccentricity, the more blue light that will be required to match the luminance of
the green light to minimise the flicker (Figure 6.2). The log ratio of the amount of blue
light absorbed centrally, where MP peaks, to that absorbed at a peripheral retinal locus
(in this case, 7°) where MP is optically undetectable, gives a measure of the individual’s
MPOD.

Figure 6.2 Principle of heterochromatic flicker photometry. At the fovea, more blue
light (large blue arrow) is required to match the luminance of the green light than at the
parafovea (reference point), as MP (indicated in yellow) is concentrated at the fovea and
is optically undetectable at the parafovea (reference point). (Image courtesy of the
MPRG, Waterford)
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Typically, there is an inter-individual range of alternation rates where flicker is
not perceived and this range is called the null zone. Customised HFP (cHFP)385 was
designed to accommodate for these differences in flicker sensitivity amongst
individuals, which are known to vary with age and disease.386, 387 If a fixed flicker
frequency is used, a subject with low flicker sensitivity (i.e., low critical flicker fusion
frequency) will most likely experience a large null flicker zone. On the other hand, a
subject with a high critical flicker frequency may not be able to eliminate flicker from
the test target, which would make the task difficult to complete. Therefore, predicted
optimal flicker frequency rates for the targets at each eccentricity (determined using an
age-guided algorithim; see Table 6.2) were used to customise the test for each subject to
facilitate accurate subject performance and reduce measurement error (see also
publication by Connolly et al379 ).

Table 6.2 Age-guided optimal flicker frequencies for Densitometer™ targets.
Age*
18-20
21-20
31-40
41-50
51-60
61-70
71-80
81+

OFF for each retinal eccentricity
0.25°
0.5°, 1°, 1.75°
7°
18
19
13
18
19
12
17
18
11
15
16
10
13
14
9
12
13
8
11
12
7
10
11
6

OFF = optimal flicker frequency;
*years

The spatial profile of MP was measured at four different retinal eccentricities:
0.25°, 0.5°, 1°, and 1.75°, with a reference point at 7°. The targets and fixation points
used for each retinal eccentricity measured are displayed in Figure 6.3 and were as
follows: the 0.25° and 0.5° eccentricities were measured using a 0.5° and 1° diameter
disc, respectively, with a 5min black fixation point at the centre; the 1° and 1.75°
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eccentricities were measured using a 20’ wide annuli with mean radii corresponding to
those eccentricities used with a centrally fixated 5min black fixation point. Values at the
reference point were obtained using a 2° diameter disc located 7° nasal to a 5min red
fixation point.

Figure 6.3 Stimuli and fixation points for each of the five targets of the Macular
Densitometer™. (Image courtesy of the MPRG, Waterford)
Room lights were dimmed for the recording of MPOD (room illuminance was
1.5 lux). The “bracketing method” previously described by Connolly et al was
employed for the measurement of MPOD in this study, as it has been found to be more
suitable for assessing older subjects than the original “method of adjustment”.379 These
two methods are described as follows:

The Method of Adjustment: The radiance button is set (by the examiner) to either the
lowest or highest blue light intensity. The subject then pushes one of the (two) radiance
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control buttons, which alters the blue/green ratio, until the beginning of the null flicker
zone is reached. They are encouraged to continue holding down the button until the end
of the null flicker zone is reached. The subject then uses the other radiance control
button to go back through the zone of no flicker, and then to continue to go back and
forth through this zone in smaller increments until they feel they have identified the
centre of this zone (i.e., their null flicker point). The radiance value at this point is
recorded. The examiner then offsets the radiance button randomly and the test is
repeated four additional times, as above. The entire procedure is then repeated for the
remaining eccentricities. MPOD is calculated using the log ratio of the measurement
radiance values with respect to the reference radiance values (obtained at 7°), using an
appropriate MPOD calculator provided by Macular Metrics (Providence, Rhode Island,
USA).
If the subject cannot identify a null flicker zone, the flicker frequency is
typically increased the by two Hz. Similarly, if the subject reports a very wide null
zone, the flicker frequency is reduced by two Hz. Further such adjustments are made if
required.

The Bracketing Method: The examiner sets the radiance button all the way to lowest
blue light intensity. The examiner then pushes the radiance button, increasing the
blue/green ratio until the subject reports no flicker. This radiance value is recorded and
this procedure repeated an additional four times. The examiner then sets the radiance
button all the way to highest blue light intensity and the procedure is repeated, as above.
For any given retinal eccentricity, a total of ten radiance values are obtained; five
approaching from the lowest blue light intensity and five approaching from highest blue
light intensity. The same procedure is repeated for the remaining eccentricities. MPOD
is calculated using, in this case, a bracketing procedure MPOD calculator.
148

All subjects were trained how to perform the HFP task at their first study visit.
MPOD data was not recorded until subjects demonstrated a high level of understanding
of the task. Reliability and reproducibility of MPOD measurements obtained using the
Macular Metrics Densitometer™ have previously been reported.388, 389

6.2.4 Blood extraction

Non-fasting blood samples were collected at baseline and 12 months by standard
venepuncture techniques for the purposes of assessing the safety (using pathology
analysis) of macular carotenoid supplementation, in particular, MZ, as it is currently the
least explored macular carotenoid. The blood was collected in two plastic collection
tubes as follows: Tube 1 (glucose) contained sodium fluoride, and tube 2 (hematology)
contained the anticoagulant dipotassium ethylene diamine tetra-acetic acid (K2EDTA).
All collection tubes were labelled with the subject’s number, visit number and date and
were inverted a minimum of eight times to ensure appropriate mixing of the blood with
each additive in the tubes.

6.2.5 Clinical pathology analysis

Clinical pathology analysis was performed on all subjects at baseline and at 12 months,
to test for any change in renal and liver function, lipid profile, hematologic profile, and
markers of inflammation, following supplementation with the macular carotenoids.
The serum tube was centrifuged within two hours of collection, and a 1mL
sample was aliquotted into a clean, labelled, plastic tube that was then transported with
the other two tubes to Biomnis Ireland (Dublin, Ireland; Irish National Accreditation
Board certified), for independent analysis. Serum levels of the following parameters
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were measured at baseline and at 12 months: sodium; potassium; chloride; urea;
creatinine; bilirubin; alanine aminotransferase (ALT); alkaline phosphatase (ALP);
aspartate aminotransferase (AST); gamma-glutamyl transferase (GGT); total protein;
albumin; globulin; calcium; magnesium; phosphate; uric acid; cholesterol-HDL (high
density lipoprotein); cholesterol-LDL; cholesterol-total; triglycerides; glucose; full
blood count + 5-part Diff; C-reactive protein (CRP) - high sensitivity (hsCRP).
Analysis at Biomnis Laboratories was conducted using one of two integrated
diagnostic immunoassay systems (Abbott Architect ci8200; Abbott Labs, Abbott Park,
IL, or Advia 120; Siemens Healthcare Diagnostics, Deerfield, IL), as appropriate. The
reference ranges for this study were obtained from the insert kits for the instrumentation
used by Biomnis Laboratories. Exceptions were the reference ranges for lipids (HDL,
LDL, total cholesterol and triglycerides), which were obtained from the European
Guidelines on Cardiovascular Disease Prevention,390 and for glucose, which were
obtained from the World Health Organisation.391

6.2.6 L/Z diet screener

A subject’s weekly intake of carotenoid rich foods (eggs, broccoli, corn, dark leafy
vegetables) was inputted into the L/Z screener (courtesy of Dr. Elizabeth Johnson, Tufts
University, Boston, USA) to give a carotenoid-based diet score. The screener was used
for control purposes, i.e. to ensure that there was no difference between
supplementation groups at baseline with respect to dietary intake of the carotenoids. In
the excel-based screener, values are weighted for frequency of intake of the food and for
bioavailability of L and Z within these foods. A ranking score reflecting the relative
intakes was generated. Evaluation of the L/Z screener against the Willet food frequency
questionnaire yielded a positive correlation that was strongly significant (p<0.01).322
The range of scores on the L/Z screener is 0 to 75. After adding foods with known
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concentrations of the L and Z into the screener, the following estimates were made: a
low dietary carotenoid intake score ranges from 0-15 (≤2mg/day); a medium dietary
carotenoid intake score ranges from 16-30 (3-13mg/day); and a high dietary carotenoid
intake score ranges from 31-75 (>13mg/day).

6.2.7 Subjective visual function (VFNq30)

An adapted version of the (Visual Function in Normals Questionnaire), a non-validated
questionnaire designed to assess subjective visual function in normal subjects, was used
in this study (Appendix 8), in an attempt to investigate the subjective response, if any,
to supplementation with the macular carotenoids. The design was loosely based on a
previously validated visual activities questionnaire.392 The questionnaire allowed the
subject to quantify their visual performance using three separate metrics: situational
analysis (SA), which required the subject to rate their visual performance in specified
daily life situations; comparative analysis (CAn), which required the subject to compare
their perceived visual performance to that of their peers/family/friends; subjective
satisfaction score (SSS), which required the subject to provide an overall estimate of
their perceived quality of vision. Each of the three metrics described was computed to
give a performance score for four different functional aspects of vision: acuity/spatial
vision, glare disability, light/dark adaptation and daily visual tasks.
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6.2.8 Stereo fundus imaging and grading

6.2.8.1 Imaging
Two sets of 30° stereoscopic colour photographs, centred on the disc, centred on the
macula, and a non-stereoscopic colour fundus photograph centred temporal to, but
including, the fovea, were obtained. This was followed by the acquisition of a single
anterior segment image centred on the pupil of each eye. All images were anonymised
and sent to the Ocular Epidemiology Reading Centre at the University of Wisconsin,
USA, for grading.
6.2.8.2 AMD lesion grading (procedure described by Klein et al)393
Early AMD is characterised by retinal drusen and pigmentary abnormalities (increased
retinal pigment and RPE depigmentation). Late AMD is characterised by areas of GA or
signs of CNV. AMD grading involves measuring different characteristics of each (e.g.
size, type and area of drusen and area of pigmentary abnormalities).
Each photo was fitted with a grid consisting of three concentric circles (central,
inner and outer subfields) and four radial lines so that the fovea is contained within the
centre circle (Figure 6.4). The radius of the innermost circle corresponds to 500µm in
the fundus of an average eye and the radii of the middle and outer circles to 1500µm
and 3000µm, respectively. This grid divides the photo into nine separate subfields
(centre circle + four inner subfields + four outer subfields). Three sets of open circles of
differing sizes were used to estimate the size of drusen, the area involving drusen and
the area involving pigmentary changes (Figure 6.5) Circles, C0, C1 and C2 have
diameters corresponding to 63µm, 125µm and 250µm, respectively. Drusen area was
quantified using the circles C1, I1 and O1, which represent 1.6% of the area of the
central, inner, and outer subfields, respectively, and by C2, I2 and O2, which represent
6.3% of the area of the same subfields.
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Figure 6.4 Grid used to define subfields at the macula.

Figure 6.5 Grid used to estimate drusen size, drusen area and area of pigmentary
changes.

Overall findings were reported on an 11-step AREDS AMD-severity scale (see
Appendix 9) The levels of increasing severity in the 11-step AREDS scale were defined
by drusen area, increased pigment, RPE depigmentation and the late AMD lesions
(signs of nv-AMD or GA). For the purposes of this study, a change of two or more steps
along the AREDS severity scale was defined as being clinically significant.394 Fundus
photographs were graded at baseline and at 12-month study visits.

6.2.9 Statistical analysis

Descriptive statistics were calculated for the entire group and for each supplementation
group, for all measured variables, including demographic, ocular, psychophysical and
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morphological data, as well as data on subjective visual functioning. Statistical analysis
was performed using the software package PASW Statistics 18.0 (IBM Corp., Somers,
NY, USA). Power and sample size calculations were performed using PASS 2008
(NCSS, LLC. Kaysville, Utah, USA).
Baseline differences between treatment groups e.g. in measures of visual
performance, age, gender etc. were assessed using analysis of variance and contingency
table analysis, as appropriate. Baseline and 12-month visit measures were compared
using the paired-samples t test. One-way ANOVA was used to test for statistically
significant differences between the three groups. Pearson correlations were used to
investigate the relationship between MPOD and a range of psychophysical measures, at
baseline. Change in AMD severity grade between the three intervention groups was
assessed using the Pearson chi-square test for contingency tables.
Following dropouts and exclusions, data from 52 subjects remained for
longitudinal analysis. A sample of this size has power of 0.85 for detecting a correlation
of 0.4 and power of 0.97 for detecting a change of half of one standard deviation on a
paired t test, assuming a 5% level of significance and a two-tailed test. For a
contingency table analysis designed to detect changes of two or more steps on the AMD
severity scale, the power of a sample of this size is 0.78 for detecting a large effect size
(W=0.5 using Cohen’s classification).395

6.3 Results
6.3.1 Baseline data

Seventy-nine eyes (of 79 subjects) were recruited into the study. Following recruitment
and a baseline visit, a total of 12 subjects were excluded following image grading (at the
University of Wisconsin); five were excluded on the basis of not having AMD and a
further seven were excluded on the basis of signs of late AMD. Following these
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exclusions, 67 eyes (of 67 subjects) remained for analysis. Twenty-three subjects were
recruited to Group 1, 25 to Group 2 and 19 to Group 3. Positive and statistically
significant relationships between MPOD and visual function, at baseline, are presented
in Table 6.3 (see also Figure 6.6 for the graphical representation of the relationships
between letter CS 2.4 cpd and MPOD at 0.25° eccentricity).

Table 6.3. The relationship between MPOD (at 0.25° eccentricity) and psychophysical
parameters of visual function, at baseline.
Variable
CDVA
Letter CS at 2.4cpd
Letter CS at 15.2cpd
CS ms 3cpd
CS pt 3cpd
GD pt 3cpd
GD pt 6cpd
GD pt 12cpd
Letter CS at 1.2cpd
Letter CS at 6.0cpd
Letter CS at 9.6cpd
CS ms 1.5cpd
CS ms 6cpd
CS ms 12cpd
CS ms 18cpd
CS pt 1.5cpd
CS pt 6cpd
CS pt 12cpd
CS pt 18cpd
GD ms 1.5cpd
GD ms 3cpd
GD ms 6cpd
GD ms 12cpd
GD ms 18cpd
GD pt 1.5cpd
GD pt 18cpd
ROS central 4°
ROS central 8°
ROS central 12°
Diet

r
0.282
0.295
0.300
0.313
0.345
0.281
0.286
0.277
0.105
0.205
0.235
0.267
0.141
0.096
0.028
0.230
0.237
0.106
-0.003
0.069
0.223
0.249
0.125
0.036
0.177
0.169
0.134
0.158

p
0.022
0.017
0.015
0.025
0.013
0.045
0.042
0.049
0.404
0.102
0.059
0.059
0.323
0.505
0.843
0.104
0.094
0.460
0.984
0.631
0.115
0.078
0.383
0.802
0.214
0.235
0.287
0.209

0.096
0.081

0.444
0.524

Abbreviations: CDVA=corrected distance visual acuity; CS=contrast sensitivity; cpd=cycles per degree;
ms=under mesopic conditions; pt=under photopic conditions; GD=glare disability; ROS=retinopic ocular
sensitivity.
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Figure 6.6 The relationship between MPOD at 0.25° and letter CS at 2.4 cpd (6/60) at
baseline.

Abbreviations: MPOD=macular pigment optical density; CS=contrast sensitivity; cpd=cycles per degree.

Of the 67 subjects, eight subjects discontinued for personal reasons, three were
not available to attend for the 12-month visit, two discontinued for health reasons
(deemed to be unrelated to intervention), one had cataract surgery on the study eye prior
to the 12-month visit, and one patient developed nv-AMD and did not re-attend, leaving
52 subjects with complete datasets for the 12-month analyses; 17 in Group 1, 21 in
Group 2, and 14 in Group 3. Baseline demographic, lifestyle, anthropometric, and visual
data for the remaining 52 subjects are presented in Table 6.4. Of note, there was no
significant difference between the groups with respect to any baseline data variables
(with the exceptional of one questionnaire variable [daily situation analysis]; p=0.046),
nor with respect to AMD grade (p=0.994; Table 6.5).
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Table 6.4 Baseline demographic, lifestyle, anthropometric and visual data.
Gender
Male
Female
Eye
Right
Left
Smoking status
Current
Past
Never
Education
Primary
Secondary
Third level
Variable

Entire group

Group 1

Group 2

Group 3

Sig.

n (%)
18 (35%)
34 (65%)

n (%)
5 (29%)
12 (71%)

n (%)
8 (38%)
13 (62%)

n (%)
5 (36%)
9 (64%)

0.851

33 (63%)
19 (37%)

9 (53%)
8 (47%)

14 (67%)
7 (33%)

10 (71%)
4 (29%)

0.525

4 (8%)
25 (48%)
23 (44%)

2 (12%)
8 (47%)
7 (41%)

2 (10%)
7 (33%)
12 (57%)

0 (0%)
10 (71%)
4 (29%)

0.224

10 (19%)
23 (44%)
19 (37%)

3 (18%)
6 (35%)
8 (47%)

2 (10%)
12 (57%)
7 (33%)

5 (36%)
5 (36%)
4 (28%)

0.270

mean ±(sd)
(n=52)

66 (8)
Age
2
26.1 (5.5)
BMI (kg/m )
CDVA (study eye)
99 (7)
CDVA (non-study eye)
95 (10)
Macular Pigment Optical Density
0.25° eccentricity
0.50 (0.25)
0.5° eccentricity
0.39 (0.22)
1.0° eccentricity
0.26 (0.15)
1.75° eccentricity
0.14 (0.11)
Letter CS (photopic conditions)
1.2 cpd
68.3 (46.4)
2.4 cpd
57.1 (41.2)
6.0 cpd
25.6 (14.8)
9.6 cpd
13.7 (8.6)
15.2 cpd
6.5 (4.9)
FVA CS (mesopic conditions) (n=39)*
Frequency (cpd)
1.5
47.8 (28.1)
3
57.1 (36.4)
6
25.9 (18.1)
12
6.0 (4.2)
18
2.6 (2.0)
FVA CS (photopic conditions) (n=39)*
Frequency (cpd)
1.5
36.0 (23.0)
3
63.3 (29.8)
6
45.5 (32.0)
12
15.2 (13.6)
18
7.2 (7.6)
FVA GD (mesopic conditions) (n=39)*

mean ±(sd) mean ±(sd) mean ±(sd)
(n=17)
(n=21)
(n=14)
65 (7)
25.5 (4.1)
99 (7)
96 (9)

64 (9)
27.1 (3.6)
99 (8)
96 (12)

70 (8)
25.2 (8.6)
98 (6)
94 (8)

0.117
0.562
0.868
0.834

0.50 (0.25)
0.38 (0.27)
0.27 (0.18)
0.16 (0.11)

0.50 (0.24)
0.41 (0.22)
0.27 (0.13)
0.15 (0.11)

0.47 (0.21)
0.36 (0.19)
0.24 (0.17)
0.11 (0.12)

0.925
0.797
0.851
0.554

73.0 (49.1)
59.7 (45.3)
29.0 (14.9)
16.0 (9.1)
7.1 (4.5)

61.2 (41.3)
56.8 (40.5)
24.3 (14.0)
12.3 (7.3)
6.2 (4.8)

73.2 (52.3)
54.3 (41.4)
23.6 (16.0)
12.9 (9.7)
6.4 (5.7)

0.674
0.938
0.530
0.399
0.827

45.6 (29.8)
47.1 (26.5)
21.0 (17.1)
4.8 (2.1)
3.1 (3.0)

46.3 (24.5)
58.6 (33.0)
25.9 (17.5)
5.6 (3.9)
2.1 (0.5)

44.6 (30.4)
58.0 (44.9)
24.3 (20.4)
6.9 (5.4)
2.4 (1.2)

0.885
0.905
0.762
0.380
0.483

34.9 (24.3)
56.6 (27.3)
40.3 (25.0)
13.4 (11.0)
6.4 (6.3)

41.1 (22.0)
66.1 (33.6)
45.1 (32.1)
14.8 (14.3)
5.8 (5.5)

31.8 (21.4)
65.4 (27.5)
41.7 (36.4)
15.2 (13.7)
8.5 (9.8)

0.657
0.492
0.965
0.993
0.691

Frequency (cpd)
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1.5
37.3 (27.0)
3
48.6 (37.9)
6
20.4 (16.0)
12
5.9 (3.7)
18
2.3 (1.1)
FVA GD (photopic conditions) (n=39)*
Frequency (cpd)
1.5
39.8 (22.8)
3
65.0 (27.1)
6
51.5 (35.3)
12
16.1 (14.3)
18
7.9 (8.0)
ROS
Central 4°
18.0 (2.2)
Central 8°
18.3 (1.8)
Central 12°
18.0 (2.2)
Subjective vision questionnaire (n=49)*
Glare SA
59 (20)
Glare CAn
55 (18)
Glare SSS
61 (25)
Acuity SA
66 (20)
Acuity CAn
56 (15)
Acuity SSS
68 (20)
Light SA
66 (17)
Light CAn
56 (14)
Light SSS
67 (19)
Daily SA
77 (15)
Daily CAn
58 (12)
Daily SSS
70 (15)
Diet score (n=50)
18.7 (11.2)

39.9 (25.2)
54.07 (43.5)
18.0 (17.3)
5.1 (3.0)
2.4 (1.6)

37.5 (28.8)
42.4 (26.8)
19.8 (14.3)
5.1 (3.1)
2.2 (0.7)

26.8 (24.1)
40.4 (40.3)
18.6 (15.9)
6.9 (4.3)
2.1 (0.5)

0.285
0.491
0.832
0.228
0.904

45.9 (26.9)
58.1 (28.0)
45.3 (27.5)
16.2 (16.7)
7.7 (9.5)

36.8 (16.1)
67.2 (31.2)
52.3 (40.5)
12.9 (11.0)
4.8 (4.1)

37.9 (23.4)
59.0 (22.1)
45.5 (38.7)
15.8 (14.2)
9.4 (8.8)

0.280
0.786
0.946
0.876
0.410

18.3 (1.9)
18.5 (1.5)
18.4 (1.7)

18.4 (1.7)
18.5 (1.6)
18.2 (2.1)

17.1 (2.9)
17.6 (2.5)
17.2 (2.7)

0.194
0.345
0.303

59 (20)
50 (19)
55 (27)
69 (20)
58 (16)
66 (22)
66 (20)
55 (17)
69 (17)
75 (13)
55 (12)
66 (14)
17.3 (10.9)

63 (21)
58 (19)
67 (25)
68 (20)
57 (13)
72 (21)
70 (17)
58 (11)
70 (21)
83 (14)
60 (13)
75 (16)
21.9 (12.7)

54 (19)
55 (15)
58 (24)
61 (19)
52 (15)
63 (18)
60 (11)
54 (13)
60 (17)
71 (16)
58 (13)
66 (13)
16.0 (8.4)

0.465
0.425
0.384
0.501
0.593
0.499
0.295
0.662
0.303
0.046
0.489
0.123
0.267

Abbreviations: BMI=body mass index; CDVA=corrected distance visual acuity; CS=contrast sensitivity;
cpd=cycles per degree; GD=glare disability; FVA=functional vision analyzer; ROS=retinotopic ocular
sensitivity; SA=situational analysis; CAn=comparative analysis; SSS=subjective satisfaction score.
Group 1: 20mg L, 2mg Z; Group 2: 10mg MZ, 10mg L, 2mg Z; Group 3: 17 mg MZ, 3 mg L, 2mg Z
* n≠52 (for entire study groups) due to either a) the absence of the test in question at study outset, b) the
patient had difficulty/could not perform the test, or c) the data was unreliable.
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Table 6.5 AMD-severity grading for entire group and intervention subgroups at
baseline.
Grade
1-2
3-4
5-6
7-8

Entire group (n=52)
9 (17.3%)
22 (42.3%)
13 (25.0%)
8 (15.4%)

Group 1 (n=17)
3 (17.6%)
8 (47.1%)
4 (23.5%)
2 (11.8%)

Group 2 (n=21)
4 (19.0%)
8 (38.1%)
5 (23.8%)
4 (19.0%)

Group 3 (n=14)
2 (14.3%)
6 (42.9%)
4 (28.6%)
2 (14.3%)

Sig.
0.994

Group 1: 20mg L, 2mg Z; Group 2: 10mg MZ, 10mg L, 2mg Z; Group 3: 17 mg MZ, 3 mg L, 2mg Z

6.3.2 Longitudinal data

Values for MPOD at each eccentricity, at baseline and 12 months, and their
corresponding p values with respect to change over time, are summarised in Table 6.6.
Of note, there were no statistically significant differences between the three
supplementation groups with respect to change in MPOD, at any eccentricity (p>0.5, for
all; determined using one-way ANOVA).

Table 6.6 Mean (±sd) MPOD at baseline and twelve months.
Group 1

Group 2

Group 3

Eccentricity

Baseline

12 months

p

Baseline

12 months

p

Baseline

12 months

p

0.25°

0.50 ±0.25

0.59 ±0.30

0.077

0.50 ±0.25

0.60 ±0.21

0.005

0.46 ±0.21

0.59 ±0.20

0.010

0.5°

0.38 ±0.27

0.47 ±0.27

0.055

0.42 ±0.22

0.50 ±0.19

0.005

0.36 ±0.19

0.46 ±0.21

0.020

1°

0.27 ±0.18

0.34 ±0.16

0.083

0.27 ±0.13

0.34 ±0.17

0.005

0.24 ±0.17

0.33 ±0.16

0.019

1.75°

0.16 ±0.11

0.21 ±0.09

0.018

0.14 ±0.11

0.22 ±0.12

0.002

0.11 ±0.12

0.19 ±0.10

0.006

Abbreviations: MPOD=macular pigment optical density; n=number of subjects
Group 1: 20mg L, 2mg Z; Group 2: 10mg MZ, 10mg L, 2mg Z; Group 3: 17 mg MZ, 3 mg L, 2mg Z

Mean values (at baseline and 12 months) for parameters measured in the study,
and their respective p values in relation to change over time, are displayed in Table 6.7.
Letter CS values at baseline and at 12 months, for the three intervention groups, for
each spatial frequency, is displayed in Figure 6.7. One-way ANOVA (and subsequent
post-hoc analysis) showed statistically significant differences between Groups 1 and 3
with respect to change in letter CS at 6.0, 9.6 and 15.2 cpd, and between Groups 2 and 3
for letter CS at 6.0 cpd (p<0.05, for all). There were no significant differences between
groups for the remaining visual performance parameters (p>0.5, for all).
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Table 6.7 Mean (±sd) values for measures of visual function and subjective visual experience, at
baseline and at 12 months.
Group 1
Baseline

12 months

CDVA (SE)

99 (7)

98 (6)

CDVA (nSE)

96 (9)

95 (9)

Group 2
p

Baseline

12 months

0.408

99 (8)

98 (5)

0.486

96 (12)

95 (11)

Group 3
p

Baseline

12 months

p

0.554

98 (6)

98 (7)

0.799

0.675

94 (8)

97 (4)

0.201

Letter CS (photopic)
1.2
73.0 (49.1)

91.8 (48.5)

0.021*

61.2 (41.3)

91.9 (53.6)

0.014*

73.2 (52.3)

92.2 (55.0)

0.081*

2.4

59.7 (45.3)

86.7 (54.2)

0.006*

56.8 (40.5)

77.8 (51.6)

0.008*

54.3 (41.4)

86.2 (52.1)

0.002*

6.0

29.0 (14.9)

38.1 (26.7)

0.098*

24.3 (14.0)

30.9 (18.8)

0.058*

23.6 (16.0)

42.2 (25.9)

0.002*

9.6

16.0 (9.1)

16.4 (9.0)

0.939*

12.3 (7.3)

17.5 (12.3)

0.066*

12.9 (9.7)

20.1 (11.9)

0.016*

15.2

7.1 (4.5)

7.8 (5.5)

0.408*

6.2 (4.8)

7.8 (6.4)

0.189*

6.4 (5.7)

8.7 (5.8)

0.005*

1.5

45.6 (29.8)

69.6 (28.2)

0.007*

46.3 (24.5)

65.5 (30.1)

0.047*

44.6 (30.4)

61.6 (29.0)

0.292*

3

47.1 (26.5)

73.9 (63.3)

0.007*

58.6 (33.0)

73.2 (38.0)

0.058*

58.0 (44.9)

90.9 (47.2)

0.175*

6

21.0 (17.1)

44.2 (91.8)

0.521*

25.9 (17.5)

38.5 (38.7)

0.278*

24.3 (20.4)

46.6 (38.6)

0.123*

12

4.8 (2.1)

13.9 (30.8)

0.109*

5.6 (3.9)

7.2 (4.2)

0.137*

6.9 (5.4)

11.3 (12.0)

0.498*

18

3.1 (3.0)

2.1 (0.5)

0.207*

2.1 (0.5)

3.2 (5.1)

0.317*

2.4 (1.2)

3.0 (2.8)

0.655*

1.5

34.9 (24.3)

47.7 (23.5)

0.007*

41.1 (22.0)

47.3 (26.3)

0.241*

31.8 (21.4)

48.9 (27.0)

0.023*

3

56.6 (27.3)

75.0 (19.9)

0.002*

66.1 (33.6)

80.2 (32.6)

0.108*

65.4 (27.5)

78.0 (34.9)

0.169*

6

40.3 (25.0)

48.4 (33.5)

0.310*

45.1 (32.1)

63.5 (49.1)

0.064*

41.7 (36.4)

55.9 (39.8)

0.192*

12

13.4 (11.0)

13.1 (11.6)

0.709*

14.8 (14.3)

28.5 (34.0)

0.118*

15.2 (13.7)

26.6 (28.7)

0.314*

18

6.4 (6.3)

5.6 (6.5)

0.498*

5.8 (5.5)

8.0 (9.5)

0.687*

8.5 (9.8)

10.6 (12.3)

0.866*

1.5

39.9 (25.2)

40.9 (23.5)

0.753*

37.5 (28.8)

42.9 (27.5)

0.289*

26.8 (24.1)

48.3 (33.1)

0.021*

3

54.07 (43.5)

47.9 (24.1)

0.439*

42.4 (26.8)

63.3 (35.9)

0.010*

40.4 (40.3)

52.9 (35.9)

0.161*

6

18.0 (17.3)

14.8 (13.0)

0.564*

19.8 (14.3)

27.6 (31.2)

0.553*

18.6 (15.9)

27.3 (29.8)

0.345*

12

5.1 (3.0)

5.6 (2.7)

0.273*

5.1 (3.1)

13.9 (28.9)

0.144*

6.9 (4.3)

5.8 (5.0)

0.115*

18

2.4 (1.6)

2.0 (0.0)

0.336*

2.2 (0.7)

5.7 (15.3)

0.655*

2.1 (0.5)

2.7 (2.7)

0.317*

1.5

45.9 (26.9)

64.1 (30.1)

0.006*

36.8 (16.1)

61.8 (27.9)

0.002*

37.9 (23.4)

64.6 (34.0)

0.058*

3

58.1 (28.0)

89.1 (42.2)

0.002*

67.2 (31.2)

99.7 (37.7)

0.006*

59.0 (22.1)

85.4 (40.3)

0.330*

6

45.3 (27.5)

58.8 (50.3)

0.000*

52.3 (40.5)

69.1 (78.7)

0.012*

45.5 (38.7)

68.6 (49.5)

0.120*

12

16.2 (16.7)

16.8 (20.6)

0.953*

12.9 (11.0)

18.7 (16.8)

0.169*

15.8 (14.2)

20.5 (22.7)

0.320*

18

7.7 (9.5)

8.8 (11.9)

0.674*

4.8 (4.1)

13.4 (21.9)

0.071*

9.4 (8.8)

10.6 (11.8)

0.993*

CS (mesopic)†
Frequency (cpd)

CS (photopic)†
Frequency (cpd)

GD (mesopic)†
Frequency (cpd)

GD (photopic)†
Frequency (cpd)

Retinotopic ocular sensitivity
Central 4°

18.3 (1.9)

18.5 (1.5)

0.271

18.4 (1.8)

18.3 (2.3)

0.640

17.5 (2.7)

17.7 (3.0)

0.718

Central 8°

18.5 (1.5)

18.7 (1.3)

0.510

18.5 (1.7)

18.4 (2.1)

0.850

18.0 (2.3)

18.0 (2.7)

0.928

Central 12°

18.4 (1.7)

18.5 (1.4)

0.442

18.1(2.2)

18.3 (2.1)

0.673

17.5 (2.6)

17.2 (3.2)

0.611

Questionnaire
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Glare SA

59 (21)

58 (17)

0.513

65 (20)

69 (25)

0.512

54 (19)

56 (15)

0.723

Glare CAn

51 (19)

50 (15)

0.655

60 (18)

60 (19)

1.000

55 (15)

51 (16)

0.257

Glare SSS

55 (28)

62 (21)

0.268

69 (23)

69 (18)

1.000

58 (24)

58 (20)

1.000

Acuity SA

70 (20)

70 (22)

0.880

68 (21)

73 (16)

0.130

61 (19)

71 (13)

0.041

Acuity CAn

59 (17)

53 (10)

0.157

57 (14)

60 (13)

0.180

52 (15)

54 (13)

0.753

Acuity SSS

66 (23)

70 (20)

0.373

73 (21)

70 (17)

0.450

63 (18)

68 (16)

0.549

Light SA

65 (21)

59 (18)

0.047

70 (18)

74 (15)

0.216

60 (11)

68 (11)

0.037

Light CAn

56 (18)

54 (9)

0.705

58 (12)

59 (16)

0.790

53 (13)

57 (8)

0.504

Light SSS

69 (17)

68 (19)

0.634

73 (19)

69 (18)

0.479

60 (17)

70 (10)

0.139

Daily SA

75 (14)

73 (15)

0.706

83 (15)

82 (19)

0.706

71 (16)

77 (12)

0.144

Daily CAn

56 (12)

57 (11)

0.655

60 (13)

62 (9)

0.527

58 (13)

58 (16)

1.000

Daily SSS

66 (15)

73 (16)

0.043

76 (16)

72 (14)

0.191

66 (13)

73 (9)

0.108

Diet score

17.3 (10.9)

23.3 (11.3)

0.044

20.6 (11.7)

26.7 (16.1)

0.020

15.3 (8.5)

27.5 (11.2)

0.006

Abbreviations: CDVA=corrected distance visual acuity; SE=study eye; nSE=non-study eye; CS=contrast
sensitivity; cpd=cycles per degree; GD=glare disability; SA=situational analysis; CAn=comparative analysis;
SSS=subjective satisfaction score
Group 1: 20mg L, 2mg Z; Group 2: 10mg MZ, 10mg L, 2mg Z; Group 3: 17 mg MZ, 3 mg L, 2mg Z
†as measured by the Functional Vision Analyzer™; n=13 for Group 1, n=14 for Group 2, n=12 for Group 3.

*the statistical tests were based on log-transformed data.
Note: The p values reported are for the paired t test (or the corresponding non-parametric test when the data
distribution was non-normal).
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Figure 6.7 Letter CS at baseline and at 12 months, for each group.
Group 1: 20mg L, 2mg Z; Group 2: 10mg MZ, 10mg L, 2mg Z; Group 3: 17 mg MZ, 3 mg L, 2mg Z
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The proportion of subjects in each intervention group exhibiting a change in
severity scale grade of two or more, considered clinically meaningful for the purpose of
this study,394 is given in Table 6.8. A change in the negative direction (i.e. -1, -2)
indicates a progression along the AMD severity scale, whereas positive integers indicate
regression (improvement). Between baseline and 12 months, there was no statistically
significant difference between treatment groups with respect to change in AMD severity
scale (p=0.455, Pearson chi-square test).
In brief, 79% of subjects exhibited no clinically meaningful change in AMD
severity grade between baseline and 12 months, with approximately 11% exhibiting
deterioration and 9% exhibiting an improvement.

Table 6.8 Change in AMD grade (11-step scale) between baseline and 12 months.
Group
1

n
17

-2
1 (5.9%)

-1
1 (5.9%)

0
10 (58.8%)

+1
3 (17.6%)

+2
+3
Sig.
1 (5.9%) 1 (5.9%) 0.455

2

21

3 (14.3%)

2 (9.5%)

11 (52.4%)

3 (14.3%)

2 (9.5%)

0

3

14

2 (14.3%)

5 (35.7%)

4 (28.6%)

2 (14.3%)

1 (7.1%)

0

Total

52 (100%) 6 (11.5%) 8 (15.4%) 25 (48.1%) 8 (15.4%) 4 (7.7%) 1 (1.9%)

Abbreviations: n=number of subjects; negative value indicates disease progression; a positive value indicates
disease regression; 0=no change in grade
Group 1: 20mg L, 2mg Z; Group 2: 10mg MZ, 10mg L, 2mg Z; Group 3: 17 mg MZ, 3 mg L, 2mg Z

Clinical pathology analysis results are reported in Table 6.9. Of note, two
variables in Group 1, two variables in Group 2 and two variables in Group 3
demonstrated statistically significant changes from baseline (in both positive and
negative directions). All variables, however, remained within their respective and
normal reference ranges.
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Table 6.9 Clinical pathology variables following supplementation with the macular carotenoids assessed at baseline and at 12 months for each of the
three intervention groups.
Pathology variable

Function of test

Reference Range (Unit)

Group 1 (n=9)*

Group 2 (n=20)*

12 months
138±3

p
0.312

Baseline
141±3

12 months
138±2

Group 3 (n=12)*

Sodium

Renal profile

135-145 (mmol/L)

Baseline
139±3

Potassium

Renal profile

3.3-5.3 (mmol/L)

4.6±0.3

4.7±0.2

0.366

4.6±0.4

4.7±0.4

p
0.001
0.475

Baseline
136±3

12 months
137±4

p
0.371

4.7±0.3

4.8±0.2

0.709

Chloride

Renal profile

98-107 (mmol/L)

104±2

106±2

0.073

104±3

104±3

0.922

103±4

103±4

0.612

Urea

Renal profile

2.5-7.7 (mmol/L)

7.2±2.4

6.5±1.4

0.174

6.1±1.1

6.6±1.5

0.073

6.7±1.5

6.0±1.7

0.053

Creatinine

Renal profile

40-90 (μmol/L)

81±13

74±10

0.086

78±14

77±15

0.299

76±19

75±17

0.681

Total protein

Liver profile

64-83 (g/L)

69±3

68±3

0.499

71±4

70±3

0.415

70±5

70±5

0.558

Albumin

Liver profile

37-52 (g/L)

41±2

40±3

0.444

43±2

42±2

0.134

41±2

42±2

0.410

Globulins

Liver profile

21-36 (g/L)

28±4

28±3

1.000

28±4

29±3

0.737

29±5

28±4

0.272

Total bilirubin

Liver profile

3.4-21.0 (μmol/L)

6.2±2.0

7.8±2.2

9.9±5.3

0.293

8.0±3.6

10.1±4.0

Liver profile

0-55 IU/L

23±8

21±8

0.050
0.426

9.1±4.7

AAT

22±6

22±6

0.752

19±3

20±5

0.001
0.279

ASA

Liver profile

5-36 IU/L

24±3

24±4

0.782

22±4

22±4

0.903

21±3

22±4

0.083

Alkaline phosphate

Liver profile

40-150 IU/L

79±27

87±31

78±20

79±20

0.501

76±11

82±17

0.114

GGT

Liver profile

9-36 IU/L

39±40

40±41

0.013
0.668

27±11

28±14

0.395

27±16

32±23

0.075

Cholesterol total

Lipid profile

<5.0 (mmol/L)

5.2±1.0

5.2±1.1

0.708

4.7±1.3

4.5±0.9

0.231

4.8±1.0

4.8±0.9

1.000

Triglycerides

Lipid profile

0.60-1.70 (mmol/L)

1.47±0.61

1.34±0.66

0.185

1.44±0.49

1.39±0.60

0.700

1.51±1.31

1.29±0.82

0.236

HDL

Lipid profile

1.00-1.55 (mmol/L)

1.51±0.37

1.43±0.31

0.063

1.31±0.33

1.24±0.28

1.46±0.47

1.46±0.51

0.942

Direct LDL

Lipid profile

<3.0 (mmol/L)

3.1±1.0

3.2±1.0

0.419

2.8±1.1

2.7±0.8

0.044
0.317

2.8±0.9

2.7±0.9

0.671

Calcium

Bone profile

2.10-2.60 (mmol/L)

2.31±0.10

2.32±0.14

0.661

2.35±0.07

2.35±0.07

0.825

2.31±0.06

2.40±0.11

Phosphate

Bone profile

0.80-1.56 (mmol/L)

1.13±0.17

1.20±0.24

0.292

1.17±0.17

1.19±0.19

0.672

1.07±0.25

1.10±0.21

0.005
0.414

Magnesium

Bone profile

0.65-1.10 (mmol/L)

0.99±0.05

0.94±0.09

0.159

0.97±0.08

0.98±0.06

0.573

0.93±0.12

0.94±0.08

0.599

Uric Acid

Bone profile

155-394 (μmol/L)

290±54

280±62

0.579

315±65

312±66

0.724

305±65

322±89

0.260

Glucose

Bone profile
Inflammation
marker

3.1-6.1 (mmol/L)

5.3±0.7

5.3±1.2

0.910

5.0±0.6

5.0±0.7

0.867

5.0±0.9

5.1±0.7

0.273

<5.0 (mg/L)

1.2±0.5

1.6±1.0

0.097

2.2±2.4

2.3±2.1

0.864

4.0±5.1

4.3±6.7

0.728

HSRP

164

Full blood count
White cell count

Haematology

3.88-10.49 (10e9/L)

6.54±2.00

5.88±1.03

0.331

6.74±1.53

6.81±1.78

0.830

6.13±1.56

5.95±1.10

0.661

Red cell count

Haematology

3.73-5.02 (10e12/L)

4.51±0.42

4.36±0.33

0.367

4.50±0.41

4.47±0.39

0.377

4.44±0.45

4.46±0.45

0.858

Haemoglobin

Haematology

11.3-15.2 (g/dL)

13.6±1.1

13.6±0.9

0.622

13.7±1.1

13.7±1.2

0.596

13.6±1.2

13.6±1.1

0.969

Haematocrit

Haematology

0.323-0.462 (L/L)

0.407±0.032

0.405±0.020

0.769

0.413±0.031

0.413±0.031

0.939

0.409±0.031

0.412±0.031

0.779

MCV

Haematology

83.1-99.1 (fL)

90.5±3.1

93.1±5.1

0.222

92.0±4.0

92.6±4.0

0.414

92.4±3.7

92.6±3.7

0.778

MCH

Haematology

28.3-33.9 (pg)

30.1±1.2

31.3±1.8

0.134

30.4±1.3

30.8±1.2

0.167

30.7±1.2

30.5±1.4

0.632

MCHC

Haematology

32.1-36.6 (g/dL)

33.3±1.0

33.6±0.8

0.357

33.1±0.8

33.3±1.2

0.523

33.2±1.1

33.0±1.0

0.468

Platelets

Haematology

164-382 (10e9/L)

332±249

249±123

0.196

258±88

250±118

0.527

244±46

254±61

0.369

Differential white cell count
Neutrophils

Haematology

1.91-7.16 (10e9/L)

3.80±1.27

3.44±0.82

0.423

4.09±1.20

4.23±1.38

0.580

3.92±1.23

3.84±1.21

0.809

Lymphocytes

Haematology

1.01-3.13 (10e9/L)

1.82±0.54

1.66±0.39

0.309

1.81±0.43

1.70±0.42

0.128

1.42±0.36

1.38±0.39

0.704

Monocytes

Haematology

0.19-0.68 (10e9/L)

0.47±0.18

0.40±0.13

0.322

0.43±0.11

0.45±0.16

0.495

0.41±0.12

0.35±0.09

0.132

Eosinophils

Haematology

0.05-0.51 (10e9/L)

0.22±0.05

0.18±0.06

0.195

0.18±0.09

0.23±0.13

0.055

0.17±0.10

0.17±0.08

1.000

Basophils

Haematology

0.02-0.15 (10e9/L)

0.05±0.03

0.05±0.02

0.505

0.05±0.02

0.07±0.04

0.063

0.04±0.02

0.06±0.03

0.042

Large unstained cells
Haematology
0.00-0.30 (10e9/L)
0.17±0.07
0.14±0.03
0.222
0.18±0.07
0.16±0.05
0.122
0.16±0.05
0.14±0.02
Abbreviations: AAT=alanine aminotransferase; ASA= aspartate aminotransferase; GGT=gamma glytamyl transpeptidase; HDL=high density lipoprotein; LDL=low density
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lipoprotein; HSCP=high sensitive reactive protein; MCV=mean corpuscular volume; MCH=mean corpuscular haemoglobin; MCHC=mean corpuscular haemoglobin concentration
Group 1: 20mg L, 2mg Z; Group 2: 10mg MZ, 10mg L, 2mg Z; Group 3: 17 mg MZ, 3 mg L, 2mg Z
*total n≠52 as data on pathology analysis was not available for all subjects at both baseline and 12 months
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6.3.3 A subsidiary six-month analysis

While the study’s primary end-point was 12 months, it was felt that the six-month data,
when viewed separately, may be of interest in terms of changes in measures of MPOD
and visual performance, particularly if one wants to consider the possible differences in
response time to the supplements. Repeated measures that would include baseline, 6 and
12 month data were not sufficiently powered due to the change in the composition of
the study cohort between baseline and 12 months (primarily due to dropouts).
Twenty-one subjects from Group 1, 22 subjects from Group 2, and 15 subjects
from Group 3 were eligible for this analysis i.e. had datasets at baseline and six months.
There were no significant differences between groups with respect to any variable at
baseline (p>0.05, for all). Values for MPOD at each eccentricity, at baseline and six
months, are summarized in Table 6.10. Of note, there were statistically significant
increases in MPOD at all eccentricities for each of the three groups (with the exception
of 0.5° in Group 3).
Table 6.11 reports those parameters of visual performance that changed
significantly between baseline and six months. In brief, two variables in Group 1, nine
variables in Group 2, and two variables in Group 3, improved significantly between
baseline and six months. Of note, mean CDVA reduced significantly between baseline
and six months in Group 1.

Table 6.10 Mean (±sd) MPOD at baseline and six months.
Group 1

Group 2

Group 3

Eccentricity

Baseline

6 months

p

Baseline

6 months

p

Baseline

6 months

p

0.25°

0.47 ±0.25

0.58 ±0.27

0.001

0.50 ±0.24

0.63 ±0.20

<0.001

0.46 ±0.20

0.55 ±0.21

0.028

0.5°

0.36 ±0.25

0.46 ±0.23

0.004

0.42 ±0.21

0.52 ±0.19

0.002

0.36 ±0.16

0.42 ±0.17

0.089

1°

0.25 ±0.17

0.35 ±0.17

0.001

0.28 ±0.13

0.38 ±0.15

<0.001

0.23 ±0.15

0.30 ±0.12

0.023

1.75°

0.15 ±0.11

0.21 ±0.12

0.010

0.15 ±0.11

0.23 ±0.11

0.004

0.11 ±0.10

0.19 ±0.10

0.006

Abbreviations: MPOD=macular pigment optical density; n=number of subjects
Group 1: 20mg L, 2mg Z; Group 2: 10mg MZ, 10mg L, 2mg Z; Group 3: 17 mg MZ, 3 mg L, 2mg Z
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Table 6.11 Visual performance parameters which displayed significant changes
between baseline and 6 months (for each study group).
Variable
Baseline Mean (±sd)
6 months Mean (±sd)
p
Group 1
99 (7)
96 (7)
0.019*
CDVA (SE)
40.29 (26.51)
47.94 (24.61)
0.013
GD pt 1.5cpd
53.94 (25.67)
79.29 (40.91)
0.019
GD pt 3cpd
Group 2
59.09 (38.71)
85.50 (48.71)
0.018
Letter CS 1.2cpd
12.32
(6.75)
22.59
(20.70)
0.018
Letter CS 9.6cpd
57.72 (33.79)
71.50 (42.39)
0.012
CS ms 3cpd
62.78 (31.06)
80.78 (33.70)
0.026
CS pt 3cpd
5.33 (5.39)
10.70 (12.55)
0.029
CS pt 18cpd
39.61 (26.81)
52.00 (37.06)
0.031
GD ms 3cpd
34.83 (16.81)
42.14 (20.85)
0.005
GD pt 1.5cpd
60.44 (30.20)
79.94 (36.11)
0.009
GD pt 3cpd
Group 3
22.07 (21.22)
30.33 (33.61)
0.026
CS ms 6cpd
16.60
(15.91)
27.80
(34.91)
0.035
GD ms 6cpd
Abbreviations: CDVA=corrected distance visual acuity; SE=study eye; GD=glare disability; pt=under
photopic conditions; cpd=cycles per degree; CS=contrast sensitivity; ms=under mesopic conditions.
*p value relates to a significant decrease in visual acuity
Group 1: 20mg L, 2mg Z; Group 2: 10mg MZ, 10mg L, 2mg Z; Group 3: 17 mg MZ, 3 mg L, 2mg Z
Note: CS and GD p values are based on log-transformed data.

6.4 Discussion
MOST AMD is a randomised single-blind clinical trial comparing the effect of
supplementation with three different macular carotenoid formulations on MPOD, visual
performance and AMD grade, over a period of twelve months, in subjects with early
AMD.
This study found a positive and statistically significant correlation, at baseline,
between MPOD and measures of visual function, including CDVA, letter CS, grating
CS under mesopic and photopic conditions at low spatial frequencies and GD under
photopic conditions at low and mid-range spatial frequencies. In other words, and in the
absence of supplementation, high MPOD is associated with better vision. Our findings
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are consistent with those of another study, which found a significant and positive
association between MPOD and both CDVA and CS (under mesopic and photopic
conditions at intermediate spatial frequencies) in subjects without disease.29 It has been
shown that, in subjects with atrophic AMD, lower MP levels are associated with poorer
CS function (the minimum amount of contrast needed to detect visual stimuli at a range
of spatial frequencies) for low spatial frequencies, although that observation did not
reach statistical significance.34
In the current study, MPOD was significantly greater at one year than at baseline
at all eccentricities for subjects supplemented with all three macular carotenoids (Group
2) and for subjects supplemented with high doses of MZ (17mg; Group 3). Although the
observed augmentation in mean MPOD at 12 months did not reach statistical
significance for subjects supplemented with high doses of L (20mg; Group 1), except at
1.75 ° eccentricity, it should be noted that the increases observed for this group at other
eccentricities were not dissimilar in magnitude to those observed for Groups 2 and 3
(standard deviations in Group 1 were, however, larger). In addition, there was no
statistically significant difference between groups with respect to change in MPOD over
the study period.Of note, the L/Z diet score increased significantly between baseline and
12 months, for all three groups, which may have also been a contributing factor in the
observed increase in MPOD.
The significant rise in MPOD across the spatial profile when all three macular
carotenoids (Group 2) are included in the formulation or when supplemented with 17mg
of MZ and small amounts of L and Z (Group 3), and especially the augmentation of MP
centrally, is neither surprising nor counter-intuitive, given the known distribution of
MP’s individual constituent carotenoids. The inclusion of MZ in the formulation is
likely to result in augmentation of MP centrally (demonstrated in Groups 2 and 3 here),
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as this is the site of dominance of this carotenoid. The inclusion of L in the formulation
(as in all groups) will result in MP augmentation at the more peripheral site of that
carotenoid’s natural dominance (1.75°), attested to by the significance of the
augmentation of MP at this locus in the high L group (Group 1). These observations are
also consistent with recently published findings,322 which revealed that
supplementation with a formulation containing MZ can (re)generate the typical central
peak of MP at the foveal centre in subjects who lack such a central peak at baseline.
Interestingly, and in addition, that study showed that subjects supplementing with all
three macular carotenoids exhibited augmentation in MPOD across their spatial profiles.
Indeed, this atypical profile (the lack of a central peak, sometimes referred to a “central
dip”), is of particular interest, as such atypical profiles, putatively attributable to an
inability to convert retinal L to retinal MZ, are associated with increased risk of
AMD.321 It would appear, therefore, that supplementation with all three macular
carotenoids results in the greatest augmentation of MPOD across its spatial profile,
thereby putatively affording the greatest protection against the (photo-) oxidative
processes known to be important in the pathogenesis of AMD. Interestingly, in vitro
work has concluded that the antioxidant capacity of the macular carotenoids is
maximised when all three macular carotenoids are present.396
In this study, supplementation with the macular carotenoids resulted in the
demonstrable improvements in CS in subjects with early AMD, but the inclusion of MZ
in the formulation was required to achieve improvements at low and high spatial
frequencies. Again, it is unsurprising that CS would improve following augmentation of
MP, especially as such augmentation was demonstrated centrally, given the
consequential enhancement of pre-receptoral filtration of blue light and attenuation of
CA and light scatter. This is particularly important for subjects with AMD, as CS is an
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important measure of visual function in patients afflicted with the condition. Studies
have shown that, when compared with VA, CS better relates to the ability to perform
tasks accurately and efficiently, to discriminate between objects177 and to judge
distances.178 A statistically significant improvement (decrease) in contrast acuity
thresholds (comparable with the reciprocal of CS) has been shown in normal subjects
supplemented with L under mesopic conditions.186 Furthermore, the observation that
supplementation with high doses of L (in the absence of MZ) resulted in improved CS
at low spatial frequencies only (and no observed change in mean CS at high spatial
frequencies) is consistent with the fact that visual function at low spatial frequencies
will be mediated by slightly eccentric retinal loci. Of note, concentrations of L are
higher in the peripheral macula, compared to the fovea.397
Previous studies have investigated the impact of macular carotenoid
supplementation on CS in subjects with AMD, with the majority of studies reporting
improvements in CS following supplementation (with L and Z),34, 169, 280, 292, 293
although no study to date has tested a formulation containing MZ. A recent study has
shown significant increases in CS at low spatial frequencies following supplementation
with either 10mg L, 20mg L, or 10mg L and 10mg Z (combined), in subjects with early
AMD, over a 48-week study period. 398 Although significant improvements were found
in CS for higher spatial frequencies (by 48 weeks), the magnitude of the differences
were less than those found at the lower spatial frequencies (across all intervention
groups). Of interest, the authors report no improvement in CS at 18 cpd in any of the
groups. This relatively poorer response at higher spatial frequencies could be
attributable to the absence of MZ in their formulation. These findings are in agreement
with those reported in the current study, which found demonstrable improvements in CS
at high spatial frequencies, but only amongst subjects who were supplemented with a
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formulation containing MZ, and not amongst subjects supplementing with high doses of
L alone.
There were observed improvements across all three groups, between baseline
and 12 months, in mean CS and GD values measured using the FVA™ for the majority
of spatial frequencies tested, although not all reached statistical significance, nor was
the distribution of the significant parameters consistent. This may have been due, at
least in part, to the reduced number of datasets collected for this particular device (n=
39). It is interesting to note, however, that mean increases in CS and GD of at least 20%
(from baseline to 12 months) were seen in 10 (of 20) variables in Group 1, in 19
variables in Group 2 and in 17 variables in Group 3. This does seem to suggest that
subjects taking a carotenoid formulation that includes MZ are more likely to have
improvements in CS and GD, compared to a formulation which does not contain this
carotenoid. These results, although speculative, do correlate with the findings of a
recent study in normals.170
MP’s capacity to filter short wavelength (blue) light at a pre-receptoral level
render it capable, in theory at least, of reducing the effect of a number of optical
aberrations. CA is the most important aberration affecting visual quality399 and
primarily relates to the defocus of short wavelength light (up to 1.2 dioptres compared
to mid wavelength light [550nm]),400 the attenuation of which is achieved by the prereceptoral absorption of blue light.401 In 1866, Max Schultze was the first to propose
the theory that the absorption of short wavelength light by MP, before it was incident
upon the underlying photoreceptors, would reduce CA, putatively improving VA,402
and this theory has been extended to include CS at a range of spatial frequencies.403, 404
The impact of CA on CS is well documented; improvements have been reported in CS
and CDVA when both chromatic and monochromatic aberrations are minimised.405 A
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study investigated CS in three different groups of pseudophakic subjects, each group
having an intra-ocular lens (IOL) implant of differing Abbe number (the lower the Abbe
number, the greater the CA produced). There was no difference in CS between the three
groups when CS was measured under 549nm monochromatic light, whereas there were
statistically significant differences in CS between groups when CS was measured under
broadband white light; the group with the IOL of lower Abbe number had poorer CS
under white light compared with the group with the IOL of higher Abbe number. These
observations suggest that CA (in this case, caused by IOLs) can degrade the quality of
the retinal image, as measured by CS.406
The impact of light scatter on CS and visibility has been eloquently described by
Wooten and Hammond33 in a review where they explore the effects of scatter by air
particles, in particular scatter caused by haze aerosols (a dispersed system of small
particles suspended in a gas,190 the most common component of the atmosphere), on
visibility i.e. “how far one can see and how well details can be resolved.” Light scatter
is wavelength-dependent for small particles (e.g. 0.2µm), such as those found in haze
aerosols. As light passes through the atmosphere, shorter wavelengths are more prone to
scatter than longer wavelengths. The scattering of short-wavelength light creates a
bluish veiling luminance, often termed “blue haze”, which, when superimposed on the
retinal image, reduces the contrast of targets being observed. The authors propose that
having MPOD of e.g. 0.5 OD units (compared with having MPOD of zero OD units)
can attenuate the veiling luminance of a short-wavelength dominant background by
17%, thereby increasing the visibility and discriminability of objects in natural viewing
conditions.
Results of the subsidiary six-month analysis has shown that, over this time
period, all three groups had comparable increases in MPOD at all eccentricities

172

following supplementation with the macular carotenoids. Statistically significant
improvements in vision in this initial six-month period favoured Group 2, where there
were a total of nine separate parameters of visual performance exhibiting improvements
during this period, compared with two parameters in both Groups 1 and 3. These
findings suggest that, within a six-month supplementation period, a formulation
containing all three macular carotenoids potentially has the greatest impact on visual
performance. This finding is supported by a similar study in normal subjects, which has
shown that supplementation with a preparation containing all three macular carotenoids
(L, Z and MZ) results in demonstrable improvements in visual performance,
improvements that are not observed amongst subjects supplementing with L and Z
alone (i.e. in the absence of MZ).170
These supplementary six-month findings, however, should only be interpreted in
conjunction with the 12-month results with full appreciation of the fact that it is not a
comparison of like with like. The apparent inconsistencies between these six-month
findings and those reported for 12 months (previously discussed), can be deemed
attributable to differences in the cohort composition at each of these time points. For
example, not only were there were dropouts between six and 12 months (n=6), there
were an additional 11 subjects who had a 12-month visit who did not attend for a sixmonth visit. It is not, therefore, possible to compare the changes observed at six months
with those observed at 12 months as the same subjects are not being analysed at each of
these time points. This is the most likely reason for the inconsistencies observed here.
There was no statistically significant change over time (either at six or 12
months) in measures of ROS in this study. This may be in part due to the relatively high
mean ROS scores at baseline (18.1 dB on average; maximum score achievable is 20dB,
thus creating a ceiling effect), the small numbers in the study and the relatively short
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follow-up (12 months). Only one study (prior to the current one) has investigated the
impact of macular carotenoid supplementation on ROS in subjects with early AMD.
This study reports a mean±sd improvement of 7.3%±13.2% in mean ROS following
supplementation with L for six months (20mg for first three months and 10mg for the
remaining three months), although the observed improvements did not reach statistical
significance. Of note, the authors did report a significant correlation between the
increase in MPOD and the increase in ROS over the study period.35 ROS has been
shown to be an effective gauge of macular function compared to, for example,
CDVA.204 However, the (albeit limited) evidence to date suggests that microperimetry
may not be capable of detecting functional improvements following macular carotenoid
supplementation, at least not within a 12 month time frame and with a relatively small
study population and with the protocol employed. Further study over a longer period
(particularly considering the chronic nature of the condition) and with a larger cohort of
subjects is warranted. Again, it should be noted that deterioration in ROS was also not
observed for any of the supplementation groups, which is important considering the
natural degenerative course of the condition. It is interesting to note that ROS was the
primary outcome measure affected by intravitreal ranibizumab in cases of nv-AMD (see
Chapter 5) and, therefore, may be more appropriate for appreciation of change in later
stages of the condition.
Another study407 has demonstrated improvements in retinal function (measured
using the multifocal elecroretinogram [mfERG]),81 following supplementation with the
macular carotenoids, in patients with early AMD over a 48-week study period. Retinal
function was assessed for six separate concentric rings of retinal eccentricity, ring 1
being closest to fixation. Following 48 weeks of supplementation with either 10mg L,
20mg L, or 10mg L and 10mg Z (combined), the authors reported statistically
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significant increases in the mfERG densities within ring 1 for all intervention groups,
with no observed changes in the placebo group. Furthermore, increases in MP were
associated with increases in mfERG densities in the central retina (rings 1 and 2, but not
in rings 3-6). Their findings are consistent with those of a previous study that reported
significant improvements in mfERG densities in the central retina amongst early AMD
patients receiving supplementation (10mg L and 1mg Z, in combination with coantioxidants) compared to placebo.408 In brief, these studies, therefore, provide
objective evidence that supplementation with the macular carotenoids benefits visual
function, and are consistent with the findings of the current study.
This study has shown that, from a morphological perspective, AMD remains
stable for at least 12 months following supplementation with the macular carotenoids
(regardless of intervention type). However, the findings presented here must be
interpreted with full appreciation of the study’s weaknesses, namely the small numbers
of subjects involved, the study’s short duration, and the absence of a placebo group. For
purposes of discussion, it is reasonable to compare our findings to the placebo group in
the recently published CARMA, which was a randomised, double blind, placebo
controlled clinical trial of L (12mg) and Z (0.6mg) supplementation with coantioxidants versus placebo in patients with early AMD.294 The study population of
CARMA is comparable with that of the current study, in terms of inclusion and
exclusion criteria, methodology of AMD grading, and demographic and geographic
considerations.294 In CARMA, at 12 months, 47.4% of eyes in the placebo arm
(108/228 eyes) exhibited any degree of progression (an increase in grade of one or more
increments) compared with 41.7% of eyes in the active arm (96/230 eyes). While there
were a slightly higher proportion of eyes in the placebo arm that progressed when
compared to the active arm, the authors report no statistically significant difference
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between these event rates (i.e. no intervention effect). Interestingly, however, in the
current study, only 27% of subjects (all of whom were supplementing with the macular
carotenoids) showed progression by one or more steps at 12 months (data on file).
Clinical pathology analysis has confirmed that, in subjects with early AMD, all
variables remained with their respective normal reference ranges following
supplementation with any of the three carotenoid formulations over a 12-month period,
contributing further to the evidence concerning the safety of these supplements. These
results follow on from those of a recent report, which found no adverse clinical
implications in young healthy subjects following six months of supplementation with a
formulation containing MZ (10.6mg), Z (1.2mg) and L (5.9mg).409

6.5 Conclusion
MP can be augmented, and CS enhanced, in subjects with early AMD who receive
supplemental macular carotenoids. A formulation containing MZ appears to offer
advantages over a formulation that does not contain MZ, in terms of improvements in
psychophysical function and in terms of MP augmentation across its spatial profile, the
latter putatively affording greater protection against (photo-)oxidative injury. However,
the results of the current study should prompt and inform a well-designed, placebocontrolled clinical trial (ideally of longer duration) of supplementation with L, Z and
MZ in subjects with AMD, where outcome measures should include visual function and
disease progression.
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Chapter 7. The relationship between augmentation of central MP and
visual performance, in subjects with low MP at baseline

7.1 Study rationale, aims and objectives
It is important to consider baseline MPOD in any sample when investigating the impact
of supplementation on MPOD augmentation and/or visual performance. MPOD values
can range from 0.0 to over 1.0 OD units,235 and are related to a range of variables, such
as ethnicity, iris colour and diet.410-412 It has been shown that MPOD response to
supplementation is related to baseline MPOD levels.323, 413
Whilst studies have commented on the response of MP to macular carotenoid
supplementation amongst subjects with low MP, the impact of macular carotenoid
supplementation on visual performance in this specific group of subjects has not been
investigated.
The lack of a central peak (commonly referred to as a “central dip”) in the
MPOD spatial profile has generated interest in recent years. A study has found this
variation in MPOD spatial profile amongst 12% of its study population.321
The purpose of these subsidiary analyses of MOST was to investigate the
relationship between central MPOD and visual performance, in early AMD subjects,
who present (at baseline) with differing levels of central MPOD. In addition, I explored
MPOD response and change in visual performance following supplementation in
subjects with a central dip in MPOD spatial profile at baseline.
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7.2 Methods
Subjects recruited for MOST AMD (Chapter 6) were further divided into tertiles based
on their baseline MPOD at 0.25° (note: MPOD was not reassessed), as follows: highest
tertile = MPOD ≥0.54; middle tertile = MPOD >0.32 and <0.54; lowest tertile = MPOD
≤ 0.32. These three groups were analysed with respect to change in central MP and with
respect to change in vision following supplementation.
An atypical central dip MPOD spatial profile was defined as MPOD at 0.25° not
exceeding MPOD at 0.5° eccentricity by more than 0.04 OD units (previously
described322 ), which is divergent from the more common spatial profile of a central
peak that declines from the foveal centre. Four of the five central dip subjects were also
in the low baseline MPOD tertile and these may, therefore, be considered a subgroup of
the low MP tertile group.
The three groups (low, medium and high baseline MP) were compared, with
respect to observed changes in MPOD and letter CS, using one-way ANOVA.

Methods of MPOD measurement and visual performance assessment are described in
Chapter 6.
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7.3 Results
The relationship between baseline MPOD and response to supplementation, in terms of
change in MPOD and letter CS, is given in Table 7.1.

Table 7.1 Comparing change in MPOD and letter CS between low, mid-range and high
baseline MPOD groups.

MPOD at 0.25°

Letter CS at 1.2cpd

Letter CS at 2.4cpd

Letter CS at 6.0cpd

Letter CS at 9.6cpd

Letter CS at 15.2cpd

MP group1
Low
Med
High
Low
Med
High
Low
Med
High
Low
Med
High
Low
Med
High
Low
Med
High

Change2
0.22 (0.13)
0.01 (0.15)
0.08 (0.13)
33.4 (59.2)
10.7 (31.7)
29.9 (42.1)
41.2 (44.0)
32.2 (32.8)
14.6 (29.2)
17.7 (19.4)
9.0 (16.7)
8.7 (15.0)
8.7 (9.9)
3.1 (9.1)
2.8 (6.2)
3.4 (3.5)
0.8 (3.9)
1.1 (4.1)

Sig.
<0.001

0.435

0.186

0.176

0.211

0.062

Abbreviations: MPOD=macular pigment optical density; MP=macular pigment; CS=contrast sensitivity;
cpd=cycles per degree; GD=glare disability; ms=mesopic conditions.
1

MP group = tertile groups according to MPOD at 0.25° eccentricity: high=top tertile; med=middle

tertile; low=bottom tertile. The low groups consisted of 15 subjects with baseline MPOD ≤ 0.32 and the
high MPOD group had 22 subjects with baseline MPOD ≥ 0.54, leaving 15 subjects in the medium tertile.
2

Change=mean change between baseline and 12 months.

Considering the increasing interest in MPOD spatial profiles,321, 322, 414, 415
change in MPOD and change in measures of visual function was explored, in subjects
who presented with a central dip at baseline. Five subjects had an atypical MPOD
spatial profile at baseline. Four of these patients were in Group 2 and one was in Group
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3. MPOD spatial profiles (at 0.25° and 0.50° eccentricity) at baseline and at twelve
months following supplementation, for each of the five subjects, are displayed in Table
7.2. The atypical MPOD spatial profile was no longer present at 12 months in four of
the five cases (the remaining subject exhibited an increase in MPOD at both 0.25° and
at 0.50°, but the central dip was not, as such, rebuilt).

Table 7.2 Central MPOD values at baseline and twelve months in subjects with an
atypical profile at baseline.
Subject
MZAMD001
MZAMD006
MZAMD039
MZAMD042
MZP2006

Group
2
2
3
2
2

Baseline
MPOD 0.25 MPOD 0.5
0.22
0.26
0.31
0.31
0.21
0.20
0.19
0.33
0.55
0.54

12 months
MPOD 0.25 MPOD 0.5
0.28
0.37
0.39
0.32
0.55
0.37
0.44
0.31
0.60
0.55

Abbreviations: MPOD=macular pigment optical density

In this group of subjects (n=5), the change in MPOD at 0.25° correlated
significantly with a change in letter CS at all spatial frequencies (Table 7.3; see Figure
7.1 for graphical representations of these relationships), but with no other parameter of
visual function (p >0.05; data not shown). In contrast, these relationships (between
change in MPOD and change in letter CS) were not significant amongst subjects with
typical MP spatial profiles at baseline (r < 0.1; p > 0.05, for all).

Table 7.3 Significant associations between change in MPOD (at 0.25° eccentricity) and
change in other parameters, in patients with an atypical MPOD profile at baseline.
Variable
CS 1.2 cpd
CS 2.4 cpd
CS 6.0 cpd
CS 9.6 cpd
CS 15.2 cpd

r
0.960
0.966
0.930
0.922
0.914

p
0.010
0.008
0.022
0.026
0.030

Abbreviations: CS=contrast sensitivity; cpd=cycles per degree
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Figure 7.1 The relationship between the change in MPOD at 0.25° and change in letter
contrast sensitivity at 1.2, 6.0 and 15.2 cpd, respectively.
Note: values for CS are presented in log form
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7.4 Discussion
The extent to which MP augments in response to carotenoid supplementation is related
to baseline MP levels,323, 413 where subjects with relatively low baseline MP are more
likely to exhibit increases in MP compared to subjects with high baseline MP (perhaps
due to a ceiling effect; of note, peak MP levels typically range between 0.0 and 1.0 OD
units,235 and are subject to dietary modification329, 340 ). This has been confirmed in the
current study, where there was a statistically significant difference between subjects in
the lowest baseline MPOD tertile (≤ 0.32 OD units) compared to subjects in the middle
or highest baseline MPOD tertiles, with respect to change in central MPOD, where the
greatest augmentation of MP was seen amongst subjects with low baseline MPOD.
However, the very low p-value reported here (0.01) should be interpreted with caution;
statistically there is nearly always a negative correlation between X (MPOD at baseline)
and Y-X (difference in MPOD between baseline and 12 months), which may account, at
least in part, for this finding.
Of interest, the data indicate that subjects with low MPOD at baseline are likely
to have the greatest improvements in CS following supplementation (with any of the
three macular carotenoid formulations), albeit not statistically significant in this small
sample. In other words, MP enrichment and detectable improvements in vision are of
greatest relevance to subjects who have poor/low MP to begin with. This has important
implications for any anticipated improvements in vision following supplementation, and
may account for the variability in the results of studies investigating the impact of
carotenoid supplementation on MPOD and vision. Interestingly, Wooten and Hammond
observed, combining data from a number of (USA-based) studies, that 43% of subjects
in the sample (n=846) had MP levels of <0.2.33 This suggests that a significant
percentage of the (Western) population may not have optimised vision because of low
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MP, which may have important implications, not only for the current population with
early AMD and reduced vision, but possibly also for professionals such as pilots,
sportspeople, drivers and soldiers. Further study in a normal population is warranted, in
this respect. In such and similar cases, measurement of MP and, where appropriate, a
carotenoid-rich diet and/or supplements, may be important to consider, even in the
absence of disease.
The spatial profile of MP and its variability has been of interest to those
investigating the role of MP, both for vision and for protection against AMD. Initial
studies reporting on the distribution of MP describe it declining exponentially with
increasing retinal eccentricity.234, 416 However, variations in its distribution have also
been reported,416, 417 one of which has been coined a “central dip”. A study (previously
discussed in section 4.5.3.3) showed that, prior to disease onset, the known risk factors
for AMD (tobacco use, family history of the condition, increasing age) are
independently associated with a relative lack of MP.320 A proportion of that study
population (12%) exhibited a central dip in their MPOD spatial profile and,
interestingly, this central dip was associated with tobacco use and increasing age,321
suggesting that such atypical MP spatial profiles may independently represent risk for
AMD. It has been hypothesised that these central dips in the MP spatial profile are
attributable to a relative lack of MZ, considering MZ is the dominant carotenoid in the
foveal centre, and may be the result of an inability among subjects with such spatial
profiles to convert retinal L to MZ (retinal MZ is formed from retinal L, but not retinal
Z). Such subjects may require this carotenoid in supplement form in order to achieve a
typical and desirable spatial profile.
Our analysis has found an association between observed changes in central
MPOD and observed changes in measures of visual performance as measured by letter
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CS, amongst subjects with a central dip at baseline. The data from this analysis has
shown normalisation of atypical MPOD spatial profiles (in 80% of cases) following
supplementation with an MZ-based formulation (I cannot comment on the response of
central dip profiles to a high L-based supplement using the results of this study). This
finding has been previously demonstrated in a study designed to investigate the effect of
supplementation on a group of subjects (normal) that exhibited a central dip in their MP
spatial profile (see section 5.5.3.3).322 The authors concluded that MP spatial profiles
characterised by central dips, can be normalised following supplementation with a
formulation containing MZ, but not with a formulation that is lacking this carotenoid (at
least not in an eight-week period). In addition, augmentation across MP’s spatial profile
required supplementation with a formulation containing all three macular carotenoids.
Interestingly, a recent study has shown that “ring-like structures” in MPOD, observed
using autoflourescence, and which are representative of central dips observed using
HFP,415 were not attenuated following supplementation with 12mg L and 2mg Z (but
no MZ).414
While the attenuation of central dips has been demonstrated through (MZ)
supplementation, the implications of this for vision have not yet been investigated. The
data from this analysis putatively suggest that subjects with atypical spatial profiles,
such as have been described, are more likely to benefit visually following
supplementation. While I fully acknowledge the obvious weakness of small numbers in
this case, the outcome is intriguing and warrants further study.
It has already been shown that central MP levels are positively related to visual
performance.29-33 However, the extent to which MP augments in response to carotenoid
supplementation has been shown to be related to baseline MP levels,323, 413 where
subjects with relatively low baseline MP are more likely to exhibit increases in MP
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compared to subjects with high baseline MP (probably due to a “ceiling effect”).
Subjects with a central dip may be similar to subjects with low central MP (and normal
MP spatial profiles) i.e. both having relatively low central MP, a condition which
facilitates a heightened uptake of these carotenoids at the macula following
supplementation. In contrast, one would expect a ceiling effect, in terms of MP (and
possibly vision), amongst subjects with relatively high amounts of MP. Therefore, MP
augmentation is of particular importance and relevance for subjects with low MP or
with a central dip in their MPOD profile. As has been previously discussed (Chapter 6),
Wooten and Hammond observed, combining data from a number of (USA-based)
studies, that 43% of subjects in the sample (n=846) had MP levels of <0.2. Kirby et al
reported that 12% of their study sample (normal, healthy individuals; study based in
Ireland) had a central dip in their MPOD spatial profile.321 Considering these
observations, the results of this study (in additional to the findings reported in section
6.3.2) suggest that there may be a significant percentage of the (Western) population
that may not have optimised vision because of low MP or because of an atypical MP
spatial profile (see Discussion, Chapter 6). This suggests that MPOD measurement
should be considered in subjects who present with poor CS and/or who present with
symptoms of glare, even in the absence of disease, the cause of which may be
attenuated with macular carotenoid supplementation, particularly in cases where
atypical profiles are observed.
The obvious weakness of this subsidiary study is the small number of subjects
involved, which prevent us drawing firm conclusions. Further trials to confirm these
findings are necessary, amongst subjects with and without AMD.
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7.5 Conclusion.
In the current study, subjects with low baseline central MPOD had the greatest increases
in MPOD and the greatest improvements in CS, when compared with subjects in the
mid-range or high baseline MPOD categories. Eighty per cent of subjects who presented
with a central dip at baseline had their MPOD spatial profile normalised following
supplementation with the macular carotenoids. This normalisation was strongly
associated with an improvement in CS at each spatial frequency. These findings indicate
that the optimisation of CS is putatively dependent on central MP levels, which should
be given due consideration when investigating the impact of macular carotenoid
supplementation on visual performance.
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Chapter 8. The relationship between retinal morphology and visual
performance, in subjects with age-related macular degeneration.

8.1 Study rationale, aims and objectives
The diagnosis of AMD is currently determined by the clinical appearance of the macula
i.e. signs of drusen (size, form and number), pigmentary and atrophic changes. A range
of AMD grading scales exist, which grade a given individual’s risk of progression to
later, more visually consequential, forms of the condition. Additional measures, such as
OCT and FFA have provided a further understanding of AMD, facilitating identification
of the presence of fluid or cysts in, or under, the retina.
In addition to clinical examination, valid evaluation of the visual consequences
of AMD is essential, not only for accurate documentation of disease status and
progression, but also to inform ophthalmologists of the impact of disease severity on
visual function and on quality of life. CDVA has been used as the primary measure of
vision to quantify disease severity in cases of AMD (and other ocular conditions), most
likely because of its ease of use, low cost and familiarity (for both patient and eye care
practitioner).14, 157 There is, however, a general consensus that it is neither a true
reflection of daily visual experience, nor of disease severity.418-420 The limitation of
CDVA is that it measures the angular resolution limits of the eye at high contrast only,
the real world presenting a myriad of different visual experiences, affected by things
such as lighting conditions, colour, colour contrast levels, which cannot be assessed by
CDVA. It has already been shown that the use of VA charts in isolation can hinder the
interpretation of patients’ functional visual difficulty in AMD,418 as well as other eye
conditions such as glaucoma, cataract and diabetic retinopathy.419, 420
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The purpose of this study was to investigate the relationship between measures
of visual performance (including CDVA) and MFT in cases of nv-AMD, and between
measures of visual performance and AMD-severity grade, in cases of early AMD, and
to explore whether other psychophysical parameters should be considered instead of, or
in addition to, CDVA, in an attempt to better understand AMD, and its impact on visual
function, and also in the design of clinical research studies.

8.2 Methods
8.2.1 Subjects

Data collected for the subjects recruited for the studies outlined in Chapters 6 and 7
were used for this cross-sectional analysis. Forty-seven subjects (with nv-AMD) were
recruited for Study 1 (VEGF) and were assessed at baseline for measures of visual
performance and measures of MFT, as outlined in Chapter 5. Sixty-six subjects (with
early AMD) were recruited for Study 2 (MOST) and were assessed at baseline with
respect to measures of visual performance and AMD-severity grade, as outlined in
Chapter 6. The psychophysical and morphological assessments utilised in the respective
studies are described in Chapters 5 and 6.

8.2.2 Statistical analysis

Pearson correlations were used to investigate bivariate relationships between measures
of foveal thickness and measures of visual performance. Multivariate analysis was used
to investigate the relationship between AMD-severity grade and measures of visual
performance.
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Assuming a 5% level of significance, and a two-tailed test, a sample of 47 has power
of 0.81 for detecting a correlation of 0.4 and a sample of 66 has power of 0.92 for
detecting a correlation of 0.4.

8.3 Results
8.3.1 Study 1

Data collected from forty-seven subjects (47 eyes) with active nv-AMD were available
for this cross sectional analysis. Statistically significant moderate correlations were
found between measures of MFT and measures of ROS at fixation, within the central 5°
and within the central 16° of fixation (Table 8.1; see Figures 8.1, 8.2 and 8.3 for
graphical representation of these respective relationships). All other measures of visual
performance were not significantly correlated with MFT (p>0.05, for all; Table 8.1). Of
note, CDVA was not significantly correlated with MFT, (r = -0.247; p = 0.094).
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Table 8.1 The relationship between MFT and measures of visual performance.
Variable
ROS fixation
ROS central 5°
ROS central 16°
CDVA
logRAD
Reading speed
Mean reading speed
PHP ta
PHP tii
FVA CS (mesopic conditions)
Frequency (cpd)
1.5
3
6
12
18
FVA CS (photopic conditions)
Frequency (cpd)
1.5
3
6
12
18
FVA GD (mesopic conditions)
Frequency (cpd)
1.5
3
6
12
18
FVA GD (photopic conditions)
Frequency (cpd)
1.5
3
6
12
18

r
-0.325
-0.344
-0.298
-0.247
0.047
0.144
0.088
-0.005
-0.047

p
0.029
0.021
0.047
0.094
0.752
0.334
0.555
0.976
0.789

-0.050
-0.088
0.002
-0.181
-

0.742
0.559
0.987
0.229
-

0.134
-0.006
-0.023
0.024
-0.019

0.374
0.969
0.879
0.875
0.898

-0.019
-0.080
0.060
-0.087
-

0.900
0.597
0.692
0.567
-

0.147
0.176
0.026
-0.069
-0.052

0.329
0.242
0.865
0.650
0.733

Abbreviations: MFT=mean foveal thickness; ROS=retinotopic ocular sensitivity; CDVA=corrected
distance visual acuity; PHP=preferential hyperacuity perimetry; ta=total area; tii=total integrated
intensity; FVA=Functional Vision Analyser; CS=contrast sensitivity; cpd=cycles per degree; GD=glare
disability.
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Figure 8.1 The relationship between mean foveal thickness (MFT) and retinotopic
ocular sensitivity (ROS) at fixation in subjects with neovascular age-related macular
degeneration.

Figure 8.2 The relationship between mean foveal thickness (MFT) and retinotopic
ocular sensitivity (ROS) within the central 5° in subjects with neovascular age-related
macular degeneration.
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Figure 8.3 The relationship between mean foveal thickness (MFT) and retinotopic
ocular sensitivity (ROS) within the central 16° in subjects with neovascular age-related
macular degeneration.

8.3.2 Study 2

Data collected from 66 subjects (66 eyes) with early AMD were available for analysis.
The eight early AMD grades were grouped as follows: Group 1 = grades 1 and 2
(n=12); Group 2 = grades 3 and 4 (n=25); Group 3 = grades 5 and 6 (n=18); Group 4 =
grades 7 and 8 (n=11). There was an inversely significant relationship between
measures of ROS and AMD-severity grade (Table 8.2 and Figure 8.4), such that, as
AMD severity increased, ROS deteriorated. No other parameters of visual function were
significantly related to AMD severity, including CDVA (p=0.37; Figure 8.5).
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Table 8.2 The relationship between AMD severity and measures of visual performance
ROS.
Variable

Group 1

Group 2

Group 3

Group 4

p

ROS central 4°

18.91 (0.75)

18.64 (1.77)

16.74 (4.01)

16.00 (3.13)

0.010

ROS central 8°

18.98 (0.62)

18.89 (1.48)

17.43 (2.89)

16.34 (2.68)

0.003

ROS central 12°

18.79 (0.87)

18.61 (1.60)

17.10 (2.73)

15.89 (2.91)

0.002

CDVA

98 (8)

100 (6)

96 (9)

99 (5)

0.373

1.2 cpd

71.5 (44.7)

81.5 (52.4)

47.3 (25.4)

39.7 (22.1)

2.4 cpd

58.1 (40.6)

65.2 (43.2)

45.3 (40.3)

40.1 (22.4)

0.006
0.126

6.0 cpd

26.9 (12.7)

29.6 (15.6)

19.9 (13.5)

23.6 (14..4)

0.242

9.6 cpd

15.5 (8.4)

16.2 (9.2)

10.2 (7.2)

12.3 (6.6)

0.079

15.2 cpd

6.5 (4.3)

7.6 (4.9)

4.5 (4.3)

6.1 (4.1)

0.064

1.5

41.4 (21.1)

47.7 (26.9)

40.2 (31.2)

47.4 (33.2)

0.428

3

50.8 (33.7)

56.8 (37.3)

41.4 (26.9)

60.0 (39.5)

0.395

6

27.3 (15.4)

24.3 (19.9)

23.1 (18.7)

20.7 (16.1)

0.822

12

4.6 (2.9)

6.0 (4.5)

6.6 (4.4)

5.1 (2.0)

0.620

18

2.7 (2.0)

2.7 (2.3)

2.3 (0.7)

2.0 (2.0)

0.760

1.5

29.4 (9.6)

34.7 (21.6)

31.9 (21.2)

45.0 (30.0)

0.618

3

57.7 (26.0)

59.1 (28.8)

60.0 (32.1)

61.3 (31.7)

0.914

6

42.9 (27.5)

47.5 (34.9)

37.6 (37.4)

37.6 (23.0)

0.396

12

12.2 (10.8)

15.1 (15.7)

12.1 (10.1)

11.7 (8.2)

0.946

18

5.9 (7.3)

7.6 (8.8)

5.4 (4.2)

4.9 (4.0)

0.926

1.5

48.2 (34.6)

32.8 (22.6)

27.6 (22.8)

27.1 (19.0)

0.391

3

38.1 (23.8)

51.0 (37.8)

38.4 (40.7)

37.7 (28.8)

0.403

6

20.2 (16.9)

19.5 (16.5)

16.6 (14.5)

21.7 (16.0)

0.901

12

6.4 (4.9)

5.8 (3.7)

5.1 (2.2)

4.0 (0)

0.522

18

2.7 (2.0)

2.2 (0.6)

3.0 (2.7)

2.0 (0)

0.467

1.5

35.7 (17.3)

39.8 (19.6)

36.0 (29.0)

39.4 (29.4)

0.721

3

66.0 (25.4)

66.6 (27.4)

50.4 (28.8)

65.3 (28.6)

0.113

6

39.7 (26.1)

53.8 (35.5)

35.6 (36.1)

51.9 (34.0)

0.211

12

15.4 (18.5)

16.5 (13.8)

10.9 (9.7)

13.9 (10.7)

0.649

7.7 (10.1)

8.4 (8.2)

5.4 (5.7)

7.0 (5.6)

0.733

Letter CS (photopic conditions)

FVA CS (mesopic conditions)
Frequency (cpd)

FVA CS (photopic conditions)
Frequency (cpd)

FVA GD (mesopic conditions)
Frequency (cpd)

FVA GD (photopic conditions)
Frequency (cpd)

18
Abbreviations: AMD=age-related macular degeneration; ROS=retinotopic ocular sensitivity;
CDVA=corrected distance visual acuity; CS=contrast sensitivity; cpd=cycles per degree;
FVA=Functional Vision Analyser; GD=glare disability.
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Figure 8.4 The relationship between AMD-severity and ROS within the central 16°.
Abbreviations: AMD=age-related macular degeneration; ROS=retinotopic ocular sensitivity.
AMD severity group defined as: group 1=grades 1 and 2; group=grades 3 and 4; group 3=grades 5 and 6;
group 4=grades 7 and 8.

Figure 8.5 The relationship between AMD-severity and CDVA. Abbreviations:
CDVA=corrected distance visual acuity; AMD=age-related macular degeneration; AMD severity group
defined as: group 1=grades 1 and 2; group=grades 3 and 4; group 3=grades 5 and 6; group 4=grades 7 and
8.

194

Baseline VA and FVA measures were available from a study involving normal
subjects (n=36)170 and were compared with the corresponding data for both the early
and nv-AMD groups. There was a statistically significant difference in age between the
three groups and, hence, age was controlled for in these analyses. As the three studies
had different inclusion criteria for levels of CVDA (6/6, 6/12 and 6/30 for the normal,
early AMD and nv-AMD studies, respectively), subjects with relatively good CDVA (≥
6/9, to allow for comparable numbers in the three groups) were selected and analysed,
across the three studies. One-way ANOVA was used to test for differences between
three groups of subjects with respect CS and GD, controlling for age and CDVA (Table
8.3).
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Table 8.3 Comparing measures of visual performance for eyes without disease, eyes
with early AMD and eyes with nv-AMD, all with relatively good CDVA
Variable
Age (years)

Normals (n=36)
51 (15)

ROS central 5°†
ROS central 16°‡

-

Early AMD (n=47)
67 (8)

Nv-AMD (n=22)
71 (11)

p
<0.001

18.0 (2.2)
17.9 (2.2)

11.9 (3.9)
12.7 (3.7)

<0.001
<0.001

FVA CS (mesopic conditions)
Frequency (cpd)
58.9 (25.3)
48.0 (26.7)
24.8 (9.0)
1.5
68.1 (34.5)
56.3 (33.2)
39.1 (20.1)
3
48.1 (29.3)
25.9 (17.9)
14.3 (11.5)
6
9.5 (8.6)
6.1 (4.0)
4.0 (0)
12
2.6 (2.7)
2.6 (1.8)
2.0 (0)
18
FVA CS (photopic conditions)
Frequency (cpd)
47.6 (25.0)
36.0 (21.6)
28.6 (15.4)
1.5
85.8 (32.7)
62.5 (28.0)
44.2 (21.1)
3
99.0 (39.6)
46.3 (32.2)
30.5 (20.4)
6
37.7 (26.8)
14.3 (12.8)
7.2 (5.6)
12
12.5
(11.2)
6.8
(7.1)
3.0 (3.6)
18
FVA GD (mesopic conditions)*
Frequency (cpd)
31.2 (21.3)
35.6 (25.2)
14.7 (8.7)
1.5
41.8 (23.5)
47.4 (34.8)
22.0 (13.3)
3
27.4 (21.5)
20.6 (15.8)
9.2 (8.1)
6
5.4
(3.1)
5.6
(3.5)
4.2 (0.9)
12
2 (0.5)
2.5 (1.7)
2 (0)
18
FVA GD (photopic conditions)*
Frequency (cpd)
54.3 (25.5)
39.6 (23.4)
25.0 (13.9)
1.5
89.4 (28.7)
65.6 (26.5)
44.0 (25.7)
3
102.1 (42.1)
50.3 (33.2)
28.2 (22.4)
6
33.2 (18.3)
15.5 (13.5)
7.7 (7.9)
12
12.9 (8.6)
7.8 (7.8)
2.8 (2.3)
18
Abbreviations: AMD=age-related macular degeneration; nv-neovascular; CDVA=corrected distance

<0.001
0.122
0.033
0.548
0.157

0.113
0.017
0.005
0.002
0.211

<0.001
0.010
0.036
0.157
0.044

0.002
<0.001
<0.001
0.055
0.230

visual acuity; ROS=retinotopic ocular sensitivity; FVA=Functional Vision Analyser; CS=contrast
sensitivity; cpd=cycles per degree; GD=glare disability; - = ROS data not available (test not performed in
this study)
†central 4° assessed in early AMD subjects
‡central 12° assessed in early AMD subjects
Note: Tests were performed on log-transformed data
*a higher lux glare source was used in the normal study compared to that used in the early and nv-AMD
studies
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Further analysis was performed to test the assumption that early AMD is of little
visual consequence. Eyes in the normal and early AMD groups, which had CDVA of ≥
6/7.5 were included in the analysis, again controlling for age (but not CDVA). The
results are presented in Table 8.4

Table 8.4 Measures of CS and GD in normal and in early AMD subjects, all with
CDVA ≥ 6/7.5
Variable
Age (years)
CDVA (study eye)

Normals (n=36)
51 (15)
108 (5)

Early AMD (n=35)
65 (9)
105 (5)

p
<0.001
<0.001

FVA CS (mesopic conditions)
Frequency (cpd)
58.9 (25.3)
48.6 (27.9)
1.5
0.048
68.1 (34.5)
56.2 (30.1)
0.143
3
48.1 (29.3)
27.0 (18.2)
6
0.013
9.5 (8.6)
6.5 (4.5)
0.357
12
2.6 (2.7)
2.7 (2.1)
0.096
18
FVA CS (photopic conditions)
Frequency (cpd)
47.6 (25.0)
34.9 (21.0)
0.193
1.5
85.8 (32.7)
63.8 (28.2)
3
0.034
99.0 (39.6)
50.1 (31.5)
6
<0.001
37.7 (26.8)
16.0 (13.9)
12
<0.001
12.5 (11.2)
7.6 (7.8)
0.266
18
FVA GD (mesopic conditions)*
Frequency (cpd)
31.2 (21.3)
34.4 (23.4)
0.185
1.5
41.8 (23.5)
50.5 (38.1)
0.234
3
27.4 (21.5)
22.1 (16.0)
0.370
6
5.4 (3.1)
6.2 (3.9)
0.155
12
2 (0.5)
2.4 (1.2)
18
0.046
FVA GD (photopic conditions)*
Frequency (cpd)
54.3 (25.5)
38.7 (23.8)
0.115
1.5
89.4 (28.7)
64.1 (24.5)
3
0.007
102.1 (42.1)
54.9 (35.3)
6
0.001
33.2 (18.3)
18.1 (14.3)
12
0.029
12.9 (8.6)
8.9 (8.3)
0.597
18
Abbreviations: AMD=age-related macular degeneration; CDVA=corrected distance visual acuity;
FVA=Functional Vision Analyser; CS=contrast sensitivity; cpd=cycles per degree; GD=glare disability;
Note: Tests were performed on log-transformed data
*a higher lux glare source was used in the normal study compared to that used in the early AMD study
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8.4 Discussion
This analysis was designed to investigate the relationship between disease severity
related features/measures of macular morphology and a number of measures of visual
function in subjects with AMD. The results of this study have shown that disease
severity (defined by MFT in cases of nv-AMD, or AMD-severity grade in cases of early
AMD) is best reflected psychophysically by measures of ROS. This is consistent with
the hypothesis that CDVA alone is not an appropriate psychophysical test to evaluate
the visual impact of AMD, in general. This is of clinical importance as CDVA is still
the most widely used test of visual function for patients with this condition and is often
the determining measure of disease impact on quality of life.
The presence of early AMD lesions are associated with a decrease in CDVA of
up to two letters or fewer when compared with eyes without AMD.163 However, the
test-retest variability of CDVA can be up to as much as two lines of letters on a
logMAR chart,164 indicating that a difference of two letters cannot be reliably
measured. Late AMD, on the other hand, is associated with a more significant decrease
in CDVA (approximately seven lines of letters), but only when signs of advanced AMD
involved the central subfields of the macula.163 It has been shown, however, that there
is no statistical difference in acuity between subjects with nv-AMD and subjects with
GA.163 CDVA is, therefore, unlikely to be a sensitive psychophysical measure to
quantify disease severity in cases of AMD. A wide acuity range has also been
demonstrated despite similar areas of atrophy in AMD, although, unsurprisingly, foveal
involvement was the key predictor of VA.165 Another study has shown that for the
same level of VA, eyes with GA have worse function, particularly for dark-adapted
vision tests and reading speed, than eyes with drusen.167 Similarly, lesion size in
subfoveal nv-AMD cannot explain the wide variations in VA.166
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Microperimetry is a thresholding technique that tests light sensitivity
incrementally at specific retinal loci (VA is testing spatial resolution of targets). The
fact that ROS is a retinotopic test allows for a finer probing of macular function that that
achieved by CDVA. Therefore, one might expect that measures of ROS are more
appropriate than CDVA, particularly for obtaining a morphology-related functional
assessment, in cases of AMD.

AMD-severity grade and visual performance: Clinical manifestations of AMD are
typically categorised into a grading scale to determine disease severity and risk of
progression to later, more visually consequential, stages of the condition. A number of
grading systems exist which define and classify the signs of AMD from fundus
photographs. The most widely used systems are the Wisconsin Age-related
Maculopathy Grading System,393 the International Classification and Grading System41
and the grading scale used in AREDS.421 In this respect, the current analysis has
involved subjects diagnosed with the early stages of the condition, based on an 11-step
AREDS grading scale. The levels of increasing severity in the 11-step AREDS scale are
defined by drusen area, increased pigment, RPE depigmentation and the late AMD
lesions (signs of nv-AMD [grade 11] or GA [grades 9 and 10]). Our study has shown
that disease severity, in cases of early AMD across its range of stages (1-8), is best
reflected by measures of ROS.
No study, to my knowledge, has reported on the relationship between ROS (or
CS or GD) with respect to a classified AMD grade, such as the AREDS scale. However,
a range of studies have looked at the relationship between clinical signs at the macula
and ROS in cases of AMD. It has been shown that in subjects with early AMD, ROS
diminishes in areas overlying drusen and/or pigment abnormalities, in the presence of
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good VA (6/6), and this reduction in sensitivity was greater when both lesions were
present.204
Another study reported a significant reduction in ROS in subjects with early
AMD compared with age-matched controls.422 The use of specialised software to
overlay the microperimetry infrared image onto the OCT retinal image facilitated the
assessment of ROS over individual druse, which was found to be significantly reduced
when compared to adjacent retinal ROS values. The integrity of the inner segment/outer
segment (IS/OS) junction, which has been shown to be a signiﬁcant predictor of VA in
macular diseases,423 was also observed to correlate significantly with ROS.422 In
addition, and compared with drusen height, diameter, volume, the integrity of the IS/OS
junction was the strongest predictor of ROS overlying drusen. Other studies have also
reported on the correlation between the integrity of the IS/OS junction and ROS for a
range of eye conditions.424-427 Although it has been shown that the IS/OS junction is
related to drusen volume, it is interesting to note that the IS/OS junction is not a feature
gradable from fundus images (and, therefore, does not contribute to any grading scale,
such as AREDS), as it can only be detected using OCT.
It has also been reported that drusen diameter, drusen height, and drusen volume
do not offer additional predictive value if the IS/OS junction integrity grading is
known.422 Indeed, Sunness et al have reported comparable sensitivity values between
drusen and non-drusen areas.428 Also, Midena et al found that the number of drusen,
the presence of focal hyperpigmentation, and the presence of RPE atrophy, did not
influence mean sensitivity values,180 suggesting that drusen alone may not account fully
for functional deficits. However, differences in methodology may account for the
discrepancies between these results and those previously discussed, particularly since
the latter studies (Sunness and Midena) utilised traditional, and considerably more
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limited, perimetry (the Fundus Camera Stimulator and the Humphrey Field Analyzer™,
respectively). The latter, when compared with microperimetry, does not allow a point to
point correlation of function and morphology, cannot facilitate real-time fundus
tracking, nor provide an appreciation of fixation stability. The Fundus Camera
Stimulator, on the other hand, facilitates visualisation of the posterior pole and retinal
location of the targets, but unlike microperimtery, does not automatically correct for a
subject’s eye movements to ensure, for example, that the desired retinal areas are being
tested.
Considering the relevance of the IS/OS junction and the fact that it is not
measurable using traditional fundus imagery, and yet is related to ROS, ROS (by
microperimetry) may, then, offer additional, and possibly more useful, information with
respect to understanding disease severity in AMD than would be provided by a
classified grading scale in isolation. A limitation of the current study is that OCT
measurements were not taken on the early AMD cohort so that the IS/OS junction
could, therefore, not be assessed.
Other methods of measuring retinal function (although not ROS) have included
the measurement of rod and cone sensitivities in isolation. Two particular studies are of
interest, involving subjects with early AMD; Remky et al investigated cone sensitivity
using short-wavelength automated perimetry,429 and Scholl et al reported on both rod
and cone sensitivity (through a technique called fine matrix mapping in scotopic and
photopic conditions, respectively).430 In both studies, retinal functional loss was
evident, even in cases of good VA. The fine matrix mapping technique (Scholl et al)
detected more rod than cone sensitivity decreases, which supports the notion that
deterioration in the rod system precedes that of the cone system in AMD.431 Both
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studies found that functional deficits correlated with fundus abnormalities (large soft
drusen and pigmentary RPE changes).
AMD-grading scales have been developed for purposes of determining disease
severity, tracking disease progression, and predicting progression to late AMD.41, 393, 421
It is interesting to note that, while the presence of high-risk drusen has been shown to be
a sensitive indicator of the risk of disease progression (i.e. if someone is going to
progress, they will be correctly identified), the specificity is relatively low (i.e. if
someone is not going to progress, there is a high chance that the scale will incorrectly
predict progression).432 Therefore, there are people who are at greater risk of
progression who are classified (according to grading scales) similarly to those who have
lower risk; a notable limitation of the clinical grading system. It is important to identify
the difference, so that subjects who are at greatest risk are those included, for example,
in trials investigating factors related to disease progression. In fact, a recent publication
has suggested that clinical vision measures (in combination with gene testing, which
cannot detect disease) may increase the power of prediction models for AMD.433
Measures of visual performance, such as ROS, could potentially be used as functional
biomarkers in AMD. Long-term prospective studies are needed in this respect.

Macular thickness and visual performance: The AREDS scale defines the stage of
AMD, from early (grades 1-8) through to late (9-11), and distinguishes nv-AMD (grade
11) from GA (grades 9 and 10) but does not subdivide these later stages. In cases of nvAMD, one way in which severity can be further quantified morphologically, is through
measures of OCT. Nv-AMD is characterised by the presence of CNV, which is
associated with the leakage of fluid (from neovascular vessels) into and/or under the
neurosensory retina in the macular region, disrupting the normal structure of the
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photoreceptors and increasing retinal thickness through the presence of fluid/cysts, as
observed on OCT. Anti-VEGF therapy functions to inhibit the action of VEGF, thereby
arresting the development of CNV and thus reducing fluid/cysts at the macula, thus
normalising retinal thickness. Therefore, one of the most important measurable
morphological features of nv-AMD is retinal thickness at the fovea. Consequently,
outcome measures that can efficiently quantify morphological as well as functional
damage (or status) are of critical importance in determining the most effective treatment
or treatment strategies.
A range of studies have previously investigated the relationship between OCT
parameters and visual function in subjects with AMD205, 425, 434-436 and other
pathological conditions of the macula, such as diabetic macular oedema.207, 437, 438 A
recent study found a statistically significant negative correlation between central retinal
thickness and central ROS in patients with nv-AMD.436 Others have also postulated
that the measurement of ROS may be a more appropriate method to assess central visual
function than conventional VA, following a study where there were significant
improvements in ROS (within the central 10° of fixation), significant decreases in
foveal thickness, but no significant improvements in CDVA, following PDT in subjects
with nv-AMD.439
In another study, a statistically significant relationship was found between RPE
lesion area and central ROS (but not CDVA) in patients with nv-AMD undergoing antiVEGF therapy, at every study visit (baseline, one week, one, two and three months).205
In that particular study, however, while the authors did not find a correlation between
measures of retinal thickness (although it decreased significantly) and visual function,
they did report a correlation between RPE lesion size and ROS. The absence of a
correlation between retinal thickness and ROS in that case may be due, at least in part,
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to the relatively small sample size (n=23) for which correlations were performed.
However, the authors postulate that the condition of the RPE may be more relevant in
terms of understanding impact on function.
There was no statistically significant correlation between measures of CS or GD
and retinal thickness in this study. However, a previous study has reported on the
inverse relationship between CS and the subretinal fluid in cases of nv-AMD.440 The
latter study involved a larger sample size (n=122), it only included previously untreated
nv-AMD subjects and also, the retinal outcome measure was the extent of subretinal
fluid (compared to MFT in the current study, although these are somewhat related).
These differences in methodology (particularly in sample size) may be the cause of the
disparity between the results of the two studies.
Considering the functional criterion for retreatment in cases of nv-AMD is based
on a change in CDVA (defined as a loss of five letters),441 the results of this particular
analysis, in combination with the results presented in Chapter 5, are of particular
importance. Treatment strategies that depend on change in a measure as crude and
insensitive as CDVA, may mean that patients are not treated early enough, timely
intervention being paramount to successful outcomes.151, 155 This hypothesis is
supported by a recent study, which explored the relationship between macular thickness,
VA and ROS in patients undergoing intravitreal ranibizumab for nv-AMD. In brief,
intravitreal ranibizumab was administered if VA or OCT showed signs of active
disease. Five (of a total of 21) eyes showed no change in VA or OCT findings, and,
therefore, required no intravitreal injections. In these eyes, mean ROS decreased by
13% during the study period, indicating that ROS can deteriorate in eyes with stable VA
and stable retinal thickness.435 This is also of relevance to the results reported in
Chapter 5.
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This study reports significant differences between normal, early and nv-AMD subjects
with respect to measures of CS and GD, under both photopic and mesopic conditions, in
spite of relatively good CDVA (≥6/9). A statistically significant difference in ROS was
also observed between the early and nv-AMD groups. This further highlights the fact
that CDVA alone cannot account for visual performance in AMD. Another study has
reported differences in foveal dark-adapted sensitivity between eyes with GA and eyes
with early AMD, and VA of 6/7.5 or better.167 Also, poor (patient-reported) visual
function in dim illumination, specifically poor dark adaptation and need for more light
when reading, has been shown in subjects with GA, despite good VA.442
A number of studies have also reported on psychophysical function in subjects
with (early and late) AMD, highlighting a range of functional abnormalities associated
with the condition, including S-cone sensitivity, flicker sensitivity, dark adaptation,
colour-match area, and photostress recovery time, which are often either undetected or
poorly quantified by traditional CDVA measures.160, 443-445 The majority of these tests,
however, have limitations in clinical or even research settings, for one or more of the
following reasons: time-consuming; reliant on significant operator expertise; necessitate
expensive equipment; require reasonably high concentration levels on the part of the
subject, which may be challenging for the population in question (AMD subjects) who
can present with poor cognitive function and/or other sensory limitations, hindering
optimal test performance.
The results of this study have also shown that measures of CS and GD differ
between normal, early and nv-AMD subjects, when CDVA is relatively good. However,
in terms of detecting change within the early and nv-AMD categories, respectively,
measures of ROS displayed the strongest correlations with retinal morphology, most
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probably due to the fact that ROS is retinotopic, which probes visual function more
deeply, compared to CS and GD (and CDVA). ROS may be considered a relatively
familiar test for patients as it resembles (in terms of patient instruction and operation)
visual field testing, which is commonly used by ophthalmologists/optometrists amongst
this study population, thus rendering it potentially more patient-friendly. In terms of
duration, the procedure for measuring ROS according to our protocol lasted
approximately five minutes per eye. In this respect, I suggest that it be considered as
measurement of visual function in a clinical setting as well as in the design of studies
investigating visual function in AMD.
Additional results, comparing normal and early AMD subjects with respect to
measures of CS and GD, have shown that, despite good CDVA, measures of CS and
GD (particularly at low-mid range spatial frequencies) are significantly worse in eyes
with early AMD compared to normals. Previous studies have shown similar results; for
example, CS functions have been shown to be depressed in subjects with early AMD,
compared with age-matched controls, both at the fovea and paracentrally (at two, five,
and ten degrees from the fovea), demonstrating that sensitivity loss is not confined to
the fovea (which is the retinal locus assessed primarily assessed by CDVA).446 It has
also been shown that subjects with early AMD have significant loss of CS at low spatial
frequencies, before the loss of high contrast VA, across a range of eccentricities,
including at the fovea itself.447 The results of the current study contribute to the
literature that challenges the general assumption that early AMD is of little visual
consequence, and suggests that CDVA alone cannot account for the impact of the
condition on visual performance. ROS data from normal subjects were not available for
our analysis; however, a significant reduction in ROS in subjects with early AMD
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compared with age-matched controls has been previously shown in eyes with CDVA of
≥6/9.422

8.5 Conclusion
Our study has contributed to the evidence germane to the relationship between disease
severity and psychophysical function. This study has shown that measures of CS and
GD differ between normal, early and nv-AMD subjects, in cases of good CDVA. ROS,
in addition to this, can also reflect macular morphology, in cases of early, and in cases
of nv-AMD, an outcome that cannot be achieved by conventional CDVA. Measures of
ROS may, in fact, provide information complementary to morphological assessment,
further highlighting the need for appropriate functional, as well as structural evaluation
in patients with this condition. This is important in terms of understanding disease status
(and its functional impact), monitoring disease progression, and also assessing the
efficacy of emerging therapies, both in clinical practice and for the purposes of research
trials. The findings of this study add to those presented in Chapter 5, where it was
shown that ROS is a useful tool in the monitoring of subjects undergoing intravitreal
ranibizumab for nv-AMD, and may be usefully incorporated into progression models
for the condition.
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Chapter 9. Conclusions and future considerations

This work was designed to investigate visual performance status and its response to
intervention, in cases of early and in cases of nv-AMD, using a range of psychophysical
tests beyond conventional CDVA.
The results reported and the conclusions drawn herein are based on the
outcomes of, a) a literature review of the evidence pertaining to the macular
carotenoids, AMD and visual performance, and b) two clinical trials, one which
investigated visual function in response to ranibizumab treatment in subjects with nvAMD, and the other, which has explored MPOD levels, visual function and AMD
progression following supplementation with three different macular carotenoid
formulations. The conclusions and the future considerations proposed as a result of the
outcomes of this work are as follows:

1. The evidence germane to the role of MP for visual performance and its putative
protective function against AMD has been reviewed. Appraising the totality of currently
available evidence, it would appear that supplementation with the macular carotenoids
offers the best means of fortifying the antioxidant defenses of the macula, thus
putatively reducing the risk of AMD and/or its progression, and of optimising visual
performance. I hope that this review of the literature will assist eyecare professionals to
make well-informed decisions with respect to the prevention and/or delay of AMD
onset and/or its progression (in anticipation of the results of RCTs), in addition to visual
performance optimisation.
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2. This study has investigated the impact of three different macular carotenoid
formulations on the augmentation of MP, on visual performance and on disease
progression, in subjects with early AMD. This study has shown that MP can be
augmented, and CS enhanced, in subjects with early AMD who receive supplemental
macular carotenoids. This is of particular interest considering the progressively
degenerative nature of AMD. No trial to date has investigated the potential of MZ with
respect to development or progression of AMD (or on visual performance in subjects
with the conditions), as it has only recently become available in supplement form. A
formulation containing MZ appears to offer advantages over a formulation that does not
contain MZ, in terms of improvements in psychophysical function and in terms of MP
augmentation across its spatial profile. However, I do believe that a supplement
containing equal concentrations (1:1:1) of the three carotenoids (L, Z and MZ) warrants
investigation, both with respect to AMD progression and visual performance.
The results of this study should prompt and inform a well-designed, placebocontrolled clinical trial (ideally of longer duration) of supplementation with L, Z and
MZ in subjects with AMD, where outcome measures should include, MPOD
augmentation, visual function and disease progression.
While the rationale suggests that MP is protective against the onset of AMD,
there have been no published trials that have investigated the potential of macular
carotenoids in this respect. This would involve recruiting subjects who are not afflicted
with the condition and evaluating macular health over time with respect to intake of the
carotenoids (compared to placebo) and with respect to MPOD. Such a trial would need
to be no less than 15 years in duration following completion of recruitment. Of note, a
unique observational study is currently underway in Ireland, entitled “The Irish
Longitudinal Study of Ageing (TILDA),”448 and is investigating health, lifestyles and
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financial status of circa 8,000 randomly selected people aged 50 years and older. A
major component of this prospective cohort study is the investigation into the
relationship between baseline MP levels and the prevalence and incidence of AMD.449
MP measurements and retinal photographs are being obtained at three separate study
waves: year one, year four and year eight. This study will investigate, for the first time,
whether baseline MP levels relate to the ultimate risk of developing AMD. However,
the gold standard interventional trial to investigate the role of macular carotenoids in
AMD prevention is still warranted.

3. This study has explored the relationship between central MPOD and visual
performance, amongst early AMD subjects who present (at baseline) with differing
levels of central MPOD. While recent studies have commented on the response of MP
to macular carotenoid supplementation amongst subjects with low MP, the impact of
macular carotenoid supplementation on visual performance in this specific group of
subjects was never previously investigated. Subjects with low baseline central MPOD
had the greatest increases in MPOD and the greatest improvements in CS, when
compared with subjects with medium or high baseline MPOD. The impact of macular
supplementation on visual performance in subjects with central dips is provocative and
warrants further study. The findings suggest that the optimisation of CS (and putatively
visual performance in general) is somewhat dependent on central MP levels. These
results should prompt further investigation amongst subjects with low MP and/or with
atypical spatial profiles (with or without disease), in particular to explore the impact of
macular carotenoid supplementation on visual performance. This may have
implications, not only for subjects afflicted with AMD, but also for subjects who
present with symptoms of glare/reduced vision, particularly those who work in
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professions where optimised vision is particularly important, such as pilots,
sportspeople, and drivers.
If MP levels are playing a role in visual performance, this then warrants the
measurement of MP in clinical practice, particularly in cases where visual symptoms
cannot be explained by refractive error or disease. The limitation associated with
reliably measuring MP, presently, is testing duration, which is of particular relevance
for a clinical setting. For example, MP measurement using the gold standard
Densitometer™ takes roughly ten minutes per eye. Other devices, such as VisuCam®
200, which may employ a shorter testing period, are limited by other factors, such as
one- (rather than dual-) wavelength technology, and the fact that measurement of
MPOD at a peripheral reference point is not considered. This field still awaits an easyto-use, patient friendly device that can reliably measure MPOD, particularly if MP
measurement is to be incorporated into routine clinical practice.
In addition, and given the growing interest in MPOD spatial profiles, a device
that can yield a spatial profile of MP (similar to that provided by the Densitometer™)
warrants consideration. Currently available commercial devices, such as the
MacuScope™ and the MPS 900, measure MP at a single retinal locus (often 0.5°
eccentricity), and cannot, therefore, detect the presence of e.g. a central dip.

4. In eyes with nv-AMD undergoing monthly intravitreal ranibizumab injections, there
have been demonstrable improvements in a range of parameters of visual function, but
no significant change in CDVA, despite a reduction in mean MFT. This finding has
important implications when attempting to understand the effect of this treatment on a
subject’s visual performance and also, for a clinician’s decision to treat/retreat/cease
treatment in patients with the condition. This work suggests that outcome measures
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other than CDVA, such as CS, GD and ROS, should not only be considered in the
design of studies investigating nv-AMD, but also in treatment and retreatment strategies
for patients with the condition, at least in eyes where baseline CDVA is relatively good.

5. This work also challenges the assumption that early AMD is not visually
consequential and suggests the use of other tests to determine visual performance and
experience, in subjects with the condition. While CDVA may not be greatly affected by
early stages of the condition, it is clear that measures such as CS and GD are depressed
compared to normal subjects and, therefore, should be considered in the diagnosis and
monitoring of patients with AMD.
Glare is an appreciable and common complaint amongst subjects, not only with
eye disease such as AMD, but also amongst those without disease. However, there is
currently no “true” GD test, which makes it difficult to conclusively comment on the
effect of glare. What has been reported is a measure of CS in the presence of glare,
which is not a measure of glare, per se. Devices are limited even in this respect. Further
investigation into the measurement of glare is warranted.

6. In terms of understanding disease severity using measures of visual function, this
study has shown that CDVA poorly reflects retinal morphology in cases of early AMD
and in cases of nv-AMD. ROS, however, appears to be a measure which is more
reflective of disease severity in these conditions, where it correlates well with AMDseverity grade (in cases of early AMD) and also with MFT (in cases of nv-AMD). It has
also been shown that, where CDVA is good, CS and GD differ between normal, early
and nv-AMD subjects. ROS, in addition, has been shown to be impacted to a different
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extent depending on whether you have early- or nv-AMD, something that is not
observed when using conventional CDVA. Measures of ROS may, in fact, provide
information complementary to morphological assessment, further highlighting the need
for appropriate functional, as well as structural evaluation in patients with this
condition. This is important in terms of understanding disease status (and its functional
impact), monitoring disease progression, and also assessing the efficacy of emerging
therapies, both in clinical practice and for the purposes of research trials. If a measure
such as CDVA is a primary outcome measure in an interventional trial, and yet it is
showing to be incapable of reflecting disease status or detecting changes in visual
performance over time, we must, therefore, question its use in such circumstances.
Also, any intervention that endeavours to improve visual function must seek to
do so from a patient’s perspective, and not just from observing increases on any given
device/chart. Currently available subjective vision questionnaires have limitations,
which have been previously discussed. While they may be capable of distinguishing
between, e.g. early and late AMD, they have not been sensitive enough, at least with
respect to the current study, to detect change following intervention. There is a need to
develop a more refined method of determining patient-perceived change in visual
performance over time.

7. This study has attempted to probe more deeply the functioning of the visual system in
subjects with AMD. However, the tests used and discussed here may or may not be
appropriate for other eye conditions, which would warrant further investigation. In
addition, the visual function measures reported here are by no means exhaustive. Other
tests and other devices should also be explored. For example, the mfERG has yielded
interesting results in other studies, where improvements were observed following
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macular carotenoid supplementation in subjects with early AMD.407, 408 The advantage
of this technique over e.g. ROS, is that it is objective, not requiring a patient response. It
is, however, relatively cumbersome. Further exploration of this method, and perhaps
how it relates to measures ROS in subjects with AMD and additionally, its response
following supplementation with an MZ-based supplement (which has not been
previously explored), may be interesting.
In general, this thesis advocates the incorporation of tests, complimentary to CDVA,
such as CS, GD, and particularly ROS, when attempting to understand disease severity
in cases of AMD. In terms of monitoring change over time, the results of this study do
seem to indicate that measures of ROS may be of particular benefit in monitoring
subjects with nv-AMD, while measures of CS and GD may be more apt in monitoring
change in subjects with early AMD. These tests should not only be considered in
clinical practice settings (optometric, ophthalmological) but also when considering
vision-related research, such that it may provide better insight into the impact on vision
in AMD and on its response to intervention, particularly when new therapies are being
investigated.
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